# ENT Liu Head & Neck Cancer Knowledge Base — full text > Complete, machine-readable text of every answer on https://www.entliu.com. Companion to /llms.txt (curated index). > Author / medical reviewer: Xiangpeng Liu, MD, Chenzhou First People’s Hospital, Chenzhou, Hunan, China. > Last reviewed: 8 November 2026. Pages: 206. Standalone Q&A: 168. > Statistics refer to GLOBOCAN 2022 unless a different year is stated. General information only, not medical advice. --- # Part 1 — Global incidence ## Worldwide cases by subsite (GLOBOCAN 2022) - **Lip + oral cavity** (C00–C06): 389,846 cases; ASR 4.0/100,000; male/female ASR 5.8 / 2.3 (incidence male/female); main driver: Tobacco, areca nut, betel quid, alcohol; UV for lip; high-incidence regions: South-Central Asia, Melanesia, Southern Africa. - **Larynx** (C32): 189,191 cases; ASR 1.9/100,000; male/female ASR 3.5 / 0.4; main driver: Tobacco + heavy alcohol; high-incidence regions: Caribbean, Eastern & Southern Europe, South Asia. - **Nasopharynx** (C11): 120,434 cases; ASR 1.3/100,000; male/female ASR 1.9 / 0.7; main driver: EBV, genetics, childhood salt-preserved fish; high-incidence regions: South-East Asia, southern China, North Africa. - **Oropharynx** (C01, C09–C10): 106,400 cases; ASR 1.1/100,000; male/female ASR 1.9 / 0.4; main driver: Persistent HPV-16 infection (high-income countries); high-incidence regions: North America, Northern/Western Europe, Australia/NZ. - **Hypopharynx** (C12–C13): 86,257 cases; ASR 0.89/100,000; male/female ASR 1.5 / 0.3; main driver: Tobacco + alcohol, iron deficiency, malnutrition; high-incidence regions: Eastern Europe, South-Central Asia. - **Salivary glands** (C07–C08): 55,083 cases; ASR 0.56/100,000; male/female ASR 0.7 / 0.5; main driver: Prior radiation, mixed/uncertain, autoimmune; high-incidence regions: Western & Central Africa (highest relative share). ## Overall incidence by world region - **Asia**: ASR 13.0/100,000; 5-year prevalence 34.7/100,000. Highest regional incidence; driven by oral cavity and nasopharyngeal cancers. - **Europe**: ASR 11.3/100,000; 5-year prevalence 69.9/100,000. High 5-year prevalence; oropharyngeal (HPV) and laryngeal cancers are prominent. - **Australia / New Zealand**: ASR 10.9/100,000; 5-year prevalence 63.6/100,000. UV-related lip cancer plus rising HPV-associated oropharyngeal cancer. - **North America**: ASR 10.7/100,000; 5-year prevalence 64.7/100,000. Oropharynx is the dominant lip/oral/pharyngeal subsite among men (43.8%). - **South America**: ASR 7.6/100,000; 5-year prevalence 28.5/100,000. Laryngeal and oropharyngeal cancers contribute substantially. - **Africa**: ASR 5.3/100,000; 5-year prevalence 8.0/100,000. Lower recorded ASR, but NPC in North Africa and salivary gland cancers in West/Central Africa are relatively prominent. - **Central America**: ASR 2.9/100,000; 5-year prevalence 8.8/100,000. Lowest recorded regional ASR; partly reflects registry coverage. ## Which tumour dominates in each region - **North America** — HPV-positive oropharyngeal cancer. 43.8% of the regional lip/oral/pharyngeal burden. ~70% of US oropharyngeal cancers are HPV-positive; oropharynx is the most common LOCP subsite among men. Clinical consequence: Painless cystic neck lump in a non-smoking man aged 40–60 → FNA with p16/HPV testing, not antibiotics. (https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/) - **Northern & Western Europe / UK** — HPV-positive oropharyngeal cancer and laryngeal cancer. HPV-attributable fraction 52–77% in the UK and Scandinavia. Denmark 63%, Sweden 72%, Norway 77%; highest oropharyngeal ASRs in men in Slovakia (11.1) and Romania (10.6). Clinical consequence: Ask for p16 testing on every oropharyngeal SCC; note that Southern Europe has <20% HPV attribution. (https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/) - **South-Central Asia (India, Bangladesh, Pakistan, Sri Lanka)** — Oral cavity cancer. 59.8% of the regional lip/oral/pharyngeal burden. India: 143,759 new oral cancers and 79,979 deaths in 2022 (ASR 10.1); male ASRs 11–13 across the region. Clinical consequence: Any ulcer, white/red patch or restricted mouth opening >2–3 weeks → oral examination and biopsy. (https://www.entliu.com/conditions/oral-cavity-cancer/) - **South-East Asia** — Nasopharyngeal carcinoma. 50.8% of the regional lip/oral/pharyngeal burden. Brunei ASR 6.4, Indonesia 6.1 (18,835 cases), Malaysia 5.9, Singapore 5.4, Vietnam 4.7; male ASR up to 9.6 in Indonesia. Clinical consequence: Unilateral blocked ear, nosebleeds or upper-neck lump → nasopharyngoscopy, MRI and EBV DNA. (https://www.entliu.com/conditions/nasopharyngeal-carcinoma/) - **Northern Africa & the Middle East** — Nasopharyngeal carcinoma. 41.8% of the regional lip/oral/pharyngeal burden. Algeria recorded 1,608 cases (ASR 3.5; 4.8 in men) and 971 deaths; intermediate endemic rates in Morocco, Tunisia, Egypt and Sudan. Clinical consequence: Distinguish NPC from sinonasal cancer with endoscopy and MRI; check EBV DNA. (https://www.entliu.com/conditions/nasopharyngeal-carcinoma/) - **Eastern Europe, Caribbean & Brazil** — Laryngeal and hypopharyngeal cancer. Hypopharynx 15.8% of Eastern Europe’s LOCP burden. Cuba male larynx ASR 14.8, Moldova 12.2, Romania 10.3; Bangladesh male hypopharynx ASR 9.3. Clinical consequence: Hoarseness >2–3 weeks → laryngoscopy; ask about organ-preserving treatment options. (https://www.entliu.com/conditions/laryngeal-cancer/) - **Australia, New Zealand & the Pacific** — Lip and head/neck skin cancer; HPV-positive oropharyngeal cancer. Lip cancer 20.5% of Australia/NZ LOCP burden; 26.5% in Melanesia. Papua New Guinea male lip ASR 8.2 and female oral cavity ASR 8.1; Australia male lip ASR 3.2. Clinical consequence: SPF lip balm, hats and skin checks; non-healing lip, ear or scalp lesion → biopsy. (https://www.entliu.com/conditions/lip-cancer/) - **East Asia (incl. South Korea, China, Japan)** — Nasopharyngeal carcinoma and thyroid cancer. NPC 36.9% of the East Asian LOCP burden; Asia holds 72.7% of global thyroid cancer cases. China 51,010 NPC cases; South Korea thyroid ASR 39.5/100,000 in women, largely from overdiagnosis. Clinical consequence: For an incidental small thyroid nodule, ask whether active surveillance is appropriate before agreeing to surgery. (https://www.entliu.com/conditions/thyroid-cancer/) ## Country-level signals - **India**: 143,759 oral cancer cases / 79,979 deaths (2022). Largest national oral cancer burden; 70–80% attributable to tobacco and areca nut. - **United States**: ≈70% of oropharyngeal cancers HPV-positive. HPV-driven disease now exceeds cervical cancer incidence among women. - **Indonesia**: 18,835 NPC cases; ASR 6.1 (9.6 in men). Second-largest national NPC burden and one of the highest ASRs. - **Malaysia / Brunei / Singapore**: NPC ASR 5.9 / 6.4 / 5.4. Nine of the ten highest national NPC ASRs are in South-East Asia. - **South Korea**: Thyroid ASR 39.5 in women, 7.6 in men. Highest in Asia; mostly ultrasound-driven overdiagnosis with stable low mortality. - **Cuba / Moldova / Romania**: Male larynx ASR 14.8 / 12.2 / 10.3. Historical tobacco and alcohol exposure pattern. - **Bangladesh**: Male hypopharynx ASR 9.3; female 1.6. Highest hypopharyngeal ASR worldwide in both sexes. - **Papua New Guinea**: Male lip ASR 8.2; female oral cavity ASR 8.1. Among the world’s highest rates for both UV- and areca-related disease. - **Algeria**: 1,608 NPC cases; ASR 3.5 (4.8 in men). North African endemic focus with a distinct age distribution. - **China**: 51,010 NPC cases; 27,169 male larynx cases. Largest absolute NPC burden and high-volume head and neck surgical practice. ## Global incidence FAQ ### Which head and neck cancer is most common worldwide? Cancer of the lip and oral cavity: 389,846 new cases in GLOBOCAN 2022 (ASR 4.0/100,000), about 41% of all head and neck cancers. Oral cavity cancer alone (excluding lip) accounted for 317,500 cases in the 2022 subsite analysis. ### Which head and neck cancer is most common in the United States? Oropharyngeal cancer is the dominant lip/oral/pharyngeal subsite among US men (43.8% of the regional burden), and roughly 70% of US oropharyngeal cancers are HPV-positive. This reflects the HPV-16 epidemic in high-income countries rather than tobacco. ### Which head and neck cancer is most common in India? Oral cavity cancer. India recorded 143,759 new cases and 79,979 deaths in 2022 — 10.2% of all Indian cancers — with men accounting for about 75%. Chewing tobacco, areca nut and betel quid explain most of the burden. ### Why is nasopharyngeal cancer so common in South-East Asia but rare in the West? Endemic NPC combines EBV infection with genetic susceptibility and childhood dietary exposure (salt-preserved fish). Nine of the ten highest national ASRs are in South-East Asia; the US ASR is about 0.4/100,000. Asia accounted for 83.3% of the 120,434 global cases in 2022. ### Is thyroid cancer really increasing, or just being detected more? Mainly being detected more. Incidence has climbed steeply with widespread neck ultrasound — South Korea has the highest reported ASR (39.5/100,000 in women) — while mortality has stayed low (global ASR 0.4). Overdiagnosis of small papillary cancers is the accepted explanation. ### Why do head and neck cancer rates differ so much between countries? Because the main causes are local exposures: HPV and HPV vaccination coverage, tobacco and areca nut chewing, alcohol, ultraviolet radiation, EBV and dietary patterns, occupational carcinogens, and the intensity of diagnostic imaging. Registry coverage also affects recorded rates. ### How many head and neck cancers were diagnosed worldwide in 2022? GLOBOCAN 2022 estimates combine to 947,211 cases across lip/oral cavity, salivary glands, oropharynx, nasopharynx, hypopharynx and larynx, with an overall age-standardised incidence of about 9.8 per 100,000. A separate 2026 subsite analysis counted 758,020 lip/oral cavity/pharyngeal cases, excluding the larynx. ### Should where I live change which symptoms I worry about? Yes, it changes the prior probability. A painless neck lump in North America points strongly toward HPV-positive oropharyngeal cancer; a non-healing cheek ulcer in South Asia toward oral cancer; unilateral nasal obstruction or a blocked ear in South-East Asia or North Africa toward nasopharyngeal carcinoma; and a non-healing lower-lip sore in Australia toward UV-related lip cancer. --- # Part 2 — Cross-topic FAQ ### What counts as a head and neck cancer? Head and neck cancers are tumours of the oral cavity, pharynx (nasopharynx, oropharynx, hypopharynx), larynx, salivary glands, nasal cavity and paranasal sinuses, thyroid, and the skin and lip of the head and neck. They are grouped by anatomy, but their causes, treatments and prognoses differ substantially by subsite. Source page: https://www.entliu.com/conditions/ ### How common is head and neck cancer worldwide? GLOBOCAN 2022 estimates combine to about 947,211 new cases across the six main head and neck cancer subsites, with an age-standardised incidence around 9.8 per 100,000. Lip and oral cavity cancer is the largest group (389,846 cases), followed by laryngeal cancer (189,191). Source page: https://www.entliu.com/global-atlas/ ### What are the earliest warning signs of head and neck cancer? A painless neck lump, a mouth ulcer or white/red patch lasting more than two to three weeks, persistent hoarseness, one-sided nasal blockage or nosebleeds, difficulty swallowing, unilateral ear pain with a normal ear, and a non-healing lip or facial sore. Persistence beyond two to three weeks — not pain — is the trigger for an ENT examination. Source page: https://www.entliu.com/guides/warning-signs/ ### How long should I wait before seeing a doctor about a mouth ulcer? No more than two weeks. A traumatic ulcer normally heals within 10–14 days after the cause is removed. Any oral ulcer, red or white patch, lump or loose tooth persisting beyond two to three weeks should be examined and usually biopsied. Source page: https://www.entliu.com/conditions/oral-cavity-cancer/early-signs/ ### Can a CT or MRI scan diagnose head and neck cancer? No. Imaging shows the size and extent of an abnormality, but a biopsy read by a head and neck pathologist is required to establish the diagnosis and tumour type before treatment. Biomarker tests (p16/HPV, EBV, PD-L1) are then added on the tissue sample. Source page: https://www.entliu.com/guides/diagnosis-and-staging/ ### What is the first test for a persistent neck lump in an adult? Ultrasound-guided fine-needle aspiration (FNA) or core biopsy plus a full head and neck endoscopic examination. An open excisional biopsy as the first step should be avoided because it can seed tumour and complicate later neck dissection and radiotherapy. Source page: https://www.entliu.com/conditions/unknown-primary-neck-cancer/first-test-for-neck-lump/ ### Is HPV-positive oropharyngeal cancer contagious? The cancer is not contagious. HPV is a common, usually transient infection transmitted between partners, but a diagnosis does not mean a partner is ill or needs cancer screening or treatment. The patient’s tumour HPV status matters because it determines staging and prognosis. Source page: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/is-it-contagious/ ### Why is oropharyngeal cancer increasing in the US and Northern Europe? Persistent HPV-16 infection now causes about 70% of US oropharyngeal cancers and 52–77% of cases in the UK and Scandinavia. HPV-positive disease is the fastest-growing head and neck cancer in high-income countries, typically in non-smoking men aged 40–60, and has roughly 85% five-year survival. Source page: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/where-is-it-common/ ### Which head and neck cancer is most common in India and South Asia? Oral cavity cancer, driven by areca nut, betel quid and smokeless tobacco. India recorded 143,759 new cases and 79,979 deaths in 2022; oral cavity cancer makes up 59.8% of the South-Central Asian lip/oral/pharyngeal burden. Source page: https://www.entliu.com/conditions/oral-cavity-cancer/why-common-in-india/ ### Which countries have the highest nasopharyngeal cancer rates? The highest age-standardised rates are in South-East Asia: Maldives 7.5 (only 36 cases), Brunei 6.4, Indonesia 6.1, Malaysia 5.9, Singapore 5.4 and Vietnam 4.7 per 100,000. North Africa is a second endemic zone; Algeria’s ASR was 3.5. About 83% of cases occur in Asia. Source page: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/where-is-it-common/ ### Why is thyroid cancer so common in South Korea? Widespread neck ultrasound detects tiny papillary cancers that would never cause harm — overdiagnosis. South Korea’s ASR (39.5/100,000 in women) is the highest in Asia, yet thyroid cancer mortality remains low (global ASR 0.4). Many small low-risk tumours can be monitored instead of operated on. Source page: https://www.entliu.com/conditions/thyroid-cancer/why-incidence-rising/ ### What is the standard treatment for early-stage head and neck cancer? One modality — surgery or radiotherapy — chosen by subsite and functional considerations. Guideline summaries quote roughly 70–90% five-year survival for stage I–II disease. Locally advanced disease requires combined treatment such as surgery plus postoperative radiotherapy/chemoradiotherapy or definitive cisplatin-based chemoradiotherapy. Source page: https://www.entliu.com/guides/treatment-by-stage/ ### Why is nasopharyngeal cancer treated with radiotherapy rather than surgery? The nasopharynx lies deep behind the nose next to the skull base and cranial nerves, so wide surgical removal is rarely feasible. The tumour is also highly radiosensitive, making IMRT (typically 33 fractions over 6–7 weeks) the curative standard; surgery is reserved for residual or recurrent disease. Source page: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/why-radiotherapy-not-surgery/ ### Can HPV-positive cancer treatment be reduced because the prognosis is good? Not outside a clinical trial. Randomised studies replacing cisplatin with cetuximab in HPV-positive disease showed worse overall survival, and reduced-dose radiotherapy remains investigational despite the drive to reduce long-term swallowing and salivary toxicity. Source page: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/treatment-de-escalation/ ### Will I lose my voice if I have laryngeal cancer? Usually not with early disease. T1–T2 glottic cancers are often cured with radiotherapy or a voice-sparing partial laryngectomy. Total laryngectomy is reserved for advanced or recurrent disease, and speech can still be restored with a tracheoesophageal voice prosthesis, an electrolarynx or oesophageal speech. Source page: https://www.entliu.com/conditions/laryngeal-cancer/will-i-lose-my-voice/ ### How often do I need follow-up after head and neck cancer treatment? NCCN survivorship guidance recommends every 1–3 months in year one, every 2–6 months in year two, every 4–8 months in years three to five, and annually thereafter. Visits include a full head and neck examination with endoscopy; TSH is checked every 6–12 months if the neck was irradiated. Source page: https://www.entliu.com/guides/follow-up-and-recurrence/ ### Why do international patients consider head and neck cancer treatment in China? The usual reasons are short waiting times, high procedural volumes for oral cancer resection and microvascular reconstruction, experience with endemic nasopharyngeal carcinoma, and lower total costs for self-paying patients. A written remote opinion based on your records should always come before travel. Source page: https://www.entliu.com/international-patients/ ### How much does head and neck cancer treatment cost in China? Illustrative planning ranges are ¥100,000–¥220,000 (about US$14,000–30,000) for oral cancer resection with free-flap reconstruction and ¥100,000–¥220,000 for a full IMRT course with chemotherapy. Immunotherapy is charged per cycle. These are budgeting figures, not quotations. Source page: https://www.entliu.com/guides/cost-of-treatment-in-china/ ### What medical records should I send before travelling to China for treatment? An English summary, original pathology report and slides or block, contrast CT/MRI/PET-CT on DICOM, p16/HPV and EBV results, full prior-treatment records, recent laboratory tests, dental clearance and current medications. A remote review should precede any booking. Source page: https://www.entliu.com/guides/records-to-bring/ ### How long will I need to stay in China for treatment? A second opinion takes about 3–7 working days; limited surgery 1–3 weeks; major resection with free-flap reconstruction 3–6 weeks; definitive radiotherapy or chemoradiotherapy 7–10 weeks; surgery plus postoperative radiotherapy 10–14 weeks. Book flexible return flights. Source page: https://www.entliu.com/guides/travel-and-aftercare/ ### Can head and neck cancer be prevented? Many cases can: HPV vaccination before exposure, stopping tobacco and areca nut, limiting heavy alcohol, UV protection for the lips and face, dust extraction in wood/nickel/leather work, and early assessment of persistent symptoms. There is no validated population screening test for most head and neck cancers. Source page: https://www.entliu.com/guides/prevention-and-hpv-vaccination/ --- # Part 3 — Condition topics and their complete question libraries ## HPV-Associated Oropharyngeal Cancer URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/ Also known as: HPV-positive OPSCC; HPV+ tonsil cancer; HPV+ base-of-tongue cancer; HPV-mediated oropharyngeal squamous cell carcinoma Classification: ICD-O-3 C01, C09–C10 Quick answer: HPV-associated oropharyngeal cancer is a squamous cell carcinoma of the tonsils or base of tongue caused by persistent high-risk human papillomavirus, usually HPV-16. It is the fastest-growing head and neck cancer in North America and Northern Europe, often affects non-smoking men aged 40–60, and has a markedly better prognosis than HPV-negative tumours. The oropharynx includes the palatine tonsils, base of tongue, soft palate and the side and back walls of the throat. In high-income countries, most cancers here are now driven by HPV-16 rather than by tobacco and alcohol. Because the tonsil crypts can hide a very small primary tumour, the first sign is frequently a painless, cystic lump in the neck rather than a visible throat sore. HPV-positive disease is a distinct biological entity. It has a separate AJCC 8th-edition staging system, responds better to radiotherapy and chemoradiotherapy, and carries roughly 85% five-year overall survival in published cohorts. All oropharyngeal squamous cell carcinomas should be tested for p16 by immunohistochemistry; confirmatory HPV DNA or RNA testing is recommended when the result changes management or trial eligibility. **Global burden (2022):** about 146,500 new oropharyngeal cancer cases (C01, C09–C10) (male ASR 2.6 and female ASR 0.5 per 100,000; 19.3% of all lip/oral/pharyngeal cancers in 2022). Oropharyngeal cancer was the most common lip/oral/pharyngeal subsite among men in North America, South America, Australia and New Zealand. **Where it is common** - North America: Oropharyngeal cancer made up 43.8% of all lip, oral cavity and pharyngeal cancers in the region — the highest share worldwide — and about 70% of US oropharyngeal cancers are HPV-positive. - Northern Europe & Scandinavia: HPV-attributable fractions of roughly 63% in Denmark, 72% in Sweden and 77% in Norway; Denmark and France have among the highest female ASRs. - United Kingdom & Western Europe: About 52% of UK oropharyngeal cancers are HPV-positive and incidence has surpassed that of cervical cancer among women. - Eastern Europe: Slovakia (male ASR 11.1) and Romania (10.6) reported the highest national oropharyngeal ASRs in the 2022 subsite analysis. - Australia & New Zealand: Oropharyngeal cancer is the most commonly diagnosed lip/oral/pharyngeal subsite among men, with HPV-related incidence rising since the 1980s. - Southern Europe: HPV-attributable fractions below 20%, showing that the same anatomical site can have a very different cause in a different region. **Risk factors** - Persistent oral infection with high-risk HPV, especially HPV-16 - Higher lifetime number of oral sex partners and sexual exposure history - Male sex — incidence in men is several times that in women - Cigarette smoking, which worsens prognosis in HPV-positive disease - HIV infection, organ transplantation or other immunosuppression - No prior HPV vaccination (vaccination is expected to reduce future incidence in younger cohorts) **Signs and symptoms** - A painless, often cystic lump in the upper neck (frequently the first and only sign) - Persistent sore throat or a sensation of a lump in the throat beyond 2–3 weeks - Difficulty or pain on swallowing, or pain radiating to one ear (referred otalgia) - One tonsil larger or firmer than the other, or a visible tonsil ulcer - Change in voice, muffled "hot potato" speech or new snoring - Unexplained weight loss, fatigue or a persistent cough in advanced disease **Diagnosis and staging** - Complete head and neck examination with flexible nasopharyngolaryngoscopy - Fine-needle aspiration (FNA) or core biopsy of the neck mass — not an open excisional biopsy, which can compromise later neck treatment - Biopsy of the primary site, often under anaesthesia or by transoral robotic surgery (TORS) when the primary is occult - p16 immunohistochemistry on all oropharyngeal squamous cell carcinomas, with HPV DNA/RNA in-situ hybridisation or PCR when confirmation is needed - Contrast CT and/or MRI of the neck and primary site; FDG PET-CT for nodal or distant staging - Chest CT, dental and nutritional assessment, and speech/swallow baseline before treatment AJCC 8th edition stages HPV-mediated (p16-positive) oropharyngeal cancer separately from HPV-negative disease. A patient with multiple neck nodes but a small tonsil primary can still be stage I in the HPV-positive system, which is why the p16 result must be known before the stage is assigned. **Treatment options** - Single-modality treatment for early disease: transoral surgical resection (TORS or laser) with neck dissection, or definitive radiotherapy alone - Concurrent chemoradiotherapy with cisplatin for locally advanced disease, or surgery followed by risk-adapted postoperative radiotherapy / chemoradiotherapy - Postoperative adjuvant treatment guided by margins, extranodal extension, perineural or lymphovascular invasion and number of positive nodes - IMRT (intensity-modulated radiotherapy) to reduce dose to salivary glands, mandible, swallowing muscles and spinal cord - Pembrolizumab or other PD-1 inhibitors, +/- chemotherapy, for recurrent or metastatic disease; PD-L1 CPS testing guides first-line immunotherapy use - Clinical-trial enrolment for treatment de-escalation — reduced-dose radiotherapy or cetuximab substitution should not be used outside a trial **Prognosis** HPV-positive oropharyngeal cancer has substantially better outcomes than HPV-negative disease: published five-year overall survival is about 85%, and NCCN summaries quote over 80% for locoregionally advanced HPV-positive disease. Prognosis is worse with a heavy smoking history, bulky nodal disease, extranodal extension and distant metastasis. **Prevention** - HPV vaccination with the 9-valent vaccine (routinely at age 11–12; catch-up according to national schedules) - Smoking cessation — continued smoking is associated with poorer response and higher second-primary risk - Limiting lifetime oral sexual exposures and using barrier protection - Routine dental and ENT examination, because no validated screening test exists for HPV-positive oropharyngeal cancer - Awareness that a painless neck lump lasting more than 2–3 weeks requires urgent FNA, not antibiotics **Treatment in China** Chinese tertiary head and neck centres manage HPV-positive oropharyngeal cancer with the same modality framework used internationally — transoral surgery, neck dissection, IMRT and cisplatin-based chemoradiotherapy — with pathology review and a written treatment plan before the patient travels. - Send the original pathology block or unstained slides: p16 and confirmatory HPV status must be verified before AJCC 8 staging and treatment planning. - Ask for a multidisciplinary plan in English that states whether the intent is surgery-first or chemoradiotherapy-first, and why. - Ask specifically about swallowing and speech preservation, feeding-tube policy, dental clearance and the rehabilitation available after IMRT. - Immunotherapy access and drug availability differ by hospital; confirm the exact agent, cycle schedule and price in writing before travel. Cost guidance: As a planning range only, international patients are often quoted ¥90,000–¥200,000 (about US$12,500–28,000) for surgery with neck dissection and reconstruction, and ¥120,000–¥220,000 for a full course of IMRT with concurrent chemotherapy. Immunotherapy is priced separately per cycle. These are budgeting figures, not a quotation; a written estimate requires review of your records. ### All 16 questions about HPV-Associated Oropharyngeal Cancer #### What is HPV-associated oropharyngeal cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** HPV-associated oropharyngeal cancer is a squamous cell carcinoma of the tonsils or base of tongue caused by persistent high-risk human papillomavirus, usually HPV-16. It is the fastest-growing head and neck cancer in North America and Northern Europe, often affects non-smoking men aged 40–60, and has a markedly better prognosis than HPV-negative tumours. The oropharynx includes the palatine tonsils, base of tongue, soft palate and the side and back walls of the throat. In high-income countries, most cancers here are now driven by HPV-16 rather than by tobacco and alcohol. Because the tonsil crypts can hide a very small primary tumour, the first sign is frequently a painless, cystic lump in the neck rather than a visible throat sore. HPV-positive disease is a distinct biological entity. It has a separate AJCC 8th-edition staging system, responds better to radiotherapy and chemoradiotherapy, and carries roughly 85% five-year overall survival in published cohorts. All oropharyngeal squamous cell carcinomas should be tested for p16 by immunohistochemistry; confirmatory HPV DNA or RNA testing is recommended when the result changes management or trial eligibility. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### Where in the world is HPV-associated oropharyngeal cancer most common? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** HPV-Associated Oropharyngeal Cancer is not evenly distributed: the highest-burden regions are North America, Northern Europe & Scandinavia and United Kingdom & Western Europe. In 2022 there were about 146,500 new oropharyngeal cancer cases (C01, C09–C10) worldwide (male ASR 2.6 and female ASR 0.5 per 100,000; 19.3% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from North America may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - North America: Oropharyngeal cancer made up 43.8% of all lip, oral cavity and pharyngeal cancers in the region — the highest share worldwide — and about 70% of US oropharyngeal cancers are HPV-positive. - Northern Europe & Scandinavia: HPV-attributable fractions of roughly 63% in Denmark, 72% in Sweden and 77% in Norway; Denmark and France have among the highest female ASRs. - United Kingdom & Western Europe: About 52% of UK oropharyngeal cancers are HPV-positive and incidence has surpassed that of cervical cancer among women. - Eastern Europe: Slovakia (male ASR 11.1) and Romania (10.6) reported the highest national oropharyngeal ASRs in the 2022 subsite analysis. - Australia & New Zealand: Oropharyngeal cancer is the most commonly diagnosed lip/oral/pharyngeal subsite among men, with HPV-related incidence rising since the 1980s. - Southern Europe: HPV-attributable fractions below 20%, showing that the same anatomical site can have a very different cause in a different region. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### What are the risk factors for HPV-associated oropharyngeal cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for HPV-associated oropharyngeal cancer are persistent oral infection with high-risk HPV, especially HPV-16, higher lifetime number of oral sex partners and sexual exposure history and male sex — incidence in men is several times that in women. Risks differ by region: North America has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Persistent oral infection with high-risk HPV, especially HPV-16 - Higher lifetime number of oral sex partners and sexual exposure history - Male sex — incidence in men is several times that in women - Cigarette smoking, which worsens prognosis in HPV-positive disease - HIV infection, organ transplantation or other immunosuppression - No prior HPV vaccination (vaccination is expected to reduce future incidence in younger cohorts) Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### What are the early signs of HPV-associated oropharyngeal cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a painless, often cystic lump in the upper neck (frequently the first and only sign), persistent sore throat or a sensation of a lump in the throat beyond 2–3 weeks, difficulty or pain on swallowing, or pain radiating to one ear (referred otalgia) and one tonsil larger or firmer than the other, or a visible tonsil ulcer. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A painless, often cystic lump in the upper neck (frequently the first and only sign) - Persistent sore throat or a sensation of a lump in the throat beyond 2–3 weeks - Difficulty or pain on swallowing, or pain radiating to one ear (referred otalgia) - One tonsil larger or firmer than the other, or a visible tonsil ulcer - Change in voice, muffled "hot potato" speech or new snoring - Unexplained weight loss, fatigue or a persistent cough in advanced disease Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### How is HPV-associated oropharyngeal cancer diagnosed and staged? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. AJCC 8th edition stages HPV-mediated (p16-positive) oropharyngeal cancer separately from HPV-negative disease. A patient with multiple neck nodes but a small tonsil primary can still be stage I in the HPV-positive system, which is why the p16 result must be known before the stage is assigned. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Complete head and neck examination with flexible nasopharyngolaryngoscopy - Fine-needle aspiration (FNA) or core biopsy of the neck mass — not an open excisional biopsy, which can compromise later neck treatment - Biopsy of the primary site, often under anaesthesia or by transoral robotic surgery (TORS) when the primary is occult - p16 immunohistochemistry on all oropharyngeal squamous cell carcinomas, with HPV DNA/RNA in-situ hybridisation or PCR when confirmation is needed - Contrast CT and/or MRI of the neck and primary site; FDG PET-CT for nodal or distant staging - Chest CT, dental and nutritional assessment, and speech/swallow baseline before treatment Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### What are the treatment options for HPV-associated oropharyngeal cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines single-modality treatment for early disease: transoral surgical resection (TORS or laser) with neck dissection, or definitive radiotherapy alone, concurrent chemoradiotherapy with cisplatin for locally advanced disease, or surgery followed by risk-adapted postoperative radiotherapy / chemoradiotherapy and postoperative adjuvant treatment guided by margins, extranodal extension, perineural or lymphovascular invasion and number of positive nodes. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Single-modality treatment for early disease: transoral surgical resection (TORS or laser) with neck dissection, or definitive radiotherapy alone - Concurrent chemoradiotherapy with cisplatin for locally advanced disease, or surgery followed by risk-adapted postoperative radiotherapy / chemoradiotherapy - Postoperative adjuvant treatment guided by margins, extranodal extension, perineural or lymphovascular invasion and number of positive nodes - IMRT (intensity-modulated radiotherapy) to reduce dose to salivary glands, mandible, swallowing muscles and spinal cord - Pembrolizumab or other PD-1 inhibitors, +/- chemotherapy, for recurrent or metastatic disease; PD-L1 CPS testing guides first-line immunotherapy use - Clinical-trial enrolment for treatment de-escalation — reduced-dose radiotherapy or cetuximab substitution should not be used outside a trial Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### What is the prognosis for HPV-associated oropharyngeal cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** HPV-positive oropharyngeal cancer has substantially better outcomes than HPV-negative disease: published five-year overall survival is about 85%, and NCCN summaries quote over 80% for locoregionally advanced HPV-positive disease. Prognosis is worse with a heavy smoking history, bulky nodal disease, extranodal extension and distant metastasis. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### Can HPV-associated oropharyngeal cancer be prevented? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for HPV-associated oropharyngeal cancer are HPV vaccination with the 9-valent vaccine (routinely at age 11–12; catch-up according to national schedules), smoking cessation — continued smoking is associated with poorer response and higher second-primary risk and limiting lifetime oral sexual exposures and using barrier protection. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - HPV vaccination with the 9-valent vaccine (routinely at age 11–12; catch-up according to national schedules) - Smoking cessation — continued smoking is associated with poorer response and higher second-primary risk - Limiting lifetime oral sexual exposures and using barrier protection - Routine dental and ENT examination, because no validated screening test exists for HPV-positive oropharyngeal cancer - Awareness that a painless neck lump lasting more than 2–3 weeks requires urgent FNA, not antibiotics Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### Is HPV-positive oropharyngeal cancer contagious, and does my partner need treatment? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/is-it-contagious/ Cluster: Understanding the disease **Answer:** The cancer itself is not contagious. HPV is a very common, usually transient infection that can be transmitted between partners, but a diagnosis of HPV-related cancer does not mean a partner is ill or needs cancer screening or treatment. Partners should follow routine national HPV vaccination and cervical screening guidance. Because HPV infection is widespread and often clears spontaneously, clinicians do not trace contacts or treat partners after an HPV-positive head and neck cancer diagnosis. What matters for the patient is tumour HPV status, since it determines staging and prognosis. Sources: HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV and Cancer / HPV vaccination (US Centers for Disease Control and Prevention, 2025) https://www.cdc.gov/hpv/index.html #### Why can a painless neck lump be the first sign of tonsil or base-of-tongue cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/why-neck-lump-first/ Cluster: Symptoms & diagnosis **Answer:** The tonsil and base of tongue contain deep crypts lined by specialised epithelium that is particularly susceptible to HPV. A very small primary tumour can spread early to cervical lymph nodes, which may enlarge into a soft, cystic, painless neck mass while the throat itself looks normal. A cystic neck mass in an adult should be treated as malignant until proven otherwise. Fine-needle aspiration, p16 immunocytochemistry on the aspirate, flexible endoscopy and imaging of the tonsil and tongue base are the standard work-up; repeatedly prescribing antibiotics is the most common cause of delay. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What does "p16-positive" mean, and is a second HPV test needed? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/p16-testing/ Cluster: Symptoms & diagnosis **Answer:** p16 is a protein that accumulates when HPV E7 disables the retinoblastoma pathway; p16 immunohistochemistry is the standard surrogate marker for HPV-driven oropharyngeal cancer. NCCN recommends p16 testing on every oropharyngeal squamous cell carcinoma, and confirmatory HPV DNA or RNA testing when the result will change staging, trial eligibility or a de-escalation decision. p16 alone is not perfectly specific outside the oropharynx, and a small proportion of p16-positive tumours are not truly HPV-driven. For a patient travelling for a second opinion, bring the original stained slides and the pathology report so the receiving centre can repeat or confirm the assay. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ #### Can treatment be reduced because HPV-positive cancer has a better prognosis? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/treatment-de-escalation/ Cluster: Treatment **Answer:** Not outside a clinical trial. Despite excellent survival, randomised studies that replaced cisplatin with cetuximab in HPV-positive disease showed worse overall survival, and reduced-dose radiotherapy strategies remain investigational. Current standard doses and combinations should be maintained for curative treatment. De-escalation is an active research question because long-term toxicity — chronic dysphagia, xerostomia, fibrosis and lower cranial neuropathies — matters greatly for patients who may live decades after treatment. Ask whether a trial is available rather than simply reducing treatment intensity. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### Should I receive the HPV vaccine after being diagnosed with HPV-positive cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/hpv-vaccine-after-diagnosis/ Cluster: Prevention & risk **Answer:** The HPV vaccine does not treat an existing cancer or clear an established infection. It can still protect against other vaccine-covered HPV types and is reasonable to discuss with your oncologist, particularly for younger patients, but it is not part of cancer treatment. Vaccination is most effective before exposure, which is why routine programmes target pre-adolescents. Family members and partners should follow their own national HPV vaccination schedule; that decision is independent of the patient’s treatment. Sources: HPV and Cancer / HPV vaccination (US Centers for Disease Control and Prevention, 2025) https://www.cdc.gov/hpv/index.html | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer #### What follow-up is needed after treatment for HPV-positive oropharyngeal cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/follow-up-schedule/ Cluster: Prognosis & follow-up **Answer:** NCCN survivorship guidance recommends visits every 1–3 months in year one, every 2–6 months in year two, every 4–8 months in years three to five, and annually thereafter. Each visit includes a symptom review and complete head and neck examination with endoscopy; TSH is checked every 6–12 months if the neck was irradiated. Baseline post-treatment imaging is recommended within six months for advanced T or N disease, but routine repeat imaging is not advised without symptoms or signs. Report new neck lumps, swallowing change, ear pain, weight loss or cough promptly. For patients returning home after treatment in China, ask for an English discharge summary, the full radiotherapy dose record, pathology report and a written follow-up schedule that a local oncologist can continue. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study (Journal of the National Cancer Institute, 2025) https://doi.org/10.1093/jnci/djaf033 #### What can a centre in China offer an international patient with HPV-positive tonsil cancer? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/treatment-in-china/ Cluster: Treatment in China **Answer:** A Chinese tertiary head and neck centre can provide pathology review with p16/HPV confirmation, contrast MRI and PET-CT staging, transoral resection with neck dissection, IMRT with or without cisplatin, and PD-1 immunotherapy for recurrent or metastatic disease. The practical advantage is usually short waiting times and coordinated scheduling of the full work-up. Before travelling, request a written opinion based on your scans and pathology stating the proposed modality sequence, expected inpatient days, and who will manage swallowing, nutrition and speech rehabilitation. If chemoradiotherapy rather than surgery is recommended at home, a second opinion is still useful to confirm the radiation plan and to check whether a surgical option would avoid long-term toxicity in your specific anatomy. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### How much does HPV-positive oropharyngeal cancer treatment cost in China? URL: https://www.entliu.com/conditions/hpv-oropharyngeal-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** As an illustrative planning range, surgery with neck dissection and reconstruction is commonly budgeted at ¥90,000–¥200,000 (roughly US$12,500–28,000) and definitive IMRT with concurrent chemotherapy at ¥120,000–¥220,000. Immunotherapy is charged per cycle and can substantially increase the total. These are not quotes. Costs vary with stage, hospital, length of stay, reconstruction, ICU needs, imported drugs and imaging. Ask for an itemised written estimate after your records are reviewed, and confirm what is included (pathology review, dental clearance, feeding tube, rehabilitation, interpreter, follow-up imaging). International patients normally pay directly rather than through Chinese public insurance; check whether your travel or international health policy covers overseas cancer treatment before booking flights. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Oral Cavity Cancer URL: https://www.entliu.com/conditions/oral-cavity-cancer/ Also known as: Mouth cancer; Oral squamous cell carcinoma (OSCC); Tongue cancer; Buccal mucosa cancer; Gingival and floor-of-mouth cancer Classification: ICD-O-3 C02–C06 (GLOBOCAN groups C00–C06 as lip + oral cavity) Quick answer: Oral cavity cancer is a squamous cell carcinoma arising on the tongue, floor of mouth, buccal (cheek) mucosa, gums, hard palate or retromolar region. It is the largest head and neck cancer subsite worldwide and is overwhelmingly concentrated in South Asia, where chewing tobacco, betel quid and areca nut are common. Surgery with clear margins and reconstruction is the main curative treatment. The oral cavity is the part of the mouth a dentist can see and touch. Unlike oropharyngeal cancer, most oral cavity cancers are caused by direct contact carcinogens — smoked and smokeless tobacco, areca nut, betel quid and heavy alcohol — rather than HPV. In India and neighbouring countries the tumour often starts on the buccal mucosa, exactly where the quid is held against the cheek. Because the mouth is visible, oral cancer should be detectable early. In practice many patients in high-burden countries present with locally advanced disease. A non-healing ulcer, a white or red patch, a lump or a loose tooth lasting more than two to three weeks should be biopsied, not treated repeatedly as an infection. **Global burden (2022):** about 317,500 new oral cavity cancer cases (C02–C06) (male ASR 4.6 and female ASR 2.0 per 100,000; 41.9% of all lip/oral/pharyngeal cancers in 2022). Using the wider GLOBOCAN grouping that includes lip (C00–C06), the 2022 total was 389,846 cases with an ASR of 4.0 per 100,000. **Where it is common** - India: 143,759 new oral cancer cases and 79,979 deaths in 2022 — 10.2% of all Indian cancers, ASR 10.1/100,000. Men account for ~75% (male ASR 15.6). Tobacco and areca nut explain roughly 70–80% of cases. - South-Central Asia (Bangladesh, Pakistan, Sri Lanka): Oral cavity cancer makes up 59.8% of all lip/oral/pharyngeal cancers in the region. Male ASRs: Sri Lanka 12.4, Bangladesh 12.0, Pakistan 11.3; female ASRs: Bangladesh 6.4, Pakistan 5.9. - Papua New Guinea & Melanesia: The highest female oral cavity ASR worldwide (8.1/100,000) and male ASR 9.6, linked to areca nut and betel quid chewing. - Southern Africa & parts of Western Africa: Oral cavity represents 48.8% of the lip/oral/pharyngeal burden in Southern Africa, with elevated male rates. - Southern & Eastern Europe: Oral cavity accounts for 38.8% of Southern European and 14.1% of Eastern European lip/oral/pharyngeal cancers, largely tobacco- and alcohol-related. - United States: About 58,000 Americans are diagnosed with oral cancer each year with around 12,000 deaths; substantially lower ASR than South Asia. **Risk factors** - Chewing betel quid / areca nut (with or without tobacco) — IARC Group 1 carcinogen - Smokeless tobacco products: gutka, khaini, zarda, snuff, toombak, iqmik - Cigarette, bidi or cigar smoking - Heavy alcohol use, with a multiplicative effect when combined with tobacco - Chronic mechanical irritation from a sharp tooth or ill-fitting denture - Oral potentially malignant disorders: leukoplakia, erythroplakia, oral submucous fibrosis - Prior head and neck cancer and, rarely, immunosuppression **Signs and symptoms** - A mouth ulcer or sore that does not heal within 2–3 weeks - A white patch (leukoplakia) or red patch (erythroplakia) on the tongue, cheek or gum - A lump, thickening or numbness in the tongue, cheek or floor of mouth - Restricted mouth opening or burning sensation from oral submucous fibrosis - Loose teeth, bleeding gums or a non-healing extraction socket - Pain or difficulty swallowing, altered speech, or a hard neck lump **Diagnosis and staging** - Incisional biopsy of the suspicious lesion — the only way to confirm invasive cancer - Bimanual palpation and measurement of the lesion, with photography for the record - Contrast CT or MRI of the oral cavity and neck to assess bone invasion, tongue muscle involvement and nodes - Ultrasound-guided FNA of any suspicious cervical node; chest CT / PET-CT for advanced disease - Dental panoramic radiograph, dental clearance and nutritional assessment before surgery or radiotherapy - Pathology review for depth of invasion, margins, perineural invasion, lymphovascular invasion and extranodal extension AJCC 8th edition TNM for oral cavity cancer incorporates depth of invasion (DOI) into the T category, because thicker tumours have a higher risk of occult neck metastasis. This is why even a clinically node-negative tongue cancer with DOI above 3–4 mm often receives an elective neck dissection or sentinel lymph node biopsy. **Treatment options** - Wide surgical excision with a macroscopic margin of at least 1 cm where anatomy permits, aiming for clear microscopic margins - Elective or therapeutic neck dissection (or sentinel node biopsy in selected early tongue cancers) - Immediate reconstruction — local flap, pedicled flap or microvascular free flap (radial forearm, anterolateral thigh, fibula for bone) - Postoperative radiotherapy for close/positive margins, pT3–T4, multiple nodes or perineural invasion; concurrent chemoradiotherapy for positive margins or extranodal extension - Primary radiotherapy or chemoradiotherapy for patients unfit for, or declining, major surgery - Immunotherapy (PD-1 inhibitors) and/or chemotherapy for recurrent or metastatic disease; clinical trials where available **Prognosis** Prognosis depends most on stage, margin status, depth of invasion and nodal involvement. Early, completely resected oral cavity cancers are commonly reported with five-year survival in the 70–90% range, whereas locally advanced disease with positive margins or extranodal extension is substantially worse. Population registry data from South Asia show lower survival than high-income countries, largely because of later stage at diagnosis. **Prevention** - Stop all forms of tobacco and areca nut / betel quid — the single most effective intervention - Limit alcohol, especially in combination with tobacco - Dental review to smooth sharp teeth and repair ill-fitting dentures - Regular oral examination by a dentist or trained clinician for high-risk users (visual inspection is low-cost and evidence-based) - Early biopsy or referral for any white/red patch or non-healing ulcer; treat oral submucous fibrosis early **Treatment in China** Chinese head and neck units perform a high volume of oral cancer resections with immediate microvascular free-flap reconstruction. For international patients the main practical benefits are short waiting times, combined ablative-and-reconstructive surgery in one admission, and a written English operative and follow-up plan. - Bring the original biopsy slides or block, contrast MRI/CT images on DICOM, a dental panoramic radiograph and any prior treatment records. - Ask whether reconstruction will use a free flap, what donor site is planned, and how speech, swallowing and tongue mobility will be rehabilitated. - Confirm in writing whether postoperative radiotherapy is anticipated, because that changes how long you must remain in China. - Ask about the pathology reporting standard (depth of invasion, margins, extranodal extension) so your local oncologist can continue follow-up. Cost guidance: As an illustrative planning range, wide excision with neck dissection and free-flap reconstruction is often budgeted at ¥100,000–¥220,000 (about US$14,000–30,000), with adjuvant radiotherapy or chemoradiotherapy adding ¥40,000–¥120,000. These are budgeting figures, not a quotation; an itemised estimate requires review of your imaging and pathology. ### All 15 questions about Oral Cavity Cancer #### What is oral cavity cancer? URL: https://www.entliu.com/conditions/oral-cavity-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Oral cavity cancer is a squamous cell carcinoma arising on the tongue, floor of mouth, buccal (cheek) mucosa, gums, hard palate or retromolar region. It is the largest head and neck cancer subsite worldwide and is overwhelmingly concentrated in South Asia, where chewing tobacco, betel quid and areca nut are common. Surgery with clear margins and reconstruction is the main curative treatment. The oral cavity is the part of the mouth a dentist can see and touch. Unlike oropharyngeal cancer, most oral cavity cancers are caused by direct contact carcinogens — smoked and smokeless tobacco, areca nut, betel quid and heavy alcohol — rather than HPV. In India and neighbouring countries the tumour often starts on the buccal mucosa, exactly where the quid is held against the cheek. Because the mouth is visible, oral cancer should be detectable early. In practice many patients in high-burden countries present with locally advanced disease. A non-healing ulcer, a white or red patch, a lump or a loose tooth lasting more than two to three weeks should be biopsied, not treated repeatedly as an infection. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Where in the world is oral cavity cancer most common? URL: https://www.entliu.com/conditions/oral-cavity-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Oral Cavity Cancer is not evenly distributed: the highest-burden regions are India, South-Central Asia (Bangladesh, Pakistan, Sri Lanka) and Papua New Guinea & Melanesia. In 2022 there were about 317,500 new oral cavity cancer cases (C02–C06) worldwide (male ASR 4.6 and female ASR 2.0 per 100,000; 41.9% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from India may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - India: 143,759 new oral cancer cases and 79,979 deaths in 2022 — 10.2% of all Indian cancers, ASR 10.1/100,000. Men account for ~75% (male ASR 15.6). Tobacco and areca nut explain roughly 70–80% of cases. - South-Central Asia (Bangladesh, Pakistan, Sri Lanka): Oral cavity cancer makes up 59.8% of all lip/oral/pharyngeal cancers in the region. Male ASRs: Sri Lanka 12.4, Bangladesh 12.0, Pakistan 11.3; female ASRs: Bangladesh 6.4, Pakistan 5.9. - Papua New Guinea & Melanesia: The highest female oral cavity ASR worldwide (8.1/100,000) and male ASR 9.6, linked to areca nut and betel quid chewing. - Southern Africa & parts of Western Africa: Oral cavity represents 48.8% of the lip/oral/pharyngeal burden in Southern Africa, with elevated male rates. - Southern & Eastern Europe: Oral cavity accounts for 38.8% of Southern European and 14.1% of Eastern European lip/oral/pharyngeal cancers, largely tobacco- and alcohol-related. - United States: About 58,000 Americans are diagnosed with oral cancer each year with around 12,000 deaths; substantially lower ASR than South Asia. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What are the risk factors for oral cavity cancer? URL: https://www.entliu.com/conditions/oral-cavity-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for oral cavity cancer are chewing betel quid / areca nut (with or without tobacco) — IARC Group 1 carcinogen, smokeless tobacco products: gutka, khaini, zarda, snuff, toombak, iqmik and cigarette, bidi or cigar smoking. Risks differ by region: India has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Chewing betel quid / areca nut (with or without tobacco) — IARC Group 1 carcinogen - Smokeless tobacco products: gutka, khaini, zarda, snuff, toombak, iqmik - Cigarette, bidi or cigar smoking - Heavy alcohol use, with a multiplicative effect when combined with tobacco - Chronic mechanical irritation from a sharp tooth or ill-fitting denture - Oral potentially malignant disorders: leukoplakia, erythroplakia, oral submucous fibrosis - Prior head and neck cancer and, rarely, immunosuppression Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What are the early signs of oral cavity cancer? URL: https://www.entliu.com/conditions/oral-cavity-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a mouth ulcer or sore that does not heal within 2–3 weeks, a white patch (leukoplakia) or red patch (erythroplakia) on the tongue, cheek or gum, a lump, thickening or numbness in the tongue, cheek or floor of mouth and restricted mouth opening or burning sensation from oral submucous fibrosis. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A mouth ulcer or sore that does not heal within 2–3 weeks - A white patch (leukoplakia) or red patch (erythroplakia) on the tongue, cheek or gum - A lump, thickening or numbness in the tongue, cheek or floor of mouth - Restricted mouth opening or burning sensation from oral submucous fibrosis - Loose teeth, bleeding gums or a non-healing extraction socket - Pain or difficulty swallowing, altered speech, or a hard neck lump Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### How is oral cavity cancer diagnosed and staged? URL: https://www.entliu.com/conditions/oral-cavity-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. AJCC 8th edition TNM for oral cavity cancer incorporates depth of invasion (DOI) into the T category, because thicker tumours have a higher risk of occult neck metastasis. This is why even a clinically node-negative tongue cancer with DOI above 3–4 mm often receives an elective neck dissection or sentinel lymph node biopsy. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Incisional biopsy of the suspicious lesion — the only way to confirm invasive cancer - Bimanual palpation and measurement of the lesion, with photography for the record - Contrast CT or MRI of the oral cavity and neck to assess bone invasion, tongue muscle involvement and nodes - Ultrasound-guided FNA of any suspicious cervical node; chest CT / PET-CT for advanced disease - Dental panoramic radiograph, dental clearance and nutritional assessment before surgery or radiotherapy - Pathology review for depth of invasion, margins, perineural invasion, lymphovascular invasion and extranodal extension Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What are the treatment options for oral cavity cancer? URL: https://www.entliu.com/conditions/oral-cavity-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines wide surgical excision with a macroscopic margin of at least 1 cm where anatomy permits, aiming for clear microscopic margins, elective or therapeutic neck dissection (or sentinel node biopsy in selected early tongue cancers) and immediate reconstruction — local flap, pedicled flap or microvascular free flap (radial forearm, anterolateral thigh, fibula for bone). Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Wide surgical excision with a macroscopic margin of at least 1 cm where anatomy permits, aiming for clear microscopic margins - Elective or therapeutic neck dissection (or sentinel node biopsy in selected early tongue cancers) - Immediate reconstruction — local flap, pedicled flap or microvascular free flap (radial forearm, anterolateral thigh, fibula for bone) - Postoperative radiotherapy for close/positive margins, pT3–T4, multiple nodes or perineural invasion; concurrent chemoradiotherapy for positive margins or extranodal extension - Primary radiotherapy or chemoradiotherapy for patients unfit for, or declining, major surgery - Immunotherapy (PD-1 inhibitors) and/or chemotherapy for recurrent or metastatic disease; clinical trials where available Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What is the prognosis for oral cavity cancer? URL: https://www.entliu.com/conditions/oral-cavity-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Prognosis depends most on stage, margin status, depth of invasion and nodal involvement. Early, completely resected oral cavity cancers are commonly reported with five-year survival in the 70–90% range, whereas locally advanced disease with positive margins or extranodal extension is substantially worse. Population registry data from South Asia show lower survival than high-income countries, largely because of later stage at diagnosis. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Can oral cavity cancer be prevented? URL: https://www.entliu.com/conditions/oral-cavity-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for oral cavity cancer are stop all forms of tobacco and areca nut / betel quid — the single most effective intervention, limit alcohol, especially in combination with tobacco and dental review to smooth sharp teeth and repair ill-fitting dentures. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Stop all forms of tobacco and areca nut / betel quid — the single most effective intervention - Limit alcohol, especially in combination with tobacco - Dental review to smooth sharp teeth and repair ill-fitting dentures - Regular oral examination by a dentist or trained clinician for high-risk users (visual inspection is low-cost and evidence-based) - Early biopsy or referral for any white/red patch or non-healing ulcer; treat oral submucous fibrosis early Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Why is oral cancer so common in India and South Asia? URL: https://www.entliu.com/conditions/oral-cavity-cancer/why-common-in-india/ Cluster: Understanding the disease **Answer:** Because chewing tobacco, betel quid and areca nut are widely used and are held directly against the cheek and gum for long periods. These products are IARC Group 1 carcinogens; an estimated 70–80% of Indian oral cancers are attributable to tobacco and areca nut, producing a characteristic buccal mucosa cancer pattern. More than 360 million people worldwide use smokeless tobacco, 77% of them in low- and middle-income countries, and use is increasing in Bangladesh, India and Nepal. A 2022 estimate attributed over 120,000 oral cancer cases (about 30%) to smokeless tobacco, areca nut or both. The same carcinogen explains the different anatomical pattern: "Indian oral cancer" frequently starts in the buccal mucosa, while tongue and floor-of-mouth cancers are more typical in smoking/drinking populations in Europe and North America. Sources: Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ #### When should a mouth ulcer be biopsied? URL: https://www.entliu.com/conditions/oral-cavity-cancer/two-week-rule/ Cluster: Symptoms & diagnosis **Answer:** Any oral ulcer, white or red patch, lump or unexplained loose tooth that persists for more than two to three weeks should be examined by a dentist or ENT surgeon and usually biopsied. Pain is not a reliable guide — early oral cancers are often painless, and repeated courses of antibiotics or antifungal treatment are the commonest cause of diagnostic delay. A biopsy is a small outpatient procedure. Non-healing extraction sockets, unilateral tonsil or tongue enlargement, numbness of the lower lip or chin and progressive limitation of mouth opening are additional red flags. Sources: About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What is depth of invasion and why does it change the operation? URL: https://www.entliu.com/conditions/oral-cavity-cancer/depth-of-invasion/ Cluster: Symptoms & diagnosis **Answer:** Depth of invasion (DOI) measures how far the tumour has grown downward from the surface, in millimetres. In AJCC 8th edition it upstages the T category, because thicker tongue and floor-of-mouth cancers have a much higher rate of microscopic neck-node spread even when the neck feels normal on examination. For this reason, a clinically node-negative oral cancer with a DOI beyond roughly 3–4 mm is commonly treated with an elective neck dissection or a sentinel lymph node biopsy at the same operation as the primary excision. Ask your surgeon for the DOI value in the pathology report. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### Will I need reconstructive (free-flap) surgery after oral cancer removal? URL: https://www.entliu.com/conditions/oral-cavity-cancer/free-flap-reconstruction/ Cluster: Treatment **Answer:** Larger defects of the tongue, floor of mouth or jaw usually require immediate reconstruction with a microvascular free flap — tissue transferred from the forearm, thigh or fibula with its blood vessels reconnected under a microscope. The goal is to restore speech, swallowing, tongue mobility and facial contour in the same admission as tumour removal. Small lesions may be closed directly or with a local flap. Ask the team about donor-site morbidity, tracheostomy policy, feeding tube duration, ICU stay and the rehabilitation plan before consenting. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What is oral submucous fibrosis and does it turn into cancer? URL: https://www.entliu.com/conditions/oral-cavity-cancer/oral-submucous-fibrosis/ Cluster: Prevention & risk **Answer:** Oral submucous fibrosis is a chronic, scarring condition caused mainly by areca nut chewing that progressively limits mouth opening and causes burning and stiffness. It is an oral potentially malignant disorder: a minority of cases undergo malignant transformation to squamous cell carcinoma, and the risk rises with continued areca nut use. Stopping areca nut is the essential first step. Management includes mouth-opening exercises, nutritional support for difficulty eating, regular photographic surveillance and biopsy of any new ulcer or patch. See the oral precancer topic in this knowledge base for the full surveillance approach. Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Why do some international patients choose oral cancer surgery in China? URL: https://www.entliu.com/conditions/oral-cavity-cancer/surgery-in-china/ Cluster: Treatment in China **Answer:** The usual reasons are short waiting times, high procedural volumes for oral cancer ablation and microvascular reconstruction, and lower total cost than private care in the US or Western Europe. Treatment can often begin within days of an in-person evaluation, which matters because delays in head and neck cancer surgery worsen outcomes. Ask for a written, English-language plan that names the planned resection, neck dissection levels, flap type, expected hospital stay, anticipated adjuvant radiotherapy and the criteria used to decide it. Also confirm how the pathology specimen will be reported (margins, DOI, extranodal extension). Do not travel on the basis of a cost estimate alone. A remote review of your biopsy and MRI should come first, and urgent airway-obstructing tumours need local stabilisation before any long flight. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What does oral cancer surgery in China cost for an international patient? URL: https://www.entliu.com/conditions/oral-cavity-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** As a planning range, wide excision with neck dissection and free-flap reconstruction is commonly budgeted at ¥100,000–¥220,000 (roughly US$14,000–30,000), with adjuvant radiotherapy or chemoradiotherapy adding ¥40,000–¥120,000. Costs vary widely with stage, flap type, ICU stay and complications. These figures are not a quotation. Request an itemised estimate that separates surgery, anaesthesia, flap monitoring/ICU, pathology, imaging, dental clearance, radiotherapy, drugs, interpreter services and accommodation. International patients usually pay directly; confirm insurance coverage before travel. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Nasopharyngeal Carcinoma URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/ Also known as: NPC; Nasopharyngeal cancer; Nasopharynx cancer Classification: ICD-O-3 C11 Quick answer: Nasopharyngeal carcinoma is an Epstein–Barr virus-associated cancer arising in the upper throat behind the nose. It is rare in most Western countries but endemic in Southeast Asia, southern China and parts of North Africa. Because of its deep location and radiosensitivity, intensity-modulated radiotherapy — not surgery — is the primary curative treatment, with chemotherapy added for locally advanced disease. The nasopharynx sits behind the nasal cavity and above the oropharynx; a small tumour there can be invisible on routine mouth examination. Endemic NPC is usually the non-keratinising subtype and is closely linked to Epstein–Barr virus (EBV), genetic susceptibility and childhood dietary exposures such as salt-preserved fish. Plasma EBV DNA is used both for risk assessment and for monitoring treatment response and recurrence. NPC differs from other head and neck cancers in three clinically important ways: it is highly radiosensitive and chemosensitive, it has a high rate of neck-node involvement at diagnosis, and surgery is reserved for residual or recurrent disease rather than for initial treatment. A painless upper-neck lump or unilateral middle-ear effusion in an adult from an endemic region should trigger nasopharyngoscopy. **Global burden (2022):** 120,434 new nasopharyngeal cancer cases worldwide (ASR 1.3 per 100,000 (men 1.9, women 0.7); 15.9% of lip/oral/pharyngeal cancers in 2022). 73,482 deaths worldwide in 2022; 61,442 (83.6%) in Asia. NPC was the most common lip/oral/pharyngeal subsite in South-Eastern Asia (50.8% of the regional burden), Northern Africa (41.8%) and Eastern Asia (36.9%). **Where it is common** - South-East Asia: 50.8% of all lip/oral/pharyngeal cancers in the region; ~35,889 cases in 2022. Highest national ASRs: Brunei 6.4, Indonesia 6.1, Malaysia 5.9, Singapore 5.4, Vietnam 4.7, Philippines 3.5. Male ASRs reach 9.6 in Indonesia and 8.9 in Malaysia. - East Asia / southern China: China recorded 51,010 cases (about 51% of the world total) with an ASR of 2.4; incidence is far higher in southern provinces such as Guangdong and Guangxi than in the north. - Northern Africa & the Middle East: NPC is the leading lip/oral/pharyngeal subsite in Northern Africa (41.8%). Algeria recorded 1,608 cases with an ASR of 3.5 (4.8 in men) and 971 deaths; Morocco, Tunisia, Egypt and Sudan also have intermediate endemic rates. - South Asia: Maldives had the highest reported ASR worldwide (7.5) but only 36 cases, illustrating how small populations can produce unstable rates. India had 6,519 cases at ASR 0.5. - North America & Europe: Rare: US ASR about 0.4 with 2,008 cases; Europe 4,513 cases. Western cases are more often keratinising and more often tobacco/alcohol associated. **Risk factors** - Epstein–Barr virus infection and high or persistently detectable plasma EBV DNA - Family clustering and inherited HLA / genetic susceptibility in endemic populations - Frequent consumption of salt-preserved fish and cured foods, especially in childhood - Cigarette smoking and heavy alcohol use (stronger association with the keratinising subtype) - Occupational exposure to wood dust, formaldehyde and certain solvents - Male sex — incidence is roughly two to three times higher in men **Signs and symptoms** - A painless lump in the upper neck (the most common presenting sign) - Unilateral nasal obstruction, discharge or nosebleeds - One-sided middle-ear effusion, muffled hearing, tinnitus or a blocked-ear sensation in an adult - Persistent headache, facial numbness or double vision from skull-base involvement - Sore throat, changes in voice, or difficulty opening the mouth in advanced disease - Unexplained weight loss; rarely, cranial nerve palsies affecting eye movement **Diagnosis and staging** - Nasal endoscopy / nasopharyngoscopy with biopsy of the primary lesion - MRI of the nasopharynx and neck with contrast — the key test for skull-base, parapharyngeal and nodal extension - Plasma EBV DNA quantification before treatment (prognostic and useful for surveillance) - FDG PET-CT or chest/abdominal imaging for N3 or metastatic staging; baseline audiometry and dental assessment - Pathology classified by WHO subtype (keratinising vs non-keratinising), with EBV-encoded RNA (EBER) in-situ hybridisation when needed - FNA rather than open biopsy for a neck mass when NPC is suspected NPC uses a separate AJCC/UICC TNM staging system reflecting its distinct behaviour: early T1 disease can already have bulky nodal involvement, and skull-base or cranial nerve involvement defines T3/T4. Stage I is treated with radiotherapy alone; stage II with radiotherapy ± concurrent chemotherapy; stage III–IVA with induction chemotherapy plus concurrent chemoradiotherapy in current Chinese and international practice. **Treatment options** - Intensity-modulated radiotherapy (IMRT) as the definitive treatment — typically 33 fractions over 6–7 weeks - Stage I: IMRT alone; Stage II: IMRT with or without concurrent cisplatin-based chemotherapy - Locally advanced (Stage III–IVA): induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy - Anti-EGFR (nimotuzumab) or PD-1 immunotherapy (toripalimab, camrelizumab, pembrolizumab) in selected protocols and in recurrent/metastatic disease, per regional guidelines - Salvage surgery or re-irradiation for local recurrence; systemic therapy for distant metastasis - Supportive care: nasal irrigation, mouth-opening and neck exercises, skin and oral care, nutrition and swallowing support **Prognosis** Because NPC is highly radiosensitive, stage I disease has five-year survival commonly above 90%, and modern IMRT series report good control for locoregionally advanced disease. Prognosis worsens with bulky nodal disease, skull-base invasion, high pre-treatment EBV DNA, detectable EBV DNA after treatment and distant metastasis. Over 90% of recurrences occur within five years, so structured follow-up matters. **Prevention** - Reduce childhood consumption of salt-preserved fish and cured meats in endemic communities - Avoid smoking and heavy alcohol use - There is currently no licensed EBV vaccine; EBV DNA and antibody screening is a research/ high-risk-region strategy, not routine worldwide - Early nasopharyngoscopy for persistent unilateral nasal or ear symptoms in endemic regions - Prompt evaluation of a painless upper-neck lump rather than a trial of antibiotics **Treatment in China** China treats the largest number of NPC patients in the world, so endemic-region centres have deep experience with IMRT planning, induction chemotherapy, EBV DNA monitoring and salvage surgery for recurrence. For international patients, the full diagnostic work-up and a 6–7 week radiotherapy course can usually be scheduled without a long wait. - Bring the original biopsy slides/blocks, MRI DICOM files, EBV DNA results and any prior chemotherapy or radiotherapy records. - Ask for the written radiotherapy prescription (total dose, fraction number, target volumes) and the chemotherapy schedule in English. - Discuss the monitoring plan: EBV DNA at defined intervals, nasopharyngoscopy, MRI, and thyroid/ hearing checks after neck irradiation. - Plan for a 7–10 week stay if radiotherapy is part of treatment, plus time for dental clearance and a post-treatment response scan. Cost guidance: The original guidance on this site quoted ¥80,000–¥150,000 (about US$11,000–21,000) for a full NPC treatment course; as a planning range for 2026, ¥90,000–¥180,000 for IMRT with chemotherapy is more realistic, with targeted agents or immunotherapy charged separately per cycle. These figures are illustrative budgeting numbers, not a quotation. ### All 15 questions about Nasopharyngeal Carcinoma #### What is nasopharyngeal carcinoma? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/what-is-it/ Cluster: Understanding the disease **Answer:** Nasopharyngeal carcinoma is an Epstein–Barr virus-associated cancer arising in the upper throat behind the nose. It is rare in most Western countries but endemic in Southeast Asia, southern China and parts of North Africa. Because of its deep location and radiosensitivity, intensity-modulated radiotherapy — not surgery — is the primary curative treatment, with chemotherapy added for locally advanced disease. The nasopharynx sits behind the nasal cavity and above the oropharynx; a small tumour there can be invisible on routine mouth examination. Endemic NPC is usually the non-keratinising subtype and is closely linked to Epstein–Barr virus (EBV), genetic susceptibility and childhood dietary exposures such as salt-preserved fish. Plasma EBV DNA is used both for risk assessment and for monitoring treatment response and recurrence. NPC differs from other head and neck cancers in three clinically important ways: it is highly radiosensitive and chemosensitive, it has a high rate of neck-node involvement at diagnosis, and surgery is reserved for residual or recurrent disease rather than for initial treatment. A painless upper-neck lump or unilateral middle-ear effusion in an adult from an endemic region should trigger nasopharyngoscopy. Sources: Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### Where in the world is nasopharyngeal carcinoma most common? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/where-is-it-common/ Cluster: Understanding the disease **Answer:** Nasopharyngeal Carcinoma is not evenly distributed: the highest-burden regions are South-East Asia, East Asia / southern China and Northern Africa & the Middle East. In 2022 there were 120,434 new nasopharyngeal cancer cases worldwide worldwide (ASR 1.3 per 100,000 (men 1.9, women 0.7); 15.9% of lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from South-East Asia may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - South-East Asia: 50.8% of all lip/oral/pharyngeal cancers in the region; ~35,889 cases in 2022. Highest national ASRs: Brunei 6.4, Indonesia 6.1, Malaysia 5.9, Singapore 5.4, Vietnam 4.7, Philippines 3.5. Male ASRs reach 9.6 in Indonesia and 8.9 in Malaysia. - East Asia / southern China: China recorded 51,010 cases (about 51% of the world total) with an ASR of 2.4; incidence is far higher in southern provinces such as Guangdong and Guangxi than in the north. - Northern Africa & the Middle East: NPC is the leading lip/oral/pharyngeal subsite in Northern Africa (41.8%). Algeria recorded 1,608 cases with an ASR of 3.5 (4.8 in men) and 971 deaths; Morocco, Tunisia, Egypt and Sudan also have intermediate endemic rates. - South Asia: Maldives had the highest reported ASR worldwide (7.5) but only 36 cases, illustrating how small populations can produce unstable rates. India had 6,519 cases at ASR 0.5. - North America & Europe: Rare: US ASR about 0.4 with 2,008 cases; Europe 4,513 cases. Western cases are more often keratinising and more often tobacco/alcohol associated. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### What are the risk factors for nasopharyngeal carcinoma? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for nasopharyngeal carcinoma are epstein–Barr virus infection and high or persistently detectable plasma EBV DNA, family clustering and inherited HLA / genetic susceptibility in endemic populations and frequent consumption of salt-preserved fish and cured foods, especially in childhood. Risks differ by region: South-East Asia has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Epstein–Barr virus infection and high or persistently detectable plasma EBV DNA - Family clustering and inherited HLA / genetic susceptibility in endemic populations - Frequent consumption of salt-preserved fish and cured foods, especially in childhood - Cigarette smoking and heavy alcohol use (stronger association with the keratinising subtype) - Occupational exposure to wood dust, formaldehyde and certain solvents - Male sex — incidence is roughly two to three times higher in men Sources: Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### What are the early signs of nasopharyngeal carcinoma? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a painless lump in the upper neck (the most common presenting sign), unilateral nasal obstruction, discharge or nosebleeds, one-sided middle-ear effusion, muffled hearing, tinnitus or a blocked-ear sensation in an adult and persistent headache, facial numbness or double vision from skull-base involvement. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A painless lump in the upper neck (the most common presenting sign) - Unilateral nasal obstruction, discharge or nosebleeds - One-sided middle-ear effusion, muffled hearing, tinnitus or a blocked-ear sensation in an adult - Persistent headache, facial numbness or double vision from skull-base involvement - Sore throat, changes in voice, or difficulty opening the mouth in advanced disease - Unexplained weight loss; rarely, cranial nerve palsies affecting eye movement Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### How is nasopharyngeal carcinoma diagnosed and staged? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. NPC uses a separate AJCC/UICC TNM staging system reflecting its distinct behaviour: early T1 disease can already have bulky nodal involvement, and skull-base or cranial nerve involvement defines T3/T4. Stage I is treated with radiotherapy alone; stage II with radiotherapy ± concurrent chemotherapy; stage III–IVA with induction chemotherapy plus concurrent chemoradiotherapy in current Chinese and international practice. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Nasal endoscopy / nasopharyngoscopy with biopsy of the primary lesion - MRI of the nasopharynx and neck with contrast — the key test for skull-base, parapharyngeal and nodal extension - Plasma EBV DNA quantification before treatment (prognostic and useful for surveillance) - FDG PET-CT or chest/abdominal imaging for N3 or metastatic staging; baseline audiometry and dental assessment - Pathology classified by WHO subtype (keratinising vs non-keratinising), with EBV-encoded RNA (EBER) in-situ hybridisation when needed - FNA rather than open biopsy for a neck mass when NPC is suspected Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### What are the treatment options for nasopharyngeal carcinoma? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines intensity-modulated radiotherapy (IMRT) as the definitive treatment — typically 33 fractions over 6–7 weeks, stage I: IMRT alone; Stage II: IMRT with or without concurrent cisplatin-based chemotherapy and locally advanced (Stage III–IVA): induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Intensity-modulated radiotherapy (IMRT) as the definitive treatment — typically 33 fractions over 6–7 weeks - Stage I: IMRT alone; Stage II: IMRT with or without concurrent cisplatin-based chemotherapy - Locally advanced (Stage III–IVA): induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy - Anti-EGFR (nimotuzumab) or PD-1 immunotherapy (toripalimab, camrelizumab, pembrolizumab) in selected protocols and in recurrent/metastatic disease, per regional guidelines - Salvage surgery or re-irradiation for local recurrence; systemic therapy for distant metastasis - Supportive care: nasal irrigation, mouth-opening and neck exercises, skin and oral care, nutrition and swallowing support Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### What is the prognosis for nasopharyngeal carcinoma? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/prognosis/ Cluster: Prognosis & follow-up **Answer:** Because NPC is highly radiosensitive, stage I disease has five-year survival commonly above 90%, and modern IMRT series report good control for locoregionally advanced disease. Prognosis worsens with bulky nodal disease, skull-base invasion, high pre-treatment EBV DNA, detectable EBV DNA after treatment and distant metastasis. Over 90% of recurrences occur within five years, so structured follow-up matters. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### Can nasopharyngeal carcinoma be prevented? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for nasopharyngeal carcinoma are reduce childhood consumption of salt-preserved fish and cured meats in endemic communities, avoid smoking and heavy alcohol use and there is currently no licensed EBV vaccine; EBV DNA and antibody screening is a research/ high-risk-region strategy, not routine worldwide. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Reduce childhood consumption of salt-preserved fish and cured meats in endemic communities - Avoid smoking and heavy alcohol use - There is currently no licensed EBV vaccine; EBV DNA and antibody screening is a research/ high-risk-region strategy, not routine worldwide - Early nasopharyngoscopy for persistent unilateral nasal or ear symptoms in endemic regions - Prompt evaluation of a painless upper-neck lump rather than a trial of antibiotics Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### Why is nasopharyngeal carcinoma treated with radiotherapy rather than surgery? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/why-radiotherapy-not-surgery/ Cluster: Treatment **Answer:** The nasopharynx lies deep behind the nose, close to the skull base, major blood vessels and cranial nerves, so wide surgical removal is rarely feasible at diagnosis. Non-keratinising NPC is also exceptionally radiosensitive and chemosensitive, making IMRT with or without chemotherapy the curative standard. Surgery is reserved for residual or locally recurrent disease. IMRT shapes the radiation dose around the tumour while limiting dose to the salivary glands, brainstem, spinal cord, temporal lobes, mandible and eyes. A typical curative course is about 33 weekday fractions over six to seven weeks. Sources: Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What does the EBV DNA blood test tell me? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/ebv-dna-test/ Cluster: Symptoms & diagnosis **Answer:** Plasma EBV DNA reflects tumour-derived viral DNA in the bloodstream. A high pre-treatment level is associated with more advanced disease and higher recurrence risk; a level that becomes undetectable after treatment suggests a good response, while a rising level on follow-up can signal recurrence before it is visible on imaging. It is not a standalone diagnostic test and not all patients have detectable levels — roughly 40% of NPC patients can be EBV DNA negative in some series. It should be interpreted alongside nasopharyngoscopy, MRI and, when indicated, PET-CT. Sources: Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) (World Cancer Research Fund International, 2022) https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ #### What side effects should I expect during IMRT for nasopharyngeal cancer? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/radiotherapy-side-effects/ Cluster: Side effects & recovery **Answer:** Common acute effects are skin redness and peeling on the neck, dry mouth and thickened saliva, taste loss, mouth sores, fatigue, nasal congestion and temporary hearing changes from middle-ear fluid. Most improve over weeks to months; dry mouth and reduced taste can persist six to twelve months or longer. Long-term considerations include xerostomia, dental caries risk, trismus (reduced mouth opening), neck fibrosis, hypothyroidism and, rarely, temporal lobe injury or skull-base osteoradionecrosis. Daily mouth-opening and neck exercises, nasal saline irrigation, meticulous dental care with fluoride, and early swallowing therapy materially reduce long-term problems. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### How is recurrence detected after nasopharyngeal cancer treatment? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/follow-up-and-recurrence/ Cluster: Prognosis & follow-up **Answer:** Follow-up combines symptom review, nasopharyngoscopy, neck examination, serial plasma EBV DNA and periodic MRI of the nasopharynx and neck; PET-CT is used when recurrence or distant metastasis is suspected. More than 90% of recurrences appear within five years, so visits are most frequent in the first two to three years. New headache, nosebleeds, facial numbness, double vision, a new neck lump or a rising EBV DNA level should be assessed promptly. Salvage surgery, re-irradiation or systemic therapy may still be curative or disease-controlling in selected local recurrences, which is a reason to keep follow-up even after a good initial response. Sources: Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Is nasopharyngeal carcinoma hereditary or contagious? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/is-it-hereditary-or-contagious/ Cluster: Understanding the disease **Answer:** NPC is not contagious in the ordinary sense, although EBV infection is extremely common worldwide and is transmitted through saliva. It is not a classic inherited cancer, but familial clustering and specific HLA and genetic variants contribute to the striking ethnic and geographic pattern, alongside childhood diet and environmental exposures. Most people infected with EBV never develop NPC. First-degree relatives in endemic regions may be offered awareness of symptoms or enrolment in local screening studies, but there is no routine genetic test recommended for the general population. Sources: Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities (Frontiers / British Journal of Biomedical Science partnership, 2025) https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ #### What does a full nasopharyngeal cancer treatment course in China involve? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/treatment-in-china/ Cluster: Treatment in China **Answer:** It typically involves one to two weeks of staging and pre-treatment preparation (MRI, PET-CT if indicated, EBV DNA, dental clearance, audiometry, nutrition), two to three cycles of induction chemotherapy when indicated, then six to seven weeks of daily IMRT with concurrent chemotherapy, followed by a response assessment and a written follow-up plan. Ask the centre to state in English who manages acute side effects, what happens if blood counts fall, whether a feeding tube is anticipated, and what records will be provided for your oncologist at home. Planning on 8–12 weeks in China is realistic for locally advanced disease. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### How much does nasopharyngeal carcinoma treatment cost in China? URL: https://www.entliu.com/conditions/nasopharyngeal-carcinoma/cost-in-china/ Cluster: Treatment in China **Answer:** As an illustrative planning range, IMRT with concurrent chemotherapy is commonly budgeted at ¥90,000–¥180,000 (roughly US$12,500–25,000). Induction chemotherapy, nimotuzumab, PD-1 immunotherapy, PET-CT and management of complications are additional. These are budgeting figures, not a quotation. The earlier version of this site quoted ¥80,000–¥150,000 (US$11,000–21,000). Costs have changed with newer agents and longer survival, so obtain an itemised written estimate after your stage and EBV DNA results are reviewed, and confirm whether it includes imaging, laboratory monitoring and dental care. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Laryngeal Cancer URL: https://www.entliu.com/conditions/laryngeal-cancer/ Also known as: Voice box cancer; Glottic cancer; Supraglottic cancer; Laryngeal squamous cell carcinoma Classification: ICD-10 C32 Quick answer: Laryngeal cancer is a squamous cell carcinoma of the voice box, usually arising on the vocal cords (glottic), above them (supraglottic) or below (subglottic). It is strongly caused by tobacco and alcohol and is concentrated in Eastern/Southern Europe, the Caribbean and parts of South America. Persistent hoarseness is the classic early sign, and voice-preserving treatment is often possible. Glottic cancers tend to cause hoarseness while still small, so they are often diagnosed earlier than other head and neck cancers and can be cured with a single modality — either radiotherapy or a voice-sparing partial laryngectomy. Supraglottic cancers are more likely to present late with a neck lump, swallowing pain or referred ear pain because the rich lymph drainage of the supraglottis allows early nodal spread. The central treatment decision in locally advanced disease is larynx preservation with concurrent chemoradiotherapy versus total laryngectomy with postoperative radiotherapy. Both can be curative; the choice depends on tumour extent, cartilage invasion, vocal cord fixation, airway status, lung function, swallowing function and the patient's ability to complete and tolerate chemoradiotherapy. **Global burden (2022):** 189,191 new laryngeal cancer cases worldwide (ASR 1.9 per 100,000 (men 3.5, women 0.4); 165,794 cases in men and 23,397 in women). about 103,359 deaths in 2022 (ASR 1.0 per 100,000). Glottic tumours predominate in registry data, accounting for 65–96% of male laryngeal cancers in registries reporting subsite. **Where it is common** - Caribbean & Cuba: Cuba had the highest estimated male ASR worldwide (14.8/100,000) in the GLOBOCAN 2022 comparison, reflecting historical heavy smoking and alcohol exposure. - Eastern Europe: Moldova (12.2) and Romania (10.3) had the next-highest male ASRs; Hungary, Slovakia, Lithuania, Belarus and Russia also carry high burdens, and Lithuania and Belarus show rising male trends. - Southern & Western Europe: Spain has long reported some of the highest regional rates (approaching 20/100,000 in some series), with France, Italy and Portugal (Azores registry ASR 11.8) also elevated. - Brazil & parts of South America: Brazil recorded 7,191 male cases in 2022 and is among the countries with the largest absolute burden; Colombia shows an increasing male trend. - South Asia: India has a substantial burden linked to bidi smoking and smokeless tobacco; the Karul registry reported male ASR 10.6. - China: China had the largest absolute number of male cases (27,169 in 2022), so Chinese head and neck units see high volumes of both partial and total laryngectomy. **Risk factors** - Cigarette, cigar, pipe or bidi smoking — the dominant and most preventable cause - Heavy alcohol use, which acts synergistically with tobacco - Combined tobacco and alcohol exposure (the highest cumulative risk) - Occupational exposures: asbestos, sulfuric acid mist, diesel fumes, coal dust and machining fluids - Gastro-oesophageal reflux disease and diets low in fruit and vegetables (weaker associations) - Male sex and older age; most cases are diagnosed in the 60–70 age group **Signs and symptoms** - Hoarseness or a change in voice lasting more than 2–3 weeks (classic for glottic cancer) - Persistent sore throat, pain on swallowing or pain referred to one ear - A lump in the neck (more typical of supraglottic tumours) - Difficulty swallowing, choking or coughing when eating - Coughing up blood, noisy breathing (stridor) or progressive breathlessness in advanced disease - Unexplained weight loss and reduced exercise tolerance **Diagnosis and staging** - Flexible laryngoscopy / stroboscopy in clinic to visualise vocal cord mobility and lesion extent - Direct laryngoscopy and biopsy under general anaesthesia for tissue diagnosis - Contrast CT or MRI of the larynx and neck to assess cartilage, paraglottic space and nodes - FDG PET-CT and chest imaging for advanced disease; FNA of suspicious neck nodes - Assessment of airway, pulmonary function, nutrition, speech/swallow baseline and dental status - Multidisciplinary tumour board review to decide larynx preservation versus surgery TNM staging separates glottic, supraglottic and subglottic primaries. Vocal cord fixation, cartilage invasion and subglottic extension upstage a tumour and reduce the chance of a functional partial laryngectomy; T4a disease with cartilage invasion is usually treated with total laryngectomy or definitive chemoradiotherapy depending on functional criteria. **Treatment options** - Carcinoma in situ and T1–T2 glottic cancer: definitive radiotherapy or transoral laser / partial laryngectomy — both aim to preserve voice - Selected supraglottic T1–T2: supraglottic partial laryngectomy or radiotherapy with neck management - Locally advanced resectable disease: total laryngectomy with neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy - Larynx-preservation protocols: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy (TPF) followed by radiotherapy in responders - Postoperative concurrent chemoradiotherapy for positive margins or extranodal extension - Recurrent/metastatic disease: PD-1 immunotherapy, chemotherapy, targeted therapy or clinical trials; best supportive care when appropriate **Prognosis** Early glottic cancer has excellent control: single-modality treatment is associated with roughly 70–90% five-year survival in guideline summaries, and many patients keep a serviceable voice. Overall global five-year survival is around 60%, falling sharply for advanced T4, node-positive or metastatic disease. Continuing to smoke after treatment increases recurrence and second-primary risk. **Prevention** - Stop smoking completely — the single most effective measure, and important even after diagnosis - Reduce or stop heavy alcohol use, particularly in combination with tobacco - Use respiratory protection and workplace controls for asbestos, acid mist, dust and fumes - Have hoarseness lasting more than 2–3 weeks assessed by an ENT specialist with laryngoscopy - Maintain good nutrition and manage reflux; neither substitutes for tobacco cessation **Treatment in China** Because China has one of the world’s largest absolute numbers of laryngeal cancer cases, specialist units perform high volumes of transoral laser surgery, partial laryngectomy, total laryngectomy and neck dissection, with speech rehabilitation and tracheoesophageal voice restoration available. - Bring the biopsy slides, laryngoscopy images/video, contrast CT or MRI on DICOM, and any pulmonary function and swallowing assessments. - Ask explicitly whether the plan is voice-preserving (radiotherapy / partial laryngectomy) or total laryngectomy, and what functional outcome is expected for speech and swallowing. - If total laryngectomy is planned, ask about primary or secondary tracheoesophageal puncture, voice prosthesis availability in your home country and stoma care training. - Request the radiotherapy dose record and pathology details (margins, cartilage invasion, extranodal extension) in English for your local team. Cost guidance: As an illustrative planning range, transoral laser or partial laryngectomy is often budgeted at ¥50,000–¥110,000 (about US$7,000–15,000); total laryngectomy with neck dissection and reconstruction ¥90,000–¥180,000; definitive chemoradiotherapy ¥100,000–¥200,000. These are budgeting figures, not a quotation. ### All 14 questions about Laryngeal Cancer #### What is laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Laryngeal cancer is a squamous cell carcinoma of the voice box, usually arising on the vocal cords (glottic), above them (supraglottic) or below (subglottic). It is strongly caused by tobacco and alcohol and is concentrated in Eastern/Southern Europe, the Caribbean and parts of South America. Persistent hoarseness is the classic early sign, and voice-preserving treatment is often possible. Glottic cancers tend to cause hoarseness while still small, so they are often diagnosed earlier than other head and neck cancers and can be cured with a single modality — either radiotherapy or a voice-sparing partial laryngectomy. Supraglottic cancers are more likely to present late with a neck lump, swallowing pain or referred ear pain because the rich lymph drainage of the supraglottis allows early nodal spread. The central treatment decision in locally advanced disease is larynx preservation with concurrent chemoradiotherapy versus total laryngectomy with postoperative radiotherapy. Both can be curative; the choice depends on tumour extent, cartilage invasion, vocal cord fixation, airway status, lung function, swallowing function and the patient's ability to complete and tolerate chemoradiotherapy. Sources: Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### Where in the world is laryngeal cancer most common? URL: https://www.entliu.com/conditions/laryngeal-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Laryngeal Cancer is not evenly distributed: the highest-burden regions are Caribbean & Cuba, Eastern Europe and Southern & Western Europe. In 2022 there were 189,191 new laryngeal cancer cases worldwide worldwide (ASR 1.9 per 100,000 (men 3.5, women 0.4); 165,794 cases in men and 23,397 in women), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from Caribbean & Cuba may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - Caribbean & Cuba: Cuba had the highest estimated male ASR worldwide (14.8/100,000) in the GLOBOCAN 2022 comparison, reflecting historical heavy smoking and alcohol exposure. - Eastern Europe: Moldova (12.2) and Romania (10.3) had the next-highest male ASRs; Hungary, Slovakia, Lithuania, Belarus and Russia also carry high burdens, and Lithuania and Belarus show rising male trends. - Southern & Western Europe: Spain has long reported some of the highest regional rates (approaching 20/100,000 in some series), with France, Italy and Portugal (Azores registry ASR 11.8) also elevated. - Brazil & parts of South America: Brazil recorded 7,191 male cases in 2022 and is among the countries with the largest absolute burden; Colombia shows an increasing male trend. - South Asia: India has a substantial burden linked to bidi smoking and smokeless tobacco; the Karul registry reported male ASR 10.6. - China: China had the largest absolute number of male cases (27,169 in 2022), so Chinese head and neck units see high volumes of both partial and total laryngectomy. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### What are the risk factors for laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for laryngeal cancer are cigarette, cigar, pipe or bidi smoking — the dominant and most preventable cause, heavy alcohol use, which acts synergistically with tobacco and combined tobacco and alcohol exposure (the highest cumulative risk). Risks differ by region: Caribbean & Cuba has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Cigarette, cigar, pipe or bidi smoking — the dominant and most preventable cause - Heavy alcohol use, which acts synergistically with tobacco - Combined tobacco and alcohol exposure (the highest cumulative risk) - Occupational exposures: asbestos, sulfuric acid mist, diesel fumes, coal dust and machining fluids - Gastro-oesophageal reflux disease and diets low in fruit and vegetables (weaker associations) - Male sex and older age; most cases are diagnosed in the 60–70 age group Sources: Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### What are the early signs of laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are hoarseness or a change in voice lasting more than 2–3 weeks (classic for glottic cancer), persistent sore throat, pain on swallowing or pain referred to one ear, a lump in the neck (more typical of supraglottic tumours) and difficulty swallowing, choking or coughing when eating. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - Hoarseness or a change in voice lasting more than 2–3 weeks (classic for glottic cancer) - Persistent sore throat, pain on swallowing or pain referred to one ear - A lump in the neck (more typical of supraglottic tumours) - Difficulty swallowing, choking or coughing when eating - Coughing up blood, noisy breathing (stridor) or progressive breathlessness in advanced disease - Unexplained weight loss and reduced exercise tolerance Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### How is laryngeal cancer diagnosed and staged? URL: https://www.entliu.com/conditions/laryngeal-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. TNM staging separates glottic, supraglottic and subglottic primaries. Vocal cord fixation, cartilage invasion and subglottic extension upstage a tumour and reduce the chance of a functional partial laryngectomy; T4a disease with cartilage invasion is usually treated with total laryngectomy or definitive chemoradiotherapy depending on functional criteria. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Flexible laryngoscopy / stroboscopy in clinic to visualise vocal cord mobility and lesion extent - Direct laryngoscopy and biopsy under general anaesthesia for tissue diagnosis - Contrast CT or MRI of the larynx and neck to assess cartilage, paraglottic space and nodes - FDG PET-CT and chest imaging for advanced disease; FNA of suspicious neck nodes - Assessment of airway, pulmonary function, nutrition, speech/swallow baseline and dental status - Multidisciplinary tumour board review to decide larynx preservation versus surgery Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### What are the treatment options for laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines carcinoma in situ and T1–T2 glottic cancer: definitive radiotherapy or transoral laser / partial laryngectomy — both aim to preserve voice, selected supraglottic T1–T2: supraglottic partial laryngectomy or radiotherapy with neck management and locally advanced resectable disease: total laryngectomy with neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Carcinoma in situ and T1–T2 glottic cancer: definitive radiotherapy or transoral laser / partial laryngectomy — both aim to preserve voice - Selected supraglottic T1–T2: supraglottic partial laryngectomy or radiotherapy with neck management - Locally advanced resectable disease: total laryngectomy with neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy - Larynx-preservation protocols: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy (TPF) followed by radiotherapy in responders - Postoperative concurrent chemoradiotherapy for positive margins or extranodal extension - Recurrent/metastatic disease: PD-1 immunotherapy, chemotherapy, targeted therapy or clinical trials; best supportive care when appropriate Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### What is the prognosis for laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Early glottic cancer has excellent control: single-modality treatment is associated with roughly 70–90% five-year survival in guideline summaries, and many patients keep a serviceable voice. Overall global five-year survival is around 60%, falling sharply for advanced T4, node-positive or metastatic disease. Continuing to smoke after treatment increases recurrence and second-primary risk. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### Can laryngeal cancer be prevented? URL: https://www.entliu.com/conditions/laryngeal-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for laryngeal cancer are stop smoking completely — the single most effective measure, and important even after diagnosis, reduce or stop heavy alcohol use, particularly in combination with tobacco and use respiratory protection and workplace controls for asbestos, acid mist, dust and fumes. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Stop smoking completely — the single most effective measure, and important even after diagnosis - Reduce or stop heavy alcohol use, particularly in combination with tobacco - Use respiratory protection and workplace controls for asbestos, acid mist, dust and fumes - Have hoarseness lasting more than 2–3 weeks assessed by an ENT specialist with laryngoscopy - Maintain good nutrition and manage reflux; neither substitutes for tobacco cessation Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 #### Will I lose my voice or my voice box if I have laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/will-i-lose-my-voice/ Cluster: Treatment **Answer:** Not necessarily. Early glottic cancer is usually cured with radiotherapy or a voice-sparing partial laryngectomy, and many patients retain a usable voice. Total laryngectomy is generally reserved for advanced tumours with cord fixation, cartilage invasion or disease that recurs after organ-preserving treatment. Even after total laryngectomy, speech can be restored with a tracheoesophageal puncture and voice prosthesis, an electrolarynx, or oesophageal speech. Ask for a preoperative meeting with a speech-language pathologist to understand the options before consenting. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### Is chemoradiotherapy as good as removing the larynx for advanced disease? URL: https://www.entliu.com/conditions/laryngeal-cancer/larynx-preservation-vs-surgery/ Cluster: Treatment **Answer:** For selected patients with locally advanced laryngeal cancer, concurrent cisplatin-based chemoradiotherapy can preserve the larynx with survival comparable to total laryngectomy. It is not suitable for everyone: extensive cartilage invasion, a destroyed larynx, severe aspiration, poor lung function or an inability to tolerate chemotherapy may favour surgery. The trade-off is long-term function. Chemoradiotherapy can leave chronic swallowing difficulty, fibrosis or a poorly functioning larynx, whereas total laryngectomy removes the larynx but reliably secures the airway and often gives better swallowing. A tumour board should document why one route is recommended for your anatomy. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### Why is laryngeal cancer so common in Eastern Europe, Cuba and parts of South America? URL: https://www.entliu.com/conditions/laryngeal-cancer/why-common-in-eastern-europe/ Cluster: Understanding the disease **Answer:** The pattern largely follows historical smoking and heavy alcohol exposure. Cuba (14.8/100,000), Moldova (12.2) and Romania (10.3) had the highest estimated male ASRs in 2022, while Spain, France, Italy, Hungary, Portugal and Brazil have long-standing high rates. In many high-income countries male rates are now falling as smoking declines. Registry data also show a strong sex difference (global male ASR 3.5 vs female 0.4) and that glottic tumours dominate. Some countries, including Lithuania, Belarus and Colombia, still show increasing male trends, which is why incidence maps need a date attached. Sources: Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) (Japanese Journal of Clinical Oncology / registry-based review, 2025) https://dx.doi.org/10.1093/jjco/hyae121 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf #### Does hoarseness always mean laryngeal cancer? URL: https://www.entliu.com/conditions/laryngeal-cancer/hoarseness-red-flag/ Cluster: Symptoms & diagnosis **Answer:** No. Most hoarseness comes from laryngitis, reflux, voice strain, nodules or a vocal cord palsy. However, any hoarseness lasting more than two to three weeks — especially in a smoker or heavy drinker over 40 — should be examined with laryngoscopy, because a small glottic cancer is highly curable when found early. Do not treat persistent hoarseness with repeated courses of antibiotics or steroids without visualising the vocal cords. Flexible laryngoscopy is a quick office procedure and is the single most useful test. Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What changes after a total laryngectomy? URL: https://www.entliu.com/conditions/laryngeal-cancer/life-after-laryngectomy/ Cluster: Side effects & recovery **Answer:** After total laryngectomy the windpipe is brought out to a permanent stoma in the neck, so breathing and smelling happen through the stoma rather than the nose and mouth. The food and air passages are separated, so swallowing is usually preserved after healing, but natural voice is lost and must be replaced with a voice prosthesis, electrolarynx or oesophageal speech. Practical issues include stoma care, humidification, showering and swimming precautions, loss of smell and taste, and the need for a speaking valve or hands-free device. Speech-language pathology, stoma nursing and a supply plan for prostheses in your home country should be arranged before discharge. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What does laryngeal cancer treatment in China cost for international patients? URL: https://www.entliu.com/conditions/laryngeal-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** Illustrative planning ranges are ¥50,000–¥110,000 (about US$7,000–15,000) for transoral laser or partial laryngectomy, ¥90,000–¥180,000 for total laryngectomy with neck dissection, and ¥100,000–¥200,000 for definitive chemoradiotherapy. Voice prostheses, long-term stoma supplies and rehabilitation are usually additional. Ask for an itemised written estimate that includes pathology, imaging, ICU or tracheostomy care, speech therapy and the number of radiotherapy fractions. Also budget for a companion and for a longer stay if chemoradiotherapy is planned. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Hypopharyngeal Cancer URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/ Also known as: Pyriform sinus cancer; Postcricoid cancer; Lower throat cancer Classification: ICD-O-3 C12–C13 Quick answer: Hypopharyngeal cancer arises in the lowest part of the throat, most often the pyriform sinus, beside and behind the voice box. It is uncommon worldwide but concentrated in South Asia and Eastern Europe, is strongly linked to tobacco and alcohol, and is usually diagnosed late because the space is silent until the tumour is large. Treatment commonly requires combined chemoradiotherapy or major surgery with reconstruction. The hypopharynx is a funnel that channels food around the larynx into the oesophagus. Because it has generous space and rich lymphatic drainage, tumours can grow unnoticed and spread to neck nodes early. A painless neck mass, progressive difficulty swallowing or pain referred to the ear may be the first sign; hoarseness and breathing difficulty appear later when the larynx is involved. Hypopharyngeal squamous cell carcinoma has among the least favourable outcomes of the head and neck subsites, largely because of advanced stage at presentation and the functional cost of treatment. Decisions about larynx preservation, reconstruction of the food passage and nutrition must be made by an experienced multidisciplinary team before the first treatment is given. **Global burden (2022):** about 86,300 new hypopharyngeal cancer cases worldwide (male ASR 1.6 and female ASR 0.3 per 100,000; 11.4% of all lip/oral/pharyngeal cancers in 2022). The wider GLOBOCAN 2022 estimate (ICD-10 C12–C13) was 86,257 cases with an ASR of 0.89 per 100,000. **Where it is common** - Eastern Europe & the Baltic states: Hypopharyngeal cancer makes up 15.8% of the region’s lip/oral/pharyngeal burden — the highest regional share. Male ASRs above 5.0 are reported in Hungary, Slovakia, Belarus and Lithuania. - South-Central Asia / Bangladesh: 15.3% of the regional burden. Bangladesh has the highest ASR worldwide in both sexes (male 9.3, female 1.6); India’s ASIR is reported at 2.1 per 100,000. - India: High absolute burden from smoking, bidi use, chewing tobacco and alcohol, frequently with late-stage presentation and nutritional deficiency. - France & Western Europe: Historically elevated rates of hypopharyngeal and supraglottic cancer associated with combined tobacco and alcohol exposure. - North America & Australia: Rates are substantially lower and have generally declined with smoking cessation; the oropharynx (HPV-driven) is now the dominant pharyngeal subsite. **Risk factors** - Heavy, long-term tobacco smoking (cigarettes, bidis, pipes) - Heavy alcohol use — the combination with tobacco is strongly synergistic - Plummer–Vinson / Paterson–Kelly syndrome: iron-deficiency anaemia, oesophageal webs and postcricoid carcinoma - Poor nutrition, low fruit and vegetable intake and micronutrient deficiency - Occupational exposures and gastro-oesophageal reflux (weaker associations) - Male sex and age over 50; prior head and neck radiotherapy **Signs and symptoms** - Progressive difficulty or pain when swallowing solids (dysphagia, odynophagia) - Persistent sore throat or a sensation of a lump in the throat - Pain radiating to one ear (referred otalgia) with a normal ear examination - A hard, painless lump in the neck — sometimes the only presenting sign - Hoarseness, noisy breathing or aspiration in advanced disease - Weight loss, fatigue and reduced oral intake **Diagnosis and staging** - Flexible nasopharyngolaryngoscopy to inspect the pyriform sinus, postcricoid region and vocal cord mobility - Fine-needle aspiration of a neck mass; avoid open biopsy of a nodal metastasis - Panendoscopy (laryngoscopy, oesophagoscopy, bronchoscopy) with biopsy under general anaesthesia - Contrast CT and/or MRI of the neck and chest; FDG PET-CT for advanced nodal or distant disease - Nutritional assessment, swallowing evaluation and dental review before treatment - Tumour board review, because synchronous oesophageal lesions and second primary tumours must be excluded TNM staging for hypopharyngeal cancer reflects tumour size, number and size of neck nodes, and distant metastasis. Involvement of the pyriform apex, postcricoid region, vocal cord fixation or thyroid/cricoid cartilage generally indicates T3–T4a disease and often removes the option of partial laryngopharyngectomy. **Treatment options** - Early T1–T2 N0 disease: primary radiotherapy or larynx-preserving partial laryngopharyngectomy with selective neck dissection - Locally advanced disease: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy followed by response-adapted radiotherapy/chemoradiotherapy - Total laryngopharyngectomy with neck dissection and reconstruction (free jejunal transfer, anterolateral thigh flap or gastric pull-up) for T4a or non-responders - Postoperative radiotherapy for close margins, multiple nodes or perineural invasion; concurrent chemoradiotherapy for positive margins or extranodal extension - Enteral feeding support (nasogastric tube or gastrostomy), speech and swallow rehabilitation, and airway management - Recurrent/metastatic disease: PD-1 immunotherapy, chemotherapy, clinical trials or palliative radiotherapy **Prognosis** Because most patients present with stage III–IV disease, five-year survival for hypopharyngeal cancer is commonly reported in the 30–50% range — lower than for glottic laryngeal cancer. Small T1–T2 tumours treated with a single modality do considerably better. Nutritional status, swallowing function, nodal burden and treatment interruptions all influence outcome. **Prevention** - Stop smoking and heavy alcohol use — the dominant modifiable risks - Diagnose and treat iron-deficiency anaemia and Plummer–Vinson syndrome - Improve nutrition and maintain a diet rich in fruit and vegetables - Assess persistent swallowing pain or a neck lump with endoscopy rather than empirical acid suppression alone - Stopping tobacco after treatment also reduces second-primary tumours in the upper aerodigestive tract **Treatment in China** International patients with hypopharyngeal cancer are usually evaluated for either organ-preserving chemoradiotherapy or total laryngopharyngectomy with immediate reconstruction of the food passage. Chinese tertiary centres with head and neck reconstructive teams can perform the ablative and reconstructive stages in a single operation. - Bring biopsy slides, panendoscopy notes, contrast CT/MRI on DICOM, PET-CT if done, and a nutritional/swallowing assessment. - Ask specifically how the pharynx will be reconstructed, whether a permanent stoma or feeding tube is expected, and what speech and swallowing rehabilitation is available. - Request a written explanation of why larynx preservation was or was not chosen, plus the chemotherapy and radiotherapy doses in English. - Plan for a longer stay: major pharyngeal reconstruction and postoperative radiotherapy can require 8–12 weeks. Cost guidance: As an illustrative planning range, total laryngopharyngectomy with free-flap reconstruction is commonly budgeted at ¥130,000–¥260,000 (about US$18,000–36,000); definitive concurrent chemoradiotherapy ¥110,000–¥220,000. Nutrition support, stoma supplies and rehabilitation are additional. These figures are not a quotation. ### All 13 questions about Hypopharyngeal Cancer #### What is hypopharyngeal cancer? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Hypopharyngeal cancer arises in the lowest part of the throat, most often the pyriform sinus, beside and behind the voice box. It is uncommon worldwide but concentrated in South Asia and Eastern Europe, is strongly linked to tobacco and alcohol, and is usually diagnosed late because the space is silent until the tumour is large. Treatment commonly requires combined chemoradiotherapy or major surgery with reconstruction. The hypopharynx is a funnel that channels food around the larynx into the oesophagus. Because it has generous space and rich lymphatic drainage, tumours can grow unnoticed and spread to neck nodes early. A painless neck mass, progressive difficulty swallowing or pain referred to the ear may be the first sign; hoarseness and breathing difficulty appear later when the larynx is involved. Hypopharyngeal squamous cell carcinoma has among the least favourable outcomes of the head and neck subsites, largely because of advanced stage at presentation and the functional cost of treatment. Decisions about larynx preservation, reconstruction of the food passage and nutrition must be made by an experienced multidisciplinary team before the first treatment is given. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### Where in the world is hypopharyngeal cancer most common? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Hypopharyngeal Cancer is not evenly distributed: the highest-burden regions are Eastern Europe & the Baltic states, South-Central Asia / Bangladesh and India. In 2022 there were about 86,300 new hypopharyngeal cancer cases worldwide worldwide (male ASR 1.6 and female ASR 0.3 per 100,000; 11.4% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from Eastern Europe & the Baltic states may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - Eastern Europe & the Baltic states: Hypopharyngeal cancer makes up 15.8% of the region’s lip/oral/pharyngeal burden — the highest regional share. Male ASRs above 5.0 are reported in Hungary, Slovakia, Belarus and Lithuania. - South-Central Asia / Bangladesh: 15.3% of the regional burden. Bangladesh has the highest ASR worldwide in both sexes (male 9.3, female 1.6); India’s ASIR is reported at 2.1 per 100,000. - India: High absolute burden from smoking, bidi use, chewing tobacco and alcohol, frequently with late-stage presentation and nutritional deficiency. - France & Western Europe: Historically elevated rates of hypopharyngeal and supraglottic cancer associated with combined tobacco and alcohol exposure. - North America & Australia: Rates are substantially lower and have generally declined with smoking cessation; the oropharynx (HPV-driven) is now the dominant pharyngeal subsite. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### What are the risk factors for hypopharyngeal cancer? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for hypopharyngeal cancer are heavy, long-term tobacco smoking (cigarettes, bidis, pipes), heavy alcohol use — the combination with tobacco is strongly synergistic and plummer–Vinson / Paterson–Kelly syndrome: iron-deficiency anaemia, oesophageal webs and postcricoid carcinoma. Risks differ by region: Eastern Europe & the Baltic states has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Heavy, long-term tobacco smoking (cigarettes, bidis, pipes) - Heavy alcohol use — the combination with tobacco is strongly synergistic - Plummer–Vinson / Paterson–Kelly syndrome: iron-deficiency anaemia, oesophageal webs and postcricoid carcinoma - Poor nutrition, low fruit and vegetable intake and micronutrient deficiency - Occupational exposures and gastro-oesophageal reflux (weaker associations) - Male sex and age over 50; prior head and neck radiotherapy Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### What are the early signs of hypopharyngeal cancer? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are progressive difficulty or pain when swallowing solids (dysphagia, odynophagia), persistent sore throat or a sensation of a lump in the throat, pain radiating to one ear (referred otalgia) with a normal ear examination and a hard, painless lump in the neck — sometimes the only presenting sign. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - Progressive difficulty or pain when swallowing solids (dysphagia, odynophagia) - Persistent sore throat or a sensation of a lump in the throat - Pain radiating to one ear (referred otalgia) with a normal ear examination - A hard, painless lump in the neck — sometimes the only presenting sign - Hoarseness, noisy breathing or aspiration in advanced disease - Weight loss, fatigue and reduced oral intake Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### How is hypopharyngeal cancer diagnosed and staged? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. TNM staging for hypopharyngeal cancer reflects tumour size, number and size of neck nodes, and distant metastasis. Involvement of the pyriform apex, postcricoid region, vocal cord fixation or thyroid/cricoid cartilage generally indicates T3–T4a disease and often removes the option of partial laryngopharyngectomy. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Flexible nasopharyngolaryngoscopy to inspect the pyriform sinus, postcricoid region and vocal cord mobility - Fine-needle aspiration of a neck mass; avoid open biopsy of a nodal metastasis - Panendoscopy (laryngoscopy, oesophagoscopy, bronchoscopy) with biopsy under general anaesthesia - Contrast CT and/or MRI of the neck and chest; FDG PET-CT for advanced nodal or distant disease - Nutritional assessment, swallowing evaluation and dental review before treatment - Tumour board review, because synchronous oesophageal lesions and second primary tumours must be excluded Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### What are the treatment options for hypopharyngeal cancer? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines early T1–T2 N0 disease: primary radiotherapy or larynx-preserving partial laryngopharyngectomy with selective neck dissection, locally advanced disease: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy followed by response-adapted radiotherapy/chemoradiotherapy and total laryngopharyngectomy with neck dissection and reconstruction (free jejunal transfer, anterolateral thigh flap or gastric pull-up) for T4a or non-responders. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Early T1–T2 N0 disease: primary radiotherapy or larynx-preserving partial laryngopharyngectomy with selective neck dissection - Locally advanced disease: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy followed by response-adapted radiotherapy/chemoradiotherapy - Total laryngopharyngectomy with neck dissection and reconstruction (free jejunal transfer, anterolateral thigh flap or gastric pull-up) for T4a or non-responders - Postoperative radiotherapy for close margins, multiple nodes or perineural invasion; concurrent chemoradiotherapy for positive margins or extranodal extension - Enteral feeding support (nasogastric tube or gastrostomy), speech and swallow rehabilitation, and airway management - Recurrent/metastatic disease: PD-1 immunotherapy, chemotherapy, clinical trials or palliative radiotherapy Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### What is the prognosis for hypopharyngeal cancer? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Because most patients present with stage III–IV disease, five-year survival for hypopharyngeal cancer is commonly reported in the 30–50% range — lower than for glottic laryngeal cancer. Small T1–T2 tumours treated with a single modality do considerably better. Nutritional status, swallowing function, nodal burden and treatment interruptions all influence outcome. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### Can hypopharyngeal cancer be prevented? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for hypopharyngeal cancer are stop smoking and heavy alcohol use — the dominant modifiable risks, diagnose and treat iron-deficiency anaemia and Plummer–Vinson syndrome and improve nutrition and maintain a diet rich in fruit and vegetables. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Stop smoking and heavy alcohol use — the dominant modifiable risks - Diagnose and treat iron-deficiency anaemia and Plummer–Vinson syndrome - Improve nutrition and maintain a diet rich in fruit and vegetables - Assess persistent swallowing pain or a neck lump with endoscopy rather than empirical acid suppression alone - Stopping tobacco after treatment also reduces second-primary tumours in the upper aerodigestive tract Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### Why is hypopharyngeal cancer usually found at an advanced stage? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/why-diagnosed-late/ Cluster: Understanding the disease **Answer:** The hypopharynx is a wide, relatively insensitive funnel, so a tumour can grow substantially before it obstructs swallowing or causes pain. Its rich lymphatic network also allows early spread to neck nodes, meaning a painless neck lump may be the first sign while the primary tumour remains symptomless. Persistent swallowing pain, unilateral ear pain with a normal ear, or an adult neck lump therefore warrants flexible endoscopy and FNA rather than symptomatic treatment. Late presentation is the main reason survival is lower than for glottic laryngeal cancer. Sources: Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### What is Plummer–Vinson syndrome and how is it linked to hypopharyngeal cancer? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/plummer-vinson/ Cluster: Understanding the disease **Answer:** Plummer–Vinson (Paterson–Kelly) syndrome is the combination of iron-deficiency anaemia, dysphagia from oesophageal webs and glossitis. It is a recognised risk factor for postcricoid hypopharyngeal and upper oesophageal squamous cell carcinoma, particularly in women, and is one reason postcricoid tumours have a distinct epidemiological profile. Treatment includes iron replacement, dilation of webs and endoscopic surveillance. Any new or progressive dysphagia in a patient with this syndrome should be re-endoscoped and biopsied. Sources: Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### How is the throat reconstructed after hypopharyngeal cancer surgery? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/reconstruction-options/ Cluster: Treatment **Answer:** When the hypopharynx and larynx are removed, the food passage must be rebuilt. Common options are a free jejunal transfer (a segment of small bowel with its vessels reconnected in the neck), a tubed anterolateral thigh or radial forearm free flap, or a gastric pull-up when the oesophagus is also involved. The choice depends on the defect length, prior surgery and general fitness. A permanent tracheostoma is usually created, and speech restoration is planned later with a voice prosthesis. Ask about swallowing studies before oral feeding resumes and about the risk of stricture or fistula. Sources: Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Will I be able to eat and swallow normally after treatment? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/swallowing-after-treatment/ Cluster: Side effects & recovery **Answer:** Swallowing is commonly affected, but most patients regain at least soft or full oral intake with rehabilitation. Chemoradiotherapy can cause strictures, fibrosis and chronic dysphagia; major reconstruction requires a structured swallowing programme and often temporary tube feeding while the new conduit heals. Early involvement of a speech-language pathologist and dietitian is associated with better functional outcomes. Continuing swallowing exercises during radiotherapy reduces long-term stricture and feeding-tube dependence. Report any new coughing with meals promptly — silent aspiration can lead to pneumonia. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Hypopharyngeal Cancer Treatment (PDQ, health professional version) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq #### What is the likely cost of hypopharyngeal cancer treatment in China? URL: https://www.entliu.com/conditions/hypopharyngeal-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** Illustrative planning ranges are ¥130,000–¥260,000 (about US$18,000–36,000) for total laryngopharyngectomy with free-flap reconstruction and ¥110,000–¥220,000 for definitive concurrent chemoradiotherapy. Nutritional support, speech/swallow therapy and stoma supplies are usually billed separately. These are budgeting figures, not a quotation. Because hypopharyngeal treatment is long and complication-prone, request a written estimate that includes ICU stay, flap monitoring, imaging, enteral feeding supplies and the anticipated length of stay before booking travel. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Thyroid Cancer URL: https://www.entliu.com/conditions/thyroid-cancer/ Also known as: Papillary thyroid carcinoma; Follicular thyroid cancer; Medullary thyroid cancer; Anaplastic thyroid cancer; Thyroid nodule Classification: ICD-10 C73 Quick answer: Thyroid cancer is a malignancy of the thyroid gland in the front of the neck, most often papillary carcinoma. Incidence has risen sharply in South Korea, the United States and parts of Europe and Asia, largely because ultrasound detects small, indolent tumours, while mortality has remained low. Many small low-risk cancers can be monitored rather than operated on immediately. A thyroid nodule is common and the great majority are benign. The worldwide rise in thyroid cancer incidence over recent decades reflects widespread ultrasound use and overdiagnosis more than a true increase in aggressive disease — death rates have stayed low and flat. Recognising this is important for international patients: a scan finding does not automatically mean an operation is urgent. When treatment is needed, the main decision is between active surveillance, hemithyroidectomy (lobectomy) and total thyroidectomy, with or without radioactive iodine and neck dissection. Medullary and anaplastic cancers are rare but require different pathways, including RET genetic testing for medullary disease and urgent multimodality care for anaplastic disease. **Global burden (2022):** about 820,000 new thyroid cancer cases worldwide (GLOBOCAN 2022 estimate) (ASR 9.1 per 100,000 overall (women 13.6, men 4.6); mortality ASR only 0.4). Asia accounted for 72.7% of global thyroid cancer cases in 2022 (596,600 cases) and 61.3% of deaths, with incidence strongly correlated with human development index and diagnostic intensity. **Where it is common** - South Korea: The highest age-standardised incidence in Asia — 7.6/100,000 in men and 39.5/100,000 in women — driven largely by intensive ultrasound screening and overdiagnosis of small papillary cancers. - China: The largest absolute burden in Asia (about 466,000 new cases in 2022 across both sexes in one GLOBOCAN-based analysis), with wide regional variation in diagnostic intensity. - United States & Canada: High and rising incidence with stable mortality; active surveillance of low-risk papillary microcarcinoma is now an accepted option in guidelines. - Italy, France & Southern Europe: Among the highest incidence rates in Europe, again largely reflecting ultrasound and opportunistic screening. - United Arab Emirates & Gulf states: A 2026 Asian analysis reported the highest thyroid cancer mortality ASR in the region (0.9 in men, 13.9 in women per 100,000), illustrating that incidence and mortality rankings can differ. - Australia & New Zealand: High detection rates in high-income health systems, with excellent survival for differentiated disease. **Risk factors** - Ionising radiation exposure to the head and neck, especially in childhood - Family history of thyroid cancer and inherited syndromes (MEN2/RET, Cowden, familial adenomatous polyposis) - Female sex — incidence is roughly three times higher in women - Iodine deficiency (follicular cancer) or, in some settings, high iodine intake - Hashimoto thyroiditis (associated with papillary carcinoma and thyroid lymphoma) - Increasing age and high ultrasound/screening exposure (detection rather than biological risk) **Signs and symptoms** - A painless, firm nodule in the front of the neck that moves on swallowing - Hoarseness or voice weakness from recurrent laryngeal nerve involvement - Difficulty swallowing or breathing, or a sensation of pressure when lying flat - Enlarged cervical lymph nodes, sometimes the only sign of papillary cancer - Rapidly enlarging neck mass and neck pain (warning signs for anaplastic or lymphoma) - Most small thyroid cancers cause no symptoms at all and are found incidentally on ultrasound **Diagnosis and staging** - Thyroid function tests (TSH) and high-resolution neck ultrasound with a structured TI-RADS report - Ultrasound-guided fine-needle aspiration (FNA) reported with the Bethesda classification - Calcitonin and CEA when medullary carcinoma is suspected; RET genetic testing if confirmed - Vocal cord assessment (laryngoscopy) before thyroid surgery, especially with hoarseness or prior neck surgery - Contrast CT/MRI for locally advanced disease, substernal extension or nodal mapping - Molecular testing of indeterminate nodules in selected cases; review by an experienced thyroid pathologist AJCC 8th edition TNM staging for differentiated thyroid cancer incorporates age at diagnosis (using 55 years as the cut-off in the current system), tumour size and gross extrathyroidal extension, nodal metastases and distant metastases. A 45-year-old with a small node-positive papillary cancer can be stage I, which is a frequent source of confusion for patients. **Treatment options** - Active surveillance with serial ultrasound for selected low-risk papillary microcarcinomas - Thyroid lobectomy for small, unifocal, intrathyroidal tumours without nodal disease - Total thyroidectomy when indicated by size, multifocality, extrathyroidal extension, nodal disease or patient preference - Therapeutic neck dissection for clinically involved nodes; radioactive iodine (I-131) for selected intermediate/high-risk differentiated cancers - TSH suppression with levothyroxine tailored to risk; lifelong hormone replacement after total thyroidectomy - Targeted therapy (e.g. multikinase inhibitors, BRAF/MEK or RET inhibitors) for progressive radioactive-iodine-refractory disease; urgent multimodality therapy for anaplastic carcinoma **Prognosis** Differentiated papillary and follicular thyroid cancer generally has excellent outcomes; five-year survival for localised papillary cancer is commonly reported above 98%, and even regional disease has high survival. Medullary carcinoma has an intermediate outlook, while anaplastic carcinoma is aggressive with short survival. Age, size, extrathyroidal extension, nodal burden, distant metastasis and histology drive individual risk. **Prevention** - Avoid unnecessary ionising radiation to the head and neck in children; use thyroid shielding when medically appropriate - Maintain adequate dietary iodine; neither deficiency nor excessive supplementation is protective against cancer - Genetic counselling and RET testing for families with MEN2 or medullary thyroid cancer - There is no recommended general-population ultrasound screening — it increases overdiagnosis without lowering mortality - Evaluate a new or growing neck nodule with ultrasound and FNA rather than repeated empirical medication **Treatment in China** Chinese tertiary centres perform very high volumes of thyroid surgery with intraoperative recurrent laryngeal nerve monitoring and parathyroid preservation. For international patients, the most valuable service is often a careful re-assessment of whether surgery is needed at all, since many incidental small nodules qualify for active surveillance. - Bring the original ultrasound images and report, FNA/Bethesda result, thyroid function tests and any molecular test results. - Ask for a written indication: surveillance, lobectomy or total thyroidectomy, with the reasons and the expected need for lifelong levothyroxine. - Ask about recurrent laryngeal nerve monitoring, postoperative calcium/parathyroid management and how vocal cord function is checked. - If radioactive iodine is proposed, confirm isotope availability, isolation requirements and the timing of whole-body scanning before you travel home. Cost guidance: As an illustrative planning range, thyroid lobectomy is often budgeted at ¥25,000–¥55,000 (about US$3,500–7,700), total thyroidectomy with neck dissection ¥45,000–¥100,000, and radioactive iodine ¥15,000–¥40,000 per treatment. These are budgeting figures, not a quotation, and a surveillance pathway costs far less than surgery. ### All 14 questions about Thyroid Cancer #### What is thyroid cancer? URL: https://www.entliu.com/conditions/thyroid-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Thyroid cancer is a malignancy of the thyroid gland in the front of the neck, most often papillary carcinoma. Incidence has risen sharply in South Korea, the United States and parts of Europe and Asia, largely because ultrasound detects small, indolent tumours, while mortality has remained low. Many small low-risk cancers can be monitored rather than operated on immediately. A thyroid nodule is common and the great majority are benign. The worldwide rise in thyroid cancer incidence over recent decades reflects widespread ultrasound use and overdiagnosis more than a true increase in aggressive disease — death rates have stayed low and flat. Recognising this is important for international patients: a scan finding does not automatically mean an operation is urgent. When treatment is needed, the main decision is between active surveillance, hemithyroidectomy (lobectomy) and total thyroidectomy, with or without radioactive iodine and neck dissection. Medullary and anaplastic cancers are rare but require different pathways, including RET genetic testing for medullary disease and urgent multimodality care for anaplastic disease. Sources: Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### Where in the world is thyroid cancer most common? URL: https://www.entliu.com/conditions/thyroid-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Thyroid Cancer is not evenly distributed: the highest-burden regions are South Korea, China and United States & Canada. In 2022 there were about 820,000 new thyroid cancer cases worldwide (GLOBOCAN 2022 estimate) worldwide (ASR 9.1 per 100,000 overall (women 13.6, men 4.6); mortality ASR only 0.4), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from South Korea may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - South Korea: The highest age-standardised incidence in Asia — 7.6/100,000 in men and 39.5/100,000 in women — driven largely by intensive ultrasound screening and overdiagnosis of small papillary cancers. - China: The largest absolute burden in Asia (about 466,000 new cases in 2022 across both sexes in one GLOBOCAN-based analysis), with wide regional variation in diagnostic intensity. - United States & Canada: High and rising incidence with stable mortality; active surveillance of low-risk papillary microcarcinoma is now an accepted option in guidelines. - Italy, France & Southern Europe: Among the highest incidence rates in Europe, again largely reflecting ultrasound and opportunistic screening. - United Arab Emirates & Gulf states: A 2026 Asian analysis reported the highest thyroid cancer mortality ASR in the region (0.9 in men, 13.9 in women per 100,000), illustrating that incidence and mortality rankings can differ. - Australia & New Zealand: High detection rates in high-income health systems, with excellent survival for differentiated disease. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### What are the risk factors for thyroid cancer? URL: https://www.entliu.com/conditions/thyroid-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for thyroid cancer are ionising radiation exposure to the head and neck, especially in childhood, family history of thyroid cancer and inherited syndromes (MEN2/RET, Cowden, familial adenomatous polyposis) and female sex — incidence is roughly three times higher in women. Risks differ by region: South Korea has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Ionising radiation exposure to the head and neck, especially in childhood - Family history of thyroid cancer and inherited syndromes (MEN2/RET, Cowden, familial adenomatous polyposis) - Female sex — incidence is roughly three times higher in women - Iodine deficiency (follicular cancer) or, in some settings, high iodine intake - Hashimoto thyroiditis (associated with papillary carcinoma and thyroid lymphoma) - Increasing age and high ultrasound/screening exposure (detection rather than biological risk) Sources: Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### What are the early signs of thyroid cancer? URL: https://www.entliu.com/conditions/thyroid-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a painless, firm nodule in the front of the neck that moves on swallowing, hoarseness or voice weakness from recurrent laryngeal nerve involvement, difficulty swallowing or breathing, or a sensation of pressure when lying flat and enlarged cervical lymph nodes, sometimes the only sign of papillary cancer. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A painless, firm nodule in the front of the neck that moves on swallowing - Hoarseness or voice weakness from recurrent laryngeal nerve involvement - Difficulty swallowing or breathing, or a sensation of pressure when lying flat - Enlarged cervical lymph nodes, sometimes the only sign of papillary cancer - Rapidly enlarging neck mass and neck pain (warning signs for anaplastic or lymphoma) - Most small thyroid cancers cause no symptoms at all and are found incidentally on ultrasound Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### How is thyroid cancer diagnosed and staged? URL: https://www.entliu.com/conditions/thyroid-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. AJCC 8th edition TNM staging for differentiated thyroid cancer incorporates age at diagnosis (using 55 years as the cut-off in the current system), tumour size and gross extrathyroidal extension, nodal metastases and distant metastases. A 45-year-old with a small node-positive papillary cancer can be stage I, which is a frequent source of confusion for patients. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Thyroid function tests (TSH) and high-resolution neck ultrasound with a structured TI-RADS report - Ultrasound-guided fine-needle aspiration (FNA) reported with the Bethesda classification - Calcitonin and CEA when medullary carcinoma is suspected; RET genetic testing if confirmed - Vocal cord assessment (laryngoscopy) before thyroid surgery, especially with hoarseness or prior neck surgery - Contrast CT/MRI for locally advanced disease, substernal extension or nodal mapping - Molecular testing of indeterminate nodules in selected cases; review by an experienced thyroid pathologist Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### What are the treatment options for thyroid cancer? URL: https://www.entliu.com/conditions/thyroid-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines active surveillance with serial ultrasound for selected low-risk papillary microcarcinomas, thyroid lobectomy for small, unifocal, intrathyroidal tumours without nodal disease and total thyroidectomy when indicated by size, multifocality, extrathyroidal extension, nodal disease or patient preference. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Active surveillance with serial ultrasound for selected low-risk papillary microcarcinomas - Thyroid lobectomy for small, unifocal, intrathyroidal tumours without nodal disease - Total thyroidectomy when indicated by size, multifocality, extrathyroidal extension, nodal disease or patient preference - Therapeutic neck dissection for clinically involved nodes; radioactive iodine (I-131) for selected intermediate/high-risk differentiated cancers - TSH suppression with levothyroxine tailored to risk; lifelong hormone replacement after total thyroidectomy - Targeted therapy (e.g. multikinase inhibitors, BRAF/MEK or RET inhibitors) for progressive radioactive-iodine-refractory disease; urgent multimodality therapy for anaplastic carcinoma Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### What is the prognosis for thyroid cancer? URL: https://www.entliu.com/conditions/thyroid-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Differentiated papillary and follicular thyroid cancer generally has excellent outcomes; five-year survival for localised papillary cancer is commonly reported above 98%, and even regional disease has high survival. Medullary carcinoma has an intermediate outlook, while anaplastic carcinoma is aggressive with short survival. Age, size, extrathyroidal extension, nodal burden, distant metastasis and histology drive individual risk. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### Can thyroid cancer be prevented? URL: https://www.entliu.com/conditions/thyroid-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for thyroid cancer are avoid unnecessary ionising radiation to the head and neck in children; use thyroid shielding when medically appropriate, maintain adequate dietary iodine; neither deficiency nor excessive supplementation is protective against cancer and genetic counselling and RET testing for families with MEN2 or medullary thyroid cancer. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Avoid unnecessary ionising radiation to the head and neck in children; use thyroid shielding when medically appropriate - Maintain adequate dietary iodine; neither deficiency nor excessive supplementation is protective against cancer - Genetic counselling and RET testing for families with MEN2 or medullary thyroid cancer - There is no recommended general-population ultrasound screening — it increases overdiagnosis without lowering mortality - Evaluate a new or growing neck nodule with ultrasound and FNA rather than repeated empirical medication Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### Why is thyroid cancer incidence rising so fast in South Korea and other wealthy countries? URL: https://www.entliu.com/conditions/thyroid-cancer/why-incidence-rising/ Cluster: Understanding the disease **Answer:** Most of the rise is overdiagnosis: widespread neck ultrasound detects tiny papillary cancers that would never have caused symptoms or death. South Korea has the highest reported incidence in Asia (39.5/100,000 in women), yet thyroid cancer mortality remains low and stable. In other words, more cancers are being found, not necessarily more dangerous ones. The 2026 Asian GLOBOCAN analysis found a strong correlation between incidence and human development index, and explicitly discussed reducing overdiagnosis as a public-health priority. This is why several guidelines now accept active surveillance for carefully selected low-risk microcarcinomas. Sources: Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 (European Journal of Cancer Prevention, 2026) https://pubmed.ncbi.nlm.nih.gov/40742826/ | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### Can a small papillary thyroid cancer be watched instead of removed? URL: https://www.entliu.com/conditions/thyroid-cancer/active-surveillance/ Cluster: Treatment **Answer:** Yes, for selected low-risk tumours — typically a small intrathyroidal papillary microcarcinoma without nodal metastases, extrathyroidal extension, aggressive cytology or unfavourable location. Active surveillance means periodic high-resolution ultrasound, with surgery if the nodule grows, nodes appear or the patient prefers treatment. It is not suitable for all patients: young age, multifocality, proximity to the recurrent laryngeal nerve or trachea, and anxiety about living with a cancer diagnosis are common reasons to choose surgery. Ask for the criteria your centre uses, in writing, before deciding. Sources: Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What does a Bethesda result on my thyroid FNA report mean? URL: https://www.entliu.com/conditions/thyroid-cancer/fna-bethesda/ Cluster: Symptoms & diagnosis **Answer:** The Bethesda System classifies thyroid fine-needle aspiration cytology into six categories from I (non-diagnostic) to VI (malignant), each with an estimated risk of malignancy and a recommended action — repeat FNA, molecular testing, lobectomy or total thyroidectomy. It is a risk-stratification tool, not a final diagnosis in the indeterminate categories. For a second opinion abroad, bring the original cytology slides as well as the written report, plus the ultrasound images showing exactly which nodule was sampled. Discrepancies between the sampled nodule and the suspicious nodule are a common reason for re-biopsy. Sources: Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid #### What are the main risks of thyroid surgery? URL: https://www.entliu.com/conditions/thyroid-cancer/surgery-risks/ Cluster: Side effects & recovery **Answer:** The specific risks are injury to the recurrent laryngeal nerve (hoarseness or, rarely, bilateral vocal cord paralysis), hypoparathyroidism with low calcium (usually temporary, occasionally permanent), bleeding, and the need for lifelong levothyroxine after total thyroidectomy. Intraoperative nerve monitoring and meticulous parathyroid preservation reduce but do not eliminate these risks. Ask whether vocal cords will be checked before and after surgery, what the centre’s rate of permanent hypocalcaemia is, and how calcium and TSH will be monitored after you return home. A written postoperative medication plan is essential for international patients. Sources: Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What follow-up is needed after thyroid cancer treatment? URL: https://www.entliu.com/conditions/thyroid-cancer/follow-up/ Cluster: Prognosis & follow-up **Answer:** Follow-up usually combines neck ultrasound, serum thyroglobulin (with anti-thyroglobulin antibodies) for differentiated cancer after total thyroidectomy, TSH and free T4 to guide levothyroxine, and calcitonin/CEA for medullary cancer. Frequency is highest in the first one to two years and decreases as the risk of recurrence falls. Bring home a written follow-up schedule, the operative and pathology reports, the radioactive iodine dose and whole-body scan report if applicable, and the exact levothyroxine dose. Thyroglobulin interpretation differs after lobectomy, so make sure your local doctor knows which operation was performed. Sources: Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### How much does thyroid cancer treatment in China cost for international patients? URL: https://www.entliu.com/conditions/thyroid-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** Illustrative planning ranges are ¥25,000–¥55,000 (about US$3,500–7,700) for lobectomy, ¥45,000–¥100,000 for total thyroidectomy with neck dissection, and ¥15,000–¥40,000 per radioactive iodine treatment. Active surveillance with ultrasound costs far less. These are budgeting figures, not a quotation. Before travelling for an incidental small nodule, ask for a remote review of the ultrasound and FNA — the most useful second opinion may be that no operation is needed. Confirm isotope availability and isolation-bed rules if radioactive iodine is proposed. Sources: Thyroid Cancer (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/thyroid --- ## Lip Cancer URL: https://www.entliu.com/conditions/lip-cancer/ Also known as: Lower lip squamous cell carcinoma; Vermilion lip cancer; Actinic cheilitis Classification: ICD-O-3 C00 (grouped with C02–C06 in some GLOBOCAN tables) Quick answer: Lip cancer is usually a squamous cell carcinoma of the dry red part of the lower lip, caused mainly by cumulative ultraviolet radiation. It is unusually common in Australia, New Zealand, Papua New Guinea and parts of Southern/Eastern Europe among fair-skinned outdoor workers. Small tumours are highly curable with limited surgery that preserves lip function. Lip cancer is grouped statistically with oral cavity cancer (C00–C06), but its causes and behaviour are different from intraoral cancer: chronic sun exposure rather than tobacco or areca nut is the main driver. The precursor lesion is actinic cheilitis — persistent dryness, scaling and fissuring of the lower lip — which is why the lower lip, receiving more direct sunlight, is affected far more often than the upper lip. Because the lesion is visible, lip cancer can be found early. A sore, crust or thickened patch on the lip that does not heal within a few weeks should be biopsied. Treatment is usually surgical excision with reconstruction of the lip, with neck dissection or radiotherapy reserved for larger or node-positive tumours. **Global burden (2022):** about 32,200 new lip cancer cases (C00) worldwide (male ASR 0.5 and female ASR 0.2 per 100,000; 4.2% of all lip/oral/pharyngeal cancers in 2022). GLOBOCAN groups lip with oral cavity (C00–C06): 389,846 new cases at ASR 4.0 per 100,000 in 2022. **Where it is common** - Papua New Guinea & Melanesia: Lip cancer accounts for 26.5% of the region’s lip/oral/pharyngeal cancers. The highest ASRs worldwide are reported in Papua New Guinea (men 8.2, women 3.3 per 100,000). - Australia & New Zealand: Lip cancer makes up 20.5% of the regional lip/oral/pharyngeal burden, historically over a third of all oral-region cancers in Australia; male ASR 3.2, female 1.1. About 90% arise on the lower lip. - Southern & Eastern Europe: Lip cancer represents 12.6% of Southern European and 14.1% of Eastern European lip/oral/pharyngeal cancers; elevated male ASRs in Portugal (3.7), Romania (3.2), Poland, Hungary, Serbia and Moldova. - Western Asia & Turkey: 14.3% of the regional lip/oral/pharyngeal burden; high cumulative sun exposure in outdoor work is the common theme. - East & South-East Asia: Among the lowest rates in the world (<2.5% of regional lip/oral/pharyngeal cancers), reflecting both less intense UV exposure and differences in skin pigmentation. **Risk factors** - Cumulative ultraviolet (UV) radiation from sun exposure, especially occupational outdoor work - Fair skin (Fitzpatrick I–III), light eyes and a history of childhood sunburn - Actinic cheilitis — a precancerous scaling, fissured condition of the lower lip - Tobacco smoking and pipe smoking (particularly for mucosal lip lesions) - Immunosuppression after organ transplantation — risk of lip SCC is markedly increased - Photosensitising medicines, male sex and age over 60 **Signs and symptoms** - A persistent sore, ulcer or crust on the lower lip that does not heal - A scaly, dry, whitish or thickened patch (actinic cheilitis) with loss of the sharp lip border - A firm lump or nodule on the vermilion, sometimes bleeding - Numbness or tingling of the lip or chin (suggesting perineural spread) - A hard lump under the chin or in the upper neck (nodal metastasis) - Difficulty moving the lip, drooling or changes in speech in advanced lesions **Diagnosis and staging** - Clinical examination of the whole lip, oral cavity and neck with palpation - Incisional or excisional biopsy of the suspicious area for histology and depth of invasion - Ultrasound or contrast CT/MRI of the neck for larger tumours; FNA of suspicious nodes - Assessment of perineural invasion, bone involvement and tumour thickness in the pathology report - Dental and sun-damage assessment, including examination for synchronous facial skin cancers - Sentinel lymph node biopsy consideration for thick or high-risk tumours Lip cancers are staged within the oral cavity / head and neck cutaneous squamous cell carcinoma systems depending on origin (dry vermilion versus mucosal lip). Tumour size, depth, bone or skin invasion, perineural invasion and nodal metastases determine whether local excision alone is sufficient or neck treatment and adjuvant radiotherapy are required. **Treatment options** - Wide local excision with primary closure for small lesions (often a V or W excision) - Lip reconstruction with local flaps (Abbe, Estlander, Karapandzic) for larger defects to preserve oral competence, speech and appearance - Mohs micrographic surgery or curettage/radiotherapy for selected superficial lesions in appropriate settings - Neck dissection or sentinel node biopsy for thick, recurrent or node-positive disease - Adjuvant radiotherapy for positive margins, perineural invasion, bone invasion or multiple nodes - Treatment of actinic cheilitis (topical therapy, laser, vermilionectomy) and field surveillance for new skin cancers **Prognosis** Small, completely excised lower-lip squamous cell carcinomas have excellent control, with five-year survival commonly reported above 90%. Prognosis falls with large size, deep invasion, perineural spread, mandibular involvement, nodal metastasis and immunosuppression. Recurrence and new UV-related skin cancers are common enough that long-term skin surveillance is standard. **Prevention** - Daily broad-spectrum SPF lip balm and reapplication after eating, drinking and swimming - Wide-brimmed hats and shade for outdoor work; avoid midday sun and tanning beds - Stop smoking, particularly pipe smoking - Treat actinic cheilitis early and have persistent lip lesions biopsied - Regular full-skin and lip checks for organ-transplant recipients and others on immunosuppression **Treatment in China** Lip cancer is uncommon in China compared with Australia or Southern Europe, so the key question for an international patient is whether the treating team routinely performs lip reconstruction. Experienced head and neck and plastic surgery units can combine tumour excision with functional lip repair in one operation. - Bring the biopsy report and slides, clinical photographs, and imaging of the neck if the lesion is large or recurrent. - Ask which reconstruction is planned and how oral competence (ability to keep liquids in the mouth), speech and appearance will be preserved. - If you are immunosuppressed after a transplant, tell the team: it changes surveillance intensity and sometimes the treatment choice. - Request a written plan for sun protection and field surveillance to continue at home. Cost guidance: As an illustrative planning range, local excision with lip reconstruction is commonly budgeted at ¥20,000–¥70,000 (about US$2,800–9,800); cases needing neck dissection, flap reconstruction and adjuvant radiotherapy may reach ¥80,000–¥160,000. These are budgeting figures, not a quotation. ### All 14 questions about Lip Cancer #### What is lip cancer? URL: https://www.entliu.com/conditions/lip-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Lip cancer is usually a squamous cell carcinoma of the dry red part of the lower lip, caused mainly by cumulative ultraviolet radiation. It is unusually common in Australia, New Zealand, Papua New Guinea and parts of Southern/Eastern Europe among fair-skinned outdoor workers. Small tumours are highly curable with limited surgery that preserves lip function. Lip cancer is grouped statistically with oral cavity cancer (C00–C06), but its causes and behaviour are different from intraoral cancer: chronic sun exposure rather than tobacco or areca nut is the main driver. The precursor lesion is actinic cheilitis — persistent dryness, scaling and fissuring of the lower lip — which is why the lower lip, receiving more direct sunlight, is affected far more often than the upper lip. Because the lesion is visible, lip cancer can be found early. A sore, crust or thickened patch on the lip that does not heal within a few weeks should be biopsied. Treatment is usually surgical excision with reconstruction of the lip, with neck dissection or radiotherapy reserved for larger or node-positive tumours. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### Where in the world is lip cancer most common? URL: https://www.entliu.com/conditions/lip-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Lip Cancer is not evenly distributed: the highest-burden regions are Papua New Guinea & Melanesia, Australia & New Zealand and Southern & Eastern Europe. In 2022 there were about 32,200 new lip cancer cases (C00) worldwide worldwide (male ASR 0.5 and female ASR 0.2 per 100,000; 4.2% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from Papua New Guinea & Melanesia may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - Papua New Guinea & Melanesia: Lip cancer accounts for 26.5% of the region’s lip/oral/pharyngeal cancers. The highest ASRs worldwide are reported in Papua New Guinea (men 8.2, women 3.3 per 100,000). - Australia & New Zealand: Lip cancer makes up 20.5% of the regional lip/oral/pharyngeal burden, historically over a third of all oral-region cancers in Australia; male ASR 3.2, female 1.1. About 90% arise on the lower lip. - Southern & Eastern Europe: Lip cancer represents 12.6% of Southern European and 14.1% of Eastern European lip/oral/pharyngeal cancers; elevated male ASRs in Portugal (3.7), Romania (3.2), Poland, Hungary, Serbia and Moldova. - Western Asia & Turkey: 14.3% of the regional lip/oral/pharyngeal burden; high cumulative sun exposure in outdoor work is the common theme. - East & South-East Asia: Among the lowest rates in the world (<2.5% of regional lip/oral/pharyngeal cancers), reflecting both less intense UV exposure and differences in skin pigmentation. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### What are the risk factors for lip cancer? URL: https://www.entliu.com/conditions/lip-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for lip cancer are cumulative ultraviolet (UV) radiation from sun exposure, especially occupational outdoor work, fair skin (Fitzpatrick I–III), light eyes and a history of childhood sunburn and actinic cheilitis — a precancerous scaling, fissured condition of the lower lip. Risks differ by region: Papua New Guinea & Melanesia has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Cumulative ultraviolet (UV) radiation from sun exposure, especially occupational outdoor work - Fair skin (Fitzpatrick I–III), light eyes and a history of childhood sunburn - Actinic cheilitis — a precancerous scaling, fissured condition of the lower lip - Tobacco smoking and pipe smoking (particularly for mucosal lip lesions) - Immunosuppression after organ transplantation — risk of lip SCC is markedly increased - Photosensitising medicines, male sex and age over 60 Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### What are the early signs of lip cancer? URL: https://www.entliu.com/conditions/lip-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a persistent sore, ulcer or crust on the lower lip that does not heal, a scaly, dry, whitish or thickened patch (actinic cheilitis) with loss of the sharp lip border, a firm lump or nodule on the vermilion, sometimes bleeding and numbness or tingling of the lip or chin (suggesting perineural spread). Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A persistent sore, ulcer or crust on the lower lip that does not heal - A scaly, dry, whitish or thickened patch (actinic cheilitis) with loss of the sharp lip border - A firm lump or nodule on the vermilion, sometimes bleeding - Numbness or tingling of the lip or chin (suggesting perineural spread) - A hard lump under the chin or in the upper neck (nodal metastasis) - Difficulty moving the lip, drooling or changes in speech in advanced lesions Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### How is lip cancer diagnosed and staged? URL: https://www.entliu.com/conditions/lip-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. Lip cancers are staged within the oral cavity / head and neck cutaneous squamous cell carcinoma systems depending on origin (dry vermilion versus mucosal lip). Tumour size, depth, bone or skin invasion, perineural invasion and nodal metastases determine whether local excision alone is sufficient or neck treatment and adjuvant radiotherapy are required. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Clinical examination of the whole lip, oral cavity and neck with palpation - Incisional or excisional biopsy of the suspicious area for histology and depth of invasion - Ultrasound or contrast CT/MRI of the neck for larger tumours; FNA of suspicious nodes - Assessment of perineural invasion, bone involvement and tumour thickness in the pathology report - Dental and sun-damage assessment, including examination for synchronous facial skin cancers - Sentinel lymph node biopsy consideration for thick or high-risk tumours Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### What are the treatment options for lip cancer? URL: https://www.entliu.com/conditions/lip-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines wide local excision with primary closure for small lesions (often a V or W excision), lip reconstruction with local flaps (Abbe, Estlander, Karapandzic) for larger defects to preserve oral competence, speech and appearance and mohs micrographic surgery or curettage/radiotherapy for selected superficial lesions in appropriate settings. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Wide local excision with primary closure for small lesions (often a V or W excision) - Lip reconstruction with local flaps (Abbe, Estlander, Karapandzic) for larger defects to preserve oral competence, speech and appearance - Mohs micrographic surgery or curettage/radiotherapy for selected superficial lesions in appropriate settings - Neck dissection or sentinel node biopsy for thick, recurrent or node-positive disease - Adjuvant radiotherapy for positive margins, perineural invasion, bone invasion or multiple nodes - Treatment of actinic cheilitis (topical therapy, laser, vermilionectomy) and field surveillance for new skin cancers Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### What is the prognosis for lip cancer? URL: https://www.entliu.com/conditions/lip-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Small, completely excised lower-lip squamous cell carcinomas have excellent control, with five-year survival commonly reported above 90%. Prognosis falls with large size, deep invasion, perineural spread, mandibular involvement, nodal metastasis and immunosuppression. Recurrence and new UV-related skin cancers are common enough that long-term skin surveillance is standard. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### Can lip cancer be prevented? URL: https://www.entliu.com/conditions/lip-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for lip cancer are daily broad-spectrum SPF lip balm and reapplication after eating, drinking and swimming, wide-brimmed hats and shade for outdoor work; avoid midday sun and tanning beds and stop smoking, particularly pipe smoking. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Daily broad-spectrum SPF lip balm and reapplication after eating, drinking and swimming - Wide-brimmed hats and shade for outdoor work; avoid midday sun and tanning beds - Stop smoking, particularly pipe smoking - Treat actinic cheilitis early and have persistent lip lesions biopsied - Regular full-skin and lip checks for organ-transplant recipients and others on immunosuppression Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### Why does lip cancer almost always affect the lower lip? URL: https://www.entliu.com/conditions/lip-cancer/why-lower-lip/ Cluster: Understanding the disease **Answer:** The lower lip’s vermilion presents a larger surface directly to overhead sunlight than the upper lip, so it receives a much higher cumulative UV dose. In SEER data roughly 90% of lip cancers arose on the lower lip, and chronic sun exposure in farmers, fishermen, foresters and other outdoor workers is the dominant risk factor. Mucosal (inner) lip cancers behave more like intraoral cancers and are more closely related to tobacco and alcohol. The distinction matters for both prevention and treatment planning. Sources: Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### What is actinic cheilitis and should it be treated? URL: https://www.entliu.com/conditions/lip-cancer/actinic-cheilitis/ Cluster: Prevention & risk **Answer:** Actinic cheilitis is chronic UV damage to the lip vermilion: persistent dryness, scaling, fissuring, colour variation and blurring of the lip border. It is considered a precancerous field change and is present in the great majority of lower-lip squamous cell carcinomas, so persistent cases should be assessed and often treated rather than ignored. Management ranges from rigorous SPF lip protection and smoking cessation to topical therapies, laser ablation or vermilionectomy (surgical removal of the lip surface). Because the whole sun-exposed field is affected, new lesions can develop elsewhere on the lip or face. Sources: Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation #### Will surgery change the appearance or function of my lip? URL: https://www.entliu.com/conditions/lip-cancer/lip-reconstruction/ Cluster: Treatment **Answer:** Small defects are usually closed directly with little visible change. Larger excisions require local flap reconstruction (for example Abbe, Estlander or Karapandzic flaps) designed to preserve the oral sphincter — the ability to seal the lips for eating, drinking, speech and holding saliva — while restoring a natural contour. Ask to see the planned incision and closure, and whether a second stage is needed for flap division. Temporary numbness and stiffness are common; revision surgery for the scar or commissure can be planned after healing if needed. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Why is lip cancer so prominent in Australia and New Zealand? URL: https://www.entliu.com/conditions/lip-cancer/australia-incidence/ Cluster: Understanding the disease **Answer:** High ambient ultraviolet radiation, a largely fair-skinned population and a history of outdoor work and recreation combine to produce one of the world’s highest lip cancer burdens. Lip cancer represents 20.5% of Australia/New Zealand lip/oral/pharyngeal cancers and historically accounted for over a third of Australian oral-region cancers. Rates have declined since the 1990s in parallel with sun-protection campaigns, while HPV-related oropharyngeal cancer has risen — a clear example of how prevention changes the mix of head and neck tumours in a country. Sources: Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 (BMC Cancer, 2013) https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### Are transplant recipients at higher risk of lip cancer? URL: https://www.entliu.com/conditions/lip-cancer/immunosuppression/ Cluster: Prevention & risk **Answer:** Yes. Long-term immunosuppression substantially increases the risk of cutaneous squamous cell carcinoma, including lip cancer — some series report a roughly twentyfold increase compared with the general population, with risk rising with the dose and duration of agents such as azathioprine. Transplant recipients should use rigorous lip and facial sun protection, have regular dermatology surveillance, and report any non-healing lip lesion early. Discuss any change to immunosuppression with the transplant team, never unilaterally. Sources: Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ #### What does lip cancer surgery cost in China for an international patient? URL: https://www.entliu.com/conditions/lip-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** As a planning range, local excision with lip reconstruction is commonly budgeted at ¥20,000–¥70,000 (about US$2,800–9,800); more advanced cases needing neck dissection, flap reconstruction and adjuvant radiotherapy may reach ¥80,000–¥160,000. These figures are illustrative and not a quotation. Because lip cancer is relatively uncommon in China, ask how many lip reconstructions the unit performs and request an English operative plan and pathology report. Small lesions may be treatable in a short trip, but radiotherapy requires a six-to-seven-week stay. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Skin Cancer of the Head and Neck URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/ Also known as: Cutaneous squamous cell carcinoma (cSCC); Basal cell carcinoma (BCC); Head and neck melanoma; Merkel cell carcinoma Classification: ICD-10 C43–C44 (head and neck skin sites) Quick answer: Skin cancers of the head and neck are tumours arising on chronically sun-exposed skin — basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma being the most common. They are especially frequent in fair-skinned populations in Australia, New Zealand and North America, and the head and neck is the most common site because it receives the highest lifetime UV dose. The head, face, ears, scalp and neck account for a disproportionate share of skin cancers even though they are a small fraction of body surface area. Basal cell carcinoma is the commonest and rarely metastasises but can be locally destructive around the eyes, nose and ear. Cutaneous squamous cell carcinoma of the head and neck has a higher risk of perineural spread and nodal metastasis than cSCC elsewhere on the body; melanoma is less common but causes most skin cancer deaths. Lesions on the ear, scalp, temple and lip deserve particular respect: these sites have thin tissue, rich lymphatic drainage and proximity to cranial nerves. A non-healing sore, a changing mole or a persistent scaly patch on the head or neck should be examined with dermoscopy and biopsied rather than treated as eczema or an infection. **Global burden (2022):** millions of skin cancers each year worldwide; GLOBOCAN 2022 estimated ASR 3.2 for melanoma of skin and 10.4 for non-melanoma skin cancer per 100,000 (ASR 3.2 (melanoma) and 10.4 (non-melanoma skin cancer) per 100,000; mortality ASR 0.5 and 0.6 respectively). Non-melanoma incidence figures exclude basal cell carcinoma in GLOBOCAN tables, so they substantially undercount the true number of skin cancers treated. **Where it is common** - Australia & New Zealand: The highest population skin cancer burden in the world, driven by high ambient UV and a predominantly fair-skinned population; head and neck sites are the most commonly treated locations. - North America: High melanoma and keratinocyte cancer incidence, particularly in older fair-skinned adults and in states with high UV exposure. - Northern & Western Europe: Rising melanoma incidence in fair-skinned populations; intermittent intense sun exposure and tanning-bed use are important drivers. - Southern Europe & the Mediterranean: High cumulative sun exposure among outdoor workers, with substantial cSCC and lip cancer burdens. - Organ-transplant recipients worldwide: Chronic immunosuppression markedly increases cSCC risk independent of geography, often with multiple and more aggressive head and neck lesions. **Risk factors** - Cumulative ultraviolet radiation and a history of blistering sunburn, especially in childhood - Fair skin, light hair/eye colour, freckling and inability to tan - Tanning-bed use and intermittent intense recreational sun exposure - Chronic immunosuppression (organ transplantation, HIV, some haematological diseases) - Previous skin cancer, actinic keratoses, arsenic or ionising radiation exposure - Increasing age, male sex and outdoor occupation **Signs and symptoms** - A sore or crusted spot on the face, ear, scalp or neck that does not heal within a few weeks - A pearly or translucent bump with visible vessels (typical of basal cell carcinoma) - A scaly, tender or rapidly growing keratotic nodule (typical of cutaneous SCC) - A changing mole — asymmetry, irregular border, varied colour, increasing diameter, evolution (ABCDE) - New numbness, tingling, facial weakness or pain near a lesion (possible perineural invasion) - Lumps in front of the ear, in the parotid region or in the neck (nodal metastasis) **Diagnosis and staging** - Full skin and head/neck examination with dermoscopy by an experienced clinician - Excisional biopsy for suspected melanoma with Breslow depth reported; incisional or punch biopsy for large facial lesions - Pathology assessment of histological subtype, Breslow thickness, ulceration, margins and perineural invasion - Ultrasound ± FNA of regional nodes (including parotid nodes) for high-risk cSCC, melanoma or Merkel cell carcinoma - MRI with contrast when perineural invasion or deep extension is suspected; CT/PET-CT for advanced disease - Sentinel lymph node biopsy for melanoma of appropriate thickness and selected high-risk tumours Melanoma uses AJCC staging based primarily on Breslow thickness, ulceration, nodal involvement and distant metastasis. Cutaneous SCC of the head and neck uses a separate high-risk framework that considers size, depth, perineural invasion, ear/lip location, immunosuppression and nodal disease; a "small" ear lesion can therefore be high stage. **Treatment options** - Wide local excision with confirmed margins; Mohs micrographic surgery for facial lesions where tissue preservation matters - Reconstruction with local flaps or skin grafts, often in partnership with plastic/oculoplastic surgery for eyelid, nose and ear defects - Sentinel lymph node biopsy for eligible melanomas; therapeutic neck/parotid dissection and adjuvant radiotherapy for nodal disease - Radiotherapy for inoperable lesions, perineural invasion, positive margins or patients unfit for surgery - Immunotherapy (PD-1 ± CTLA-4 inhibitors) and BRAF/MEK targeted therapy for advanced melanoma; PD-1 inhibitors for advanced cSCC and Merkel cell carcinoma - Field treatment of actinic keratoses and structured lifelong skin surveillance **Prognosis** Localised basal cell carcinoma is almost always curable, and thin localised melanoma has five-year survival commonly above 90%. Prognosis worsens with thick or ulcerated melanoma, nodal metastasis, head and neck cSCC with perineural invasion, and immunosuppression. Because UV damage is field-wide, new primary skin cancers are common and long-term surveillance is essential. **Prevention** - Daily broad-spectrum sunscreen, protective clothing and wide-brimmed hats, and shade at peak UV hours - Avoid tanning beds entirely - Regular self-examination of the face, ears, scalp and neck; periodic clinician skin checks for high-risk patients - Prompt biopsy of any non-healing or changing lesion, especially on the ear, scalp or lip - Enhanced dermatology surveillance and sun protection for organ-transplant recipients **Treatment in China** Head and neck skin cancer is less common in China than in Australia, New Zealand or North America, so international patients should confirm that the treating unit has experience with Mohs surgery, parotid/neck nodal management, perineural imaging and facial reconstruction, and can provide the immunotherapy agents used at home. - Bring the original pathology slides, Breslow depth or high-risk features, dermoscopic photographs and any sentinel node results. - Ask whether the planned wide local excision margin and reconstruction match the standards in your home country, and whether Mohs surgery is available. - If immunotherapy or targeted therapy is part of your plan, confirm the exact drug, dose, cycle schedule, stock availability and price in writing before travel. - Request the full pathology and operative report in English so your dermatologist or oncologist can continue surveillance. Cost guidance: As an illustrative planning range, wide local excision with local flap reconstruction is commonly budgeted at ¥20,000–¥80,000 (about US$2,800–11,000); neck/parotid dissection with adjuvant radiotherapy ¥80,000–¥180,000. Modern immunotherapy is charged per cycle and can dominate the total. These figures are not a quotation. ### All 14 questions about Skin Cancer of the Head and Neck #### What is skin cancer of the head and neck? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Skin cancers of the head and neck are tumours arising on chronically sun-exposed skin — basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma being the most common. They are especially frequent in fair-skinned populations in Australia, New Zealand and North America, and the head and neck is the most common site because it receives the highest lifetime UV dose. The head, face, ears, scalp and neck account for a disproportionate share of skin cancers even though they are a small fraction of body surface area. Basal cell carcinoma is the commonest and rarely metastasises but can be locally destructive around the eyes, nose and ear. Cutaneous squamous cell carcinoma of the head and neck has a higher risk of perineural spread and nodal metastasis than cSCC elsewhere on the body; melanoma is less common but causes most skin cancer deaths. Lesions on the ear, scalp, temple and lip deserve particular respect: these sites have thin tissue, rich lymphatic drainage and proximity to cranial nerves. A non-healing sore, a changing mole or a persistent scaly patch on the head or neck should be examined with dermoscopy and biopsied rather than treated as eczema or an infection. Sources: Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Where in the world is skin cancer of the head and neck most common? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Skin Cancer of the Head and Neck is not evenly distributed: the highest-burden regions are Australia & New Zealand, North America and Northern & Western Europe. In 2022 there were millions of skin cancers each year worldwide; GLOBOCAN 2022 estimated ASR 3.2 for melanoma of skin and 10.4 for non-melanoma skin cancer per 100,000 worldwide (ASR 3.2 (melanoma) and 10.4 (non-melanoma skin cancer) per 100,000; mortality ASR 0.5 and 0.6 respectively), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from Australia & New Zealand may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - Australia & New Zealand: The highest population skin cancer burden in the world, driven by high ambient UV and a predominantly fair-skinned population; head and neck sites are the most commonly treated locations. - North America: High melanoma and keratinocyte cancer incidence, particularly in older fair-skinned adults and in states with high UV exposure. - Northern & Western Europe: Rising melanoma incidence in fair-skinned populations; intermittent intense sun exposure and tanning-bed use are important drivers. - Southern Europe & the Mediterranean: High cumulative sun exposure among outdoor workers, with substantial cSCC and lip cancer burdens. - Organ-transplant recipients worldwide: Chronic immunosuppression markedly increases cSCC risk independent of geography, often with multiple and more aggressive head and neck lesions. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What are the risk factors for skin cancer of the head and neck? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for skin cancer of the head and neck are cumulative ultraviolet radiation and a history of blistering sunburn, especially in childhood, fair skin, light hair/eye colour, freckling and inability to tan and tanning-bed use and intermittent intense recreational sun exposure. Risks differ by region: Australia & New Zealand has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Cumulative ultraviolet radiation and a history of blistering sunburn, especially in childhood - Fair skin, light hair/eye colour, freckling and inability to tan - Tanning-bed use and intermittent intense recreational sun exposure - Chronic immunosuppression (organ transplantation, HIV, some haematological diseases) - Previous skin cancer, actinic keratoses, arsenic or ionising radiation exposure - Increasing age, male sex and outdoor occupation Sources: Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What are the early signs of skin cancer of the head and neck? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a sore or crusted spot on the face, ear, scalp or neck that does not heal within a few weeks, a pearly or translucent bump with visible vessels (typical of basal cell carcinoma), a scaly, tender or rapidly growing keratotic nodule (typical of cutaneous SCC) and a changing mole — asymmetry, irregular border, varied colour, increasing diameter, evolution (ABCDE). Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A sore or crusted spot on the face, ear, scalp or neck that does not heal within a few weeks - A pearly or translucent bump with visible vessels (typical of basal cell carcinoma) - A scaly, tender or rapidly growing keratotic nodule (typical of cutaneous SCC) - A changing mole — asymmetry, irregular border, varied colour, increasing diameter, evolution (ABCDE) - New numbness, tingling, facial weakness or pain near a lesion (possible perineural invasion) - Lumps in front of the ear, in the parotid region or in the neck (nodal metastasis) Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### How is skin cancer of the head and neck diagnosed and staged? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. Melanoma uses AJCC staging based primarily on Breslow thickness, ulceration, nodal involvement and distant metastasis. Cutaneous SCC of the head and neck uses a separate high-risk framework that considers size, depth, perineural invasion, ear/lip location, immunosuppression and nodal disease; a "small" ear lesion can therefore be high stage. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Full skin and head/neck examination with dermoscopy by an experienced clinician - Excisional biopsy for suspected melanoma with Breslow depth reported; incisional or punch biopsy for large facial lesions - Pathology assessment of histological subtype, Breslow thickness, ulceration, margins and perineural invasion - Ultrasound ± FNA of regional nodes (including parotid nodes) for high-risk cSCC, melanoma or Merkel cell carcinoma - MRI with contrast when perineural invasion or deep extension is suspected; CT/PET-CT for advanced disease - Sentinel lymph node biopsy for melanoma of appropriate thickness and selected high-risk tumours Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What are the treatment options for skin cancer of the head and neck? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines wide local excision with confirmed margins; Mohs micrographic surgery for facial lesions where tissue preservation matters, reconstruction with local flaps or skin grafts, often in partnership with plastic/oculoplastic surgery for eyelid, nose and ear defects and sentinel lymph node biopsy for eligible melanomas; therapeutic neck/parotid dissection and adjuvant radiotherapy for nodal disease. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Wide local excision with confirmed margins; Mohs micrographic surgery for facial lesions where tissue preservation matters - Reconstruction with local flaps or skin grafts, often in partnership with plastic/oculoplastic surgery for eyelid, nose and ear defects - Sentinel lymph node biopsy for eligible melanomas; therapeutic neck/parotid dissection and adjuvant radiotherapy for nodal disease - Radiotherapy for inoperable lesions, perineural invasion, positive margins or patients unfit for surgery - Immunotherapy (PD-1 ± CTLA-4 inhibitors) and BRAF/MEK targeted therapy for advanced melanoma; PD-1 inhibitors for advanced cSCC and Merkel cell carcinoma - Field treatment of actinic keratoses and structured lifelong skin surveillance Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What is the prognosis for skin cancer of the head and neck? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Localised basal cell carcinoma is almost always curable, and thin localised melanoma has five-year survival commonly above 90%. Prognosis worsens with thick or ulcerated melanoma, nodal metastasis, head and neck cSCC with perineural invasion, and immunosuppression. Because UV damage is field-wide, new primary skin cancers are common and long-term surveillance is essential. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Can skin cancer of the head and neck be prevented? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for skin cancer of the head and neck are daily broad-spectrum sunscreen, protective clothing and wide-brimmed hats, and shade at peak UV hours, avoid tanning beds entirely and regular self-examination of the face, ears, scalp and neck; periodic clinician skin checks for high-risk patients. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Daily broad-spectrum sunscreen, protective clothing and wide-brimmed hats, and shade at peak UV hours - Avoid tanning beds entirely - Regular self-examination of the face, ears, scalp and neck; periodic clinician skin checks for high-risk patients - Prompt biopsy of any non-healing or changing lesion, especially on the ear, scalp or lip - Enhanced dermatology surveillance and sun protection for organ-transplant recipients Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Why are skin cancers so common on the head and neck? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/why-head-and-neck/ Cluster: Understanding the disease **Answer:** The face, ears, scalp and neck receive the highest lifetime cumulative ultraviolet dose of any body area and are rarely covered by clothing. Combined with thin skin, plentiful lymphatics and proximity to cranial nerves, this makes the head and neck both the most frequent site of skin cancer and the site where relatively small tumours can behave aggressively. This is why Australia and New Zealand, with high ambient UV and a largely fair-skinned population, carry the world’s highest skin cancer burden, and why public-health sun protection campaigns have measurable effects on incidence decades later. Sources: Ultraviolet radiation and skin cancer (fact sheet) (World Health Organization, 2024) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf #### What is the difference between basal cell carcinoma, squamous cell carcinoma and melanoma? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/bcc-vs-scc-vs-melanoma/ Cluster: Understanding the disease **Answer:** Basal cell carcinoma grows slowly and almost never spreads to nodes but can destroy local tissue, especially around the eye, nose and ear. Cutaneous squamous cell carcinoma grows faster and can spread to parotid or neck nodes, particularly on the head and neck. Melanoma is less common but has the greatest metastatic potential and causes most skin cancer deaths. The distinction is made by biopsy, not by appearance alone. Treatment margins, need for sentinel node biopsy and surveillance intensity differ substantially between the three, so insist on a written pathology report before planning surgery. Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What does perineural invasion mean in a head and neck skin cancer? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/perineural-invasion/ Cluster: Symptoms & diagnosis **Answer:** Perineural invasion means tumour cells are tracking along a nerve sheath. On the head and neck it is clinically important because it can cause pain, numbness, tingling or facial weakness, allows spread well beyond the visible lesion toward the skull base, and usually changes treatment to wider excision with contrast MRI and adjuvant radiotherapy. Any new facial numbness, twitching, weakness or burning pain near a skin lesion should be reported immediately, even if the skin looks better after a biopsy or cream. Early imaging and multidisciplinary planning are essential. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Is Mohs surgery appropriate for facial skin cancer? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/mohs-surgery/ Cluster: Treatment **Answer:** Mohs micrographic surgery removes the tumour layer by layer with immediate microscopic margin control, sparing the maximum amount of normal tissue. It is particularly useful for basal cell and squamous cell cancers on the eyelids, nose, lips and ears, and for recurrent or poorly defined lesions where standard margins would cause avoidable deformity. It is not the usual choice for melanoma or for tumours with nodal spread. Ask whether a Mohs-trained surgeon is available and how the resulting defect will be reconstructed — the reconstructive plan is often as important as the excision. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Can I continue immunotherapy for melanoma or advanced skin cancer while in China? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/immunotherapy-availability/ Cluster: Treatment in China **Answer:** Often yes, but it must be arranged in advance. PD-1 inhibitors, CTLA-4 inhibitors and BRAF/MEK targeted agents are used in Chinese tertiary centres, yet the specific brand, dose, cycle interval, stock and price may differ from your home regimen. Continuing an established regimen without a verified plan risks an unplanned treatment gap. Bring the exact drug name, dose, cycle dates, last infusion date, recent imaging and any immune-related adverse-event history. Ask for a written continuation plan and for the cycle schedule in English; also confirm how immune-related side effects would be managed while you are abroad. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What does head and neck skin cancer treatment cost in China? URL: https://www.entliu.com/conditions/head-and-neck-skin-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** Illustrative planning ranges are ¥20,000–¥80,000 (about US$2,800–11,000) for wide excision with local flap reconstruction and ¥80,000–¥180,000 for neck or parotid dissection with adjuvant radiotherapy. Immunotherapy and targeted agents are charged per cycle and may exceed the surgical cost. These are budgeting figures, not a quotation. Request an itemised written estimate covering pathology review, Mohs or margin control, reconstruction, imaging and drug costs. Because these tumours are less common in China, verifying the centre’s experience is as important as comparing prices. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Salivary Gland Tumours URL: https://www.entliu.com/conditions/salivary-gland-tumors/ Also known as: Parotid tumour; Submandibular gland tumour; Pleomorphic adenoma; Warthin tumour; Mucoepidermoid carcinoma; Adenoid cystic carcinoma Classification: ICD-O-3 C07–C08 Quick answer: Salivary gland tumours are a diverse group of benign and malignant growths in the parotid, submandibular, sublingual and minor salivary glands. They are rare worldwide, with comparatively higher relative rates in parts of Western and Central Africa. Most parotid tumours are benign, but facial nerve weakness, rapid growth or pain suggest malignancy and require specialist surgery. Roughly four in five salivary gland tumours arise in the parotid gland in front of the ear, and the majority of those are benign — pleomorphic adenoma and Warthin tumour being the commonest. Tumours of the submandibular and minor salivary glands (for example on the palate) have a higher probability of being malignant, so site is an important part of the assessment. Salivary gland cancers are unusual among head and neck tumours because histology drives management more than size. Adenoid cystic carcinoma, for instance, grows slowly but tracks along nerves and can recur many years later; mucoepidermoid and salivary duct carcinomas behave quite differently. A core biopsy or expert FNA review is therefore valuable before planning the operation. **Global burden (2022):** about 55,100 new salivary gland cancer cases worldwide (male ASR 0.7 and female ASR 0.5 per 100,000; 7.3% of all lip/oral/pharyngeal cancers in 2022). GLOBOCAN 2022 reported 55,083 cases with an ASR of 0.56 per 100,000. Benign tumours are far more common but are not counted in cancer registries. **Where it is common** - Western Africa: Salivary gland cancers represent 21.8% of the region’s lip/oral/pharyngeal cancer burden — the highest relative share worldwide — with Burkina Faso reporting the highest female ASR (1.2/100,000). - Central Africa: 16.1% of the regional lip/oral/pharyngeal burden; salivary gland cancer is the most common subsite in men in Benin, Chad and Togo in the 2022 analysis. - Haiti & the Caribbean: Haiti reported one of the highest male ASRs (1.9/100,000) in the subsite analysis, illustrating small-population variation. - South-Central Asia: Among the lowest relative shares (4.0%), because oral cavity cancer dominates the regional burden. - Europe & North America: Low absolute rates but well-characterised histology; prior radiotherapy, smoking (Warthin tumour) and autoimmune disease are recognised associations. **Risk factors** - Previous ionising radiation to the head and neck (including childhood radiotherapy) - Cigarette smoking — strongly associated with Warthin tumour - Sjögren syndrome and other autoimmune disease (lymphoma / MALT) - Occupational exposure to nickel compounds, silica, wood or leather dust in some studies - Prior benign pleomorphic adenoma, which can rarely transform into carcinoma ex pleomorphic adenoma - Viral associations in specific subtypes (e.g. EBV in lymphoepithelial carcinoma in endemic populations) **Signs and symptoms** - A painless, slowly growing lump in front of or below the ear (parotid) or under the jaw - Weakness or asymmetry of facial movement — a warning sign for malignant invasion - Rapid growth, pain, skin fixation, ulceration or numbness - A swelling on the palate, inside the cheek or on the upper lip (minor salivary glands) - Difficulty opening the mouth or swallowing with deep-lobe tumours - Hard lumps in the neck from nodal spread in high-grade cancers **Diagnosis and staging** - Clinical examination including facial nerve function and bimanual palpation of the oral cavity - High-resolution ultrasound plus contrast MRI (best for deep-lobe, perineural and skull-base extension) or CT when bone detail is needed - Ultrasound-guided core-needle biopsy or FNA reported by a head and neck cytopathologist - Assessment of facial nerve involvement, skin/ bone fixation and cervical nodes - Chest imaging and PET-CT for high-grade or advanced malignant histology - Multidisciplinary review, because the operation differs markedly between benign and malignant pathology AJCC TNM staging for major salivary gland cancers uses tumour size, extraparenchymal extension, facial nerve involvement, nodal metastases and distant metastasis. Unlike squamous cell carcinoma of the oral cavity, grade and histological subtype are often more important for adjuvant treatment decisions than T category alone. **Treatment options** - Superficial or total parotidectomy with identification and preservation of the facial nerve for benign and low-grade tumours - Excision of submandibular or minor gland tumours with appropriate margins; avoid simple "shelling out" of a pleomorphic adenoma because of recurrence risk - Neck dissection for high-grade, node-positive or advanced malignant tumours - Adjuvant radiotherapy for high grade, positive margins, perineural invasion, nodal disease or adenoid cystic carcinoma; neutron/proton therapy in selected centres - Systemic therapy, targeted therapy or clinical trials for unresectable, recurrent or metastatic disease - Observation of small asymptomatic Warthin tumours in older or high-risk patients may be reasonable **Prognosis** Benign pleomorphic adenoma has excellent outcomes after complete excision. Low-grade malignant tumours often have five-year survival above 80%, while high-grade tumours, salivary duct carcinoma and node-positive disease do considerably worse. Adenoid cystic carcinoma is notable for late local recurrence and distant metastasis, so follow-up extends beyond five years; facial nerve function and chronic recurrence are the main quality-of-life issues. **Prevention** - Avoid unnecessary head and neck radiation, especially in children - Stop smoking — relevant to Warthin tumour and overall head and neck cancer risk - Use respiratory protection in dust- and nickel-exposed occupations - Have any persistent parotid or submandibular lump imaged and sampled rather than observed indefinitely - Long-term follow-up after pleomorphic adenoma to detect rare malignant transformation **Treatment in China** Parotid and submandibular surgery is a standard part of Chinese ENT/head and neck practice, with intraoperative facial nerve monitoring and immediate reconstruction available in tertiary centres. For international patients, a key question is whether a benign tumour can be removed with minimal dissection and preserved nerve function. - Bring ultrasound/MRI images on DICOM and the FNA or core biopsy report and slides; histology changes the operation substantially. - Ask whether facial nerve monitoring is used, what the expected temporary weakness rate is, and how the nerve would be managed if it is involved. - Request written pathology including margin status, grade, perineural invasion and lymphovascular invasion. - For adenoid cystic carcinoma, ask about the long-term surveillance plan, since late recurrence is characteristic. Cost guidance: As an illustrative planning range, parotidectomy for a benign tumour is commonly budgeted at ¥25,000–¥60,000 (about US$3,500–8,400); malignant tumour surgery with neck dissection and adjuvant radiotherapy ¥70,000–¥170,000. These are budgeting figures, not a quotation. ### All 14 questions about Salivary Gland Tumours #### What is salivary gland tumours? URL: https://www.entliu.com/conditions/salivary-gland-tumors/what-is-it/ Cluster: Understanding the disease **Answer:** Salivary gland tumours are a diverse group of benign and malignant growths in the parotid, submandibular, sublingual and minor salivary glands. They are rare worldwide, with comparatively higher relative rates in parts of Western and Central Africa. Most parotid tumours are benign, but facial nerve weakness, rapid growth or pain suggest malignancy and require specialist surgery. Roughly four in five salivary gland tumours arise in the parotid gland in front of the ear, and the majority of those are benign — pleomorphic adenoma and Warthin tumour being the commonest. Tumours of the submandibular and minor salivary glands (for example on the palate) have a higher probability of being malignant, so site is an important part of the assessment. Salivary gland cancers are unusual among head and neck tumours because histology drives management more than size. Adenoid cystic carcinoma, for instance, grows slowly but tracks along nerves and can recur many years later; mucoepidermoid and salivary duct carcinomas behave quite differently. A core biopsy or expert FNA review is therefore valuable before planning the operation. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Where in the world is salivary gland tumours most common? URL: https://www.entliu.com/conditions/salivary-gland-tumors/where-is-it-common/ Cluster: Understanding the disease **Answer:** Salivary Gland Tumours is not evenly distributed: the highest-burden regions are Western Africa, Central Africa and Haiti & the Caribbean. In 2022 there were about 55,100 new salivary gland cancer cases worldwide worldwide (male ASR 0.7 and female ASR 0.5 per 100,000; 7.3% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from Western Africa may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - Western Africa: Salivary gland cancers represent 21.8% of the region’s lip/oral/pharyngeal cancer burden — the highest relative share worldwide — with Burkina Faso reporting the highest female ASR (1.2/100,000). - Central Africa: 16.1% of the regional lip/oral/pharyngeal burden; salivary gland cancer is the most common subsite in men in Benin, Chad and Togo in the 2022 analysis. - Haiti & the Caribbean: Haiti reported one of the highest male ASRs (1.9/100,000) in the subsite analysis, illustrating small-population variation. - South-Central Asia: Among the lowest relative shares (4.0%), because oral cavity cancer dominates the regional burden. - Europe & North America: Low absolute rates but well-characterised histology; prior radiotherapy, smoking (Warthin tumour) and autoimmune disease are recognised associations. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What are the risk factors for salivary gland tumours? URL: https://www.entliu.com/conditions/salivary-gland-tumors/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for salivary gland tumours are previous ionising radiation to the head and neck (including childhood radiotherapy), cigarette smoking — strongly associated with Warthin tumour and sjögren syndrome and other autoimmune disease (lymphoma / MALT). Risks differ by region: Western Africa has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Previous ionising radiation to the head and neck (including childhood radiotherapy) - Cigarette smoking — strongly associated with Warthin tumour - Sjögren syndrome and other autoimmune disease (lymphoma / MALT) - Occupational exposure to nickel compounds, silica, wood or leather dust in some studies - Prior benign pleomorphic adenoma, which can rarely transform into carcinoma ex pleomorphic adenoma - Viral associations in specific subtypes (e.g. EBV in lymphoepithelial carcinoma in endemic populations) Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What are the early signs of salivary gland tumours? URL: https://www.entliu.com/conditions/salivary-gland-tumors/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a painless, slowly growing lump in front of or below the ear (parotid) or under the jaw, weakness or asymmetry of facial movement — a warning sign for malignant invasion, rapid growth, pain, skin fixation, ulceration or numbness and a swelling on the palate, inside the cheek or on the upper lip (minor salivary glands). Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A painless, slowly growing lump in front of or below the ear (parotid) or under the jaw - Weakness or asymmetry of facial movement — a warning sign for malignant invasion - Rapid growth, pain, skin fixation, ulceration or numbness - A swelling on the palate, inside the cheek or on the upper lip (minor salivary glands) - Difficulty opening the mouth or swallowing with deep-lobe tumours - Hard lumps in the neck from nodal spread in high-grade cancers Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### How is salivary gland tumours diagnosed and staged? URL: https://www.entliu.com/conditions/salivary-gland-tumors/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. AJCC TNM staging for major salivary gland cancers uses tumour size, extraparenchymal extension, facial nerve involvement, nodal metastases and distant metastasis. Unlike squamous cell carcinoma of the oral cavity, grade and histological subtype are often more important for adjuvant treatment decisions than T category alone. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Clinical examination including facial nerve function and bimanual palpation of the oral cavity - High-resolution ultrasound plus contrast MRI (best for deep-lobe, perineural and skull-base extension) or CT when bone detail is needed - Ultrasound-guided core-needle biopsy or FNA reported by a head and neck cytopathologist - Assessment of facial nerve involvement, skin/ bone fixation and cervical nodes - Chest imaging and PET-CT for high-grade or advanced malignant histology - Multidisciplinary review, because the operation differs markedly between benign and malignant pathology Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What are the treatment options for salivary gland tumours? URL: https://www.entliu.com/conditions/salivary-gland-tumors/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines superficial or total parotidectomy with identification and preservation of the facial nerve for benign and low-grade tumours, excision of submandibular or minor gland tumours with appropriate margins; avoid simple "shelling out" of a pleomorphic adenoma because of recurrence risk and neck dissection for high-grade, node-positive or advanced malignant tumours. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Superficial or total parotidectomy with identification and preservation of the facial nerve for benign and low-grade tumours - Excision of submandibular or minor gland tumours with appropriate margins; avoid simple "shelling out" of a pleomorphic adenoma because of recurrence risk - Neck dissection for high-grade, node-positive or advanced malignant tumours - Adjuvant radiotherapy for high grade, positive margins, perineural invasion, nodal disease or adenoid cystic carcinoma; neutron/proton therapy in selected centres - Systemic therapy, targeted therapy or clinical trials for unresectable, recurrent or metastatic disease - Observation of small asymptomatic Warthin tumours in older or high-risk patients may be reasonable Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What is the prognosis for salivary gland tumours? URL: https://www.entliu.com/conditions/salivary-gland-tumors/prognosis/ Cluster: Prognosis & follow-up **Answer:** Benign pleomorphic adenoma has excellent outcomes after complete excision. Low-grade malignant tumours often have five-year survival above 80%, while high-grade tumours, salivary duct carcinoma and node-positive disease do considerably worse. Adenoid cystic carcinoma is notable for late local recurrence and distant metastasis, so follow-up extends beyond five years; facial nerve function and chronic recurrence are the main quality-of-life issues. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Can salivary gland tumours be prevented? URL: https://www.entliu.com/conditions/salivary-gland-tumors/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for salivary gland tumours are avoid unnecessary head and neck radiation, especially in children, stop smoking — relevant to Warthin tumour and overall head and neck cancer risk and use respiratory protection in dust- and nickel-exposed occupations. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Avoid unnecessary head and neck radiation, especially in children - Stop smoking — relevant to Warthin tumour and overall head and neck cancer risk - Use respiratory protection in dust- and nickel-exposed occupations - Have any persistent parotid or submandibular lump imaged and sampled rather than observed indefinitely - Long-term follow-up after pleomorphic adenoma to detect rare malignant transformation Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) (European Medicines Agency, 2025) https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Is a parotid lump usually cancer? URL: https://www.entliu.com/conditions/salivary-gland-tumors/is-it-cancer/ Cluster: Understanding the disease **Answer:** No. Most parotid gland tumours are benign, particularly pleomorphic adenoma and Warthin tumour. Features that raise concern are rapid growth, pain, facial nerve weakness, hard fixation to skin or deep tissue, numbness and neck nodes. Tumours in the submandibular or minor salivary glands have a higher chance of being malignant. A slow-growing, painless lump still needs imaging and tissue sampling: pleomorphic adenomas can slowly enlarge, rarely undergo malignant transformation, and become harder to remove without nerve injury the longer they are left. Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ #### Will surgery damage the facial nerve? URL: https://www.entliu.com/conditions/salivary-gland-tumors/facial-nerve-preservation/ Cluster: Treatment **Answer:** For benign and most low-grade tumours, the facial nerve is identified and preserved, often with intraoperative nerve monitoring. Temporary weakness of part of the face is not uncommon from nerve manipulation and usually recovers over weeks to months. The nerve is sacrificed only when it is directly invaded by cancer and cannot be separated, in which case reconstruction may be planned. Ask your surgeon about their approach to the nerve, the expected rate of temporary and permanent weakness, and whether facial reanimation (nerve graft, muscle transfer or static procedures) is available if needed. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Why can’t a benign parotid lump simply be "shelled out"? URL: https://www.entliu.com/conditions/salivary-gland-tumors/why-not-shell-out/ Cluster: Treatment **Answer:** Pleomorphic adenomas have microscopic extensions beyond their capsule and a thin, incomplete pseudocapsule. Simply enucleating the lump leaves tumour cells behind and risks multifocal recurrence that is much harder to remove later, often with greater risk to the facial nerve. Formal superficial or total parotidectomy with nerve preservation is the standard. Recurrent pleomorphic adenoma is frequently multinodular and may require more extensive surgery and radiotherapy. The first operation is the best opportunity for cure with the least morbidity. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Why does adenoid cystic carcinoma need such long follow-up? URL: https://www.entliu.com/conditions/salivary-gland-tumors/adenoid-cystic-followup/ Cluster: Prognosis & follow-up **Answer:** Adenoid cystic carcinoma has a characteristic pattern of slow growth, perineural spread and late local recurrence or lung metastasis — sometimes five, ten or more years after apparently successful treatment. Short-term survival can look excellent even when long-term control is uncertain. Surveillance therefore extends well beyond five years and includes the skull base along nerve pathways, chest imaging and attention to new numbness, pain or facial weakness. Ask for a written long-term plan that a local team can continue. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### Why do salivary gland cancers make up a larger share of head and neck cancer in parts of Africa? URL: https://www.entliu.com/conditions/salivary-gland-tumors/africa-pattern/ Cluster: Understanding the disease **Answer:** The 2022 subsite analysis found the highest relative shares in Western Africa (21.8%) and Central Africa (16.1%), with high male ASRs in Haiti and Togo. These figures mostly reflect the comparatively low rates of other lip/oral/pharyngeal subsites in those regions plus registry and diagnostic variation, rather than a proven single environmental cause. Relative share is not the same as absolute risk: salivary gland cancer remains rare everywhere. Registry coverage and histopathology access in low-resource settings also influence how tumours are classified, so country rankings should be interpreted cautiously. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en #### What does salivary gland surgery cost in China for international patients? URL: https://www.entliu.com/conditions/salivary-gland-tumors/cost-in-china/ Cluster: Treatment in China **Answer:** Illustrative planning ranges are ¥25,000–¥60,000 (about US$3,500–8,400) for parotidectomy for a benign tumour and ¥70,000–¥170,000 for malignant tumour surgery with neck dissection and adjuvant radiotherapy. These are budgeting figures, not a quotation. Ask whether facial nerve monitoring, pathology review, a short inpatient stay and any physiotherapy are included. If radiotherapy is likely after a high-grade tumour, plan for a six-to-seven-week stay rather than a short surgical trip. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Sinonasal Cancer URL: https://www.entliu.com/conditions/sinonasal-cancer/ Also known as: Nasal cavity cancer; Paranasal sinus cancer; Maxillary sinus cancer; Esthesioneuroblastoma; Sinonasal undifferentiated carcinoma Classification: ICD-O-3 C30–C31 Quick answer: Sinonasal cancer is a rare group of tumours arising in the nasal cavity and paranasal sinuses, including squamous cell carcinoma, adenocarcinoma, melanoma, lymphoma and esthesioneuroblastoma. There is no strong endemic country, but well-defined occupational clusters occur in industrialised countries — especially wood-dust-associated ethmoid adenocarcinoma. Symptoms mimic chronic sinusitis, so diagnosis is often delayed. Sinonasal malignancies account for only a few percent of head and neck cancers, but they are unusually heterogeneous: more than a dozen histological types occur in a small anatomical space. The maxillary sinus is the most frequently involved sinus; the ethmoid sinus is classically associated with wood-dust exposure. Because the sinuses are air-filled cavities, tumours can become large before producing signs. The single most important diagnostic lesson is that unilateral, persistent nasal symptoms are not 'just sinusitis'. One-sided blockage, bleeding, loss of smell, facial numbness, double vision, a swollen cheek or palate, or a loose upper tooth should prompt nasal endoscopy and contrast imaging. Biopsy should be planned after imaging when a vascular tumour or skull-base lesion is possible. **Global burden (2022):** roughly 3–5% of all head and neck malignancies; incidence around 0.5–1 case per 100,000 per year in Western registries (no single global ASR — sinonasal sites are grouped within C30–C31 and are too rare for stable country rankings). Rarity plus varied coding means registry figures must be interpreted with caution; occupational cohort studies are more informative than national rankings. **Where it is common** - Europe (occupational clusters): Wood-dust exposure in furniture, cabinet-making and sawmill workers is a recognised cause of ethmoid sinus adenocarcinoma, with well-documented occupational cohorts in France, Italy, Germany and the Nordic countries. - North America: Occupational nickel, chromium, formaldehyde and wood-dust exposures plus HPV-associated sinonasal squamous cell carcinoma are the main recognised risk patterns. - East Asia: Sinonasal undifferentiated carcinoma and EBV-associated sinonasal lymphoepithelial lesions are reported more often in EBV-endemic Asian populations, though all types remain rare. - North Africa & the Middle East: Nasopharyngeal carcinoma rather than sinonasal cancer dominates this region; distinguishing the two requires endoscopy and MRI because symptoms overlap. - No true endemic region: Unlike NPC or oral cavity cancer, sinonasal cancer shows no strong population-level geographic hotspot; exposure history matters more than nationality. **Risk factors** - Occupational wood dust (especially hardwood) — IARC Group 1 carcinogen for sinonasal adenocarcinoma - Nickel compounds, hexavalent chromium, leather dust, formaldehyde and certain solvents - Cigarette smoking and, for some histological types, high-risk HPV infection - EBV in sinonasal lymphoepithelial carcinoma in endemic populations - Inverted papilloma — a benign but locally aggressive tumour that can harbour or progress to squamous cell carcinoma - Prior radiotherapy to the head and neck **Signs and symptoms** - Persistent one-sided nasal obstruction or discharge that does not respond to treatment - Recurrent unilateral nosebleeds or blood-stained discharge - Reduced or lost sense of smell, facial pressure or a unilateral headache - Facial numbness, cheek swelling, loose upper teeth or a palatal swelling - Double vision, protruding eye (proptosis) or excessive tearing from orbital involvement - A neck lump, or cranial nerve changes in advanced skull-base disease **Diagnosis and staging** - Nasal endoscopy with rigid or flexible scopes and photographic documentation - Contrast MRI for soft tissue, perineural and skull-base extension; dedicated sinus CT for bone detail - Image-planned biopsy (avoid blind biopsy of vascular lesions or encephaloceles) with expert head and neck pathology review - Immunohistochemistry for HPV/p16, EBV (EBER), melanoma, lymphoma and neuroendocrine markers as indicated - Neck imaging and PET-CT/chest imaging for high-grade or advanced disease; ophthalmology and neurosurgery input when the orbit or skull base is involved - Multidisciplinary skull-base tumour board before any resection Staging is site- and histology-specific (AJCC for nasal cavity/ethmoid and maxillary sinus; separate systems for esthesioneuroblastoma and mucosal melanoma). Extension to the orbit, skull base, cribriform plate, pterygoid region or dura usually indicates advanced T category and determines whether an endoscopic or open craniofacial resection is feasible. **Treatment options** - Endoscopic endonasal skull-base resection for selected tumours, or craniofacial resection with orbital/skull-base reconstruction - Postoperative radiotherapy (often IMRT or proton therapy) for most malignant and advanced tumours; concurrent chemoradiotherapy in selected histologies - Neck dissection or nodal radiotherapy for node-positive squamous cell carcinoma, SNUC or melanoma - Systemic therapy for sinonasal undifferentiated carcinoma, small-cell carcinoma, lymphoma and melanoma; immunotherapy for mucosal melanoma and PD-L1-positive squamous tumours - Complete excision of inverted papilloma with surveillance for recurrence or malignant transformation - Reconstruction, orbital/dural repair, olfactory and dental rehabilitation, and long-term endoscopic surveillance **Prognosis** Outcome is driven more by histology and skull-base/orbital extension than by country. Localised, completely resected low-grade tumours can be controlled long-term, whereas sinonasal undifferentiated carcinoma, mucosal melanoma and tumours with dural or brain involvement have substantially poorer survival. Overall five-year survival across all types is commonly reported around 50–60% in mixed series. **Prevention** - Local exhaust ventilation, dust suppression and fitted respiratory protection in wood, leather, nickel and chromium work - Smoking cessation and appropriate HPV vaccination according to national schedules - Occupational health surveillance for exposed workers with persistent unilateral nasal symptoms - Complete removal and long-term endoscopic follow-up of inverted papilloma - Early nasal endoscopy for unilateral blockage, bleeding or smell loss lasting more than a few weeks **Treatment in China** Chinese tertiary centres with endoscopic skull-base teams can offer image-guided sinonasal resection and reconstruction, plus IMRT and pathology review. Because these tumours are rare, international patients should verify the centre’s specific experience with their histological subtype and with proton therapy if skull-base dosing is a concern. - Bring the biopsy slides for re-review (histology and HPV/EBV/melanoma markers), plus contrast MRI and dedicated sinus CT on DICOM. - Ask whether the planned approach is purely endoscopic or combined craniofacial, and how the skull base and orbit would be reconstructed. - Request a written radiotherapy plan specifying dose, technique (IMRT vs proton) and target volumes in English. - Confirm drug availability if immunotherapy or targeted therapy is part of the plan; rare histologies often need agents that are not stocked everywhere. Cost guidance: As an illustrative planning range, endoscopic resection is commonly budgeted at ¥50,000–¥130,000 (about US$7,000–18,000); combined craniofacial resection with reconstruction and adjuvant radiotherapy ¥130,000–¥280,000. Proton therapy and immunotherapy are priced separately. These are budgeting figures, not a quotation. ### All 13 questions about Sinonasal Cancer #### What is sinonasal cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Sinonasal cancer is a rare group of tumours arising in the nasal cavity and paranasal sinuses, including squamous cell carcinoma, adenocarcinoma, melanoma, lymphoma and esthesioneuroblastoma. There is no strong endemic country, but well-defined occupational clusters occur in industrialised countries — especially wood-dust-associated ethmoid adenocarcinoma. Symptoms mimic chronic sinusitis, so diagnosis is often delayed. Sinonasal malignancies account for only a few percent of head and neck cancers, but they are unusually heterogeneous: more than a dozen histological types occur in a small anatomical space. The maxillary sinus is the most frequently involved sinus; the ethmoid sinus is classically associated with wood-dust exposure. Because the sinuses are air-filled cavities, tumours can become large before producing signs. The single most important diagnostic lesson is that unilateral, persistent nasal symptoms are not 'just sinusitis'. One-sided blockage, bleeding, loss of smell, facial numbness, double vision, a swollen cheek or palate, or a loose upper tooth should prompt nasal endoscopy and contrast imaging. Biopsy should be planned after imaging when a vascular tumour or skull-base lesion is possible. Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### Where in the world is sinonasal cancer most common? URL: https://www.entliu.com/conditions/sinonasal-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Sinonasal Cancer is not evenly distributed: the highest-burden regions are Europe (occupational clusters), North America and East Asia. In 2022 there were roughly 3–5% of all head and neck malignancies; incidence around 0.5–1 case per 100,000 per year in Western registries worldwide (no single global ASR — sinonasal sites are grouped within C30–C31 and are too rare for stable country rankings), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from Europe (occupational clusters) may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - Europe (occupational clusters): Wood-dust exposure in furniture, cabinet-making and sawmill workers is a recognised cause of ethmoid sinus adenocarcinoma, with well-documented occupational cohorts in France, Italy, Germany and the Nordic countries. - North America: Occupational nickel, chromium, formaldehyde and wood-dust exposures plus HPV-associated sinonasal squamous cell carcinoma are the main recognised risk patterns. - East Asia: Sinonasal undifferentiated carcinoma and EBV-associated sinonasal lymphoepithelial lesions are reported more often in EBV-endemic Asian populations, though all types remain rare. - North Africa & the Middle East: Nasopharyngeal carcinoma rather than sinonasal cancer dominates this region; distinguishing the two requires endoscopy and MRI because symptoms overlap. - No true endemic region: Unlike NPC or oral cavity cancer, sinonasal cancer shows no strong population-level geographic hotspot; exposure history matters more than nationality. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What are the risk factors for sinonasal cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for sinonasal cancer are occupational wood dust (especially hardwood) — IARC Group 1 carcinogen for sinonasal adenocarcinoma, nickel compounds, hexavalent chromium, leather dust, formaldehyde and certain solvents and cigarette smoking and, for some histological types, high-risk HPV infection. Risks differ by region: Europe (occupational clusters) has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Occupational wood dust (especially hardwood) — IARC Group 1 carcinogen for sinonasal adenocarcinoma - Nickel compounds, hexavalent chromium, leather dust, formaldehyde and certain solvents - Cigarette smoking and, for some histological types, high-risk HPV infection - EBV in sinonasal lymphoepithelial carcinoma in endemic populations - Inverted papilloma — a benign but locally aggressive tumour that can harbour or progress to squamous cell carcinoma - Prior radiotherapy to the head and neck Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What are the early signs of sinonasal cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are persistent one-sided nasal obstruction or discharge that does not respond to treatment, recurrent unilateral nosebleeds or blood-stained discharge, reduced or lost sense of smell, facial pressure or a unilateral headache and facial numbness, cheek swelling, loose upper teeth or a palatal swelling. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - Persistent one-sided nasal obstruction or discharge that does not respond to treatment - Recurrent unilateral nosebleeds or blood-stained discharge - Reduced or lost sense of smell, facial pressure or a unilateral headache - Facial numbness, cheek swelling, loose upper teeth or a palatal swelling - Double vision, protruding eye (proptosis) or excessive tearing from orbital involvement - A neck lump, or cranial nerve changes in advanced skull-base disease Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### How is sinonasal cancer diagnosed and staged? URL: https://www.entliu.com/conditions/sinonasal-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. Staging is site- and histology-specific (AJCC for nasal cavity/ethmoid and maxillary sinus; separate systems for esthesioneuroblastoma and mucosal melanoma). Extension to the orbit, skull base, cribriform plate, pterygoid region or dura usually indicates advanced T category and determines whether an endoscopic or open craniofacial resection is feasible. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Nasal endoscopy with rigid or flexible scopes and photographic documentation - Contrast MRI for soft tissue, perineural and skull-base extension; dedicated sinus CT for bone detail - Image-planned biopsy (avoid blind biopsy of vascular lesions or encephaloceles) with expert head and neck pathology review - Immunohistochemistry for HPV/p16, EBV (EBER), melanoma, lymphoma and neuroendocrine markers as indicated - Neck imaging and PET-CT/chest imaging for high-grade or advanced disease; ophthalmology and neurosurgery input when the orbit or skull base is involved - Multidisciplinary skull-base tumour board before any resection Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What are the treatment options for sinonasal cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines endoscopic endonasal skull-base resection for selected tumours, or craniofacial resection with orbital/skull-base reconstruction, postoperative radiotherapy (often IMRT or proton therapy) for most malignant and advanced tumours; concurrent chemoradiotherapy in selected histologies and neck dissection or nodal radiotherapy for node-positive squamous cell carcinoma, SNUC or melanoma. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Endoscopic endonasal skull-base resection for selected tumours, or craniofacial resection with orbital/skull-base reconstruction - Postoperative radiotherapy (often IMRT or proton therapy) for most malignant and advanced tumours; concurrent chemoradiotherapy in selected histologies - Neck dissection or nodal radiotherapy for node-positive squamous cell carcinoma, SNUC or melanoma - Systemic therapy for sinonasal undifferentiated carcinoma, small-cell carcinoma, lymphoma and melanoma; immunotherapy for mucosal melanoma and PD-L1-positive squamous tumours - Complete excision of inverted papilloma with surveillance for recurrence or malignant transformation - Reconstruction, orbital/dural repair, olfactory and dental rehabilitation, and long-term endoscopic surveillance Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### What is the prognosis for sinonasal cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** Outcome is driven more by histology and skull-base/orbital extension than by country. Localised, completely resected low-grade tumours can be controlled long-term, whereas sinonasal undifferentiated carcinoma, mucosal melanoma and tumours with dural or brain involvement have substantially poorer survival. Overall five-year survival across all types is commonly reported around 50–60% in mixed series. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### Can sinonasal cancer be prevented? URL: https://www.entliu.com/conditions/sinonasal-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for sinonasal cancer are local exhaust ventilation, dust suppression and fitted respiratory protection in wood, leather, nickel and chromium work, smoking cessation and appropriate HPV vaccination according to national schedules and occupational health surveillance for exposed workers with persistent unilateral nasal symptoms. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Local exhaust ventilation, dust suppression and fitted respiratory protection in wood, leather, nickel and chromium work - Smoking cessation and appropriate HPV vaccination according to national schedules - Occupational health surveillance for exposed workers with persistent unilateral nasal symptoms - Complete removal and long-term endoscopic follow-up of inverted papilloma - Early nasal endoscopy for unilateral blockage, bleeding or smell loss lasting more than a few weeks Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### How can I tell sinusitis from sinonasal cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/sinusitis-or-cancer/ Cluster: Symptoms & diagnosis **Answer:** You cannot reliably tell from symptoms alone. Sinusitis is usually bilateral, fluctuates and responds to treatment, whereas a tumour tends to cause persistent one-sided blockage, bleeding, smell loss, facial numbness, cheek or palate swelling, loose upper teeth or double vision. Any unilateral symptom lasting more than a few weeks warrants nasal endoscopy and imaging. Repeated courses of antibiotics and steroids are the commonest cause of delayed diagnosis. Endoscopy is a short outpatient procedure and, combined with contrast MRI, distinguishes inflammatory disease from a mass in most cases. Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html #### Is wood dust really a cause of sinus cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/wood-dust/ Cluster: Understanding the disease **Answer:** Yes. Occupational exposure to hardwood dust is classified by IARC as a cause of sinonasal adenocarcinoma, particularly of the ethmoid sinuses, and is one of the clearest occupational links in head and neck oncology. Risk rises with duration and intensity of exposure, often with a latency of several decades. Cabinet makers, furniture workers, sawmill workers and joiners in Europe have been the best-studied cohorts. Local exhaust ventilation, dust extraction, respiratory protection and health surveillance are effective preventive measures; tell your doctor your full occupational history. Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What is an inverted papilloma and can it become cancer? URL: https://www.entliu.com/conditions/sinonasal-cancer/inverted-papilloma/ Cluster: Understanding the disease **Answer:** An inverted papilloma is a benign but locally aggressive sinonasal tumour that recurs if incompletely removed and is associated with squamous cell carcinoma in a minority of cases — either synchronous or at a later recurrence. Complete endoscopic excision of its attachment site and long-term surveillance are therefore standard. HPV (especially low-risk types 6 and 11) is frequently detected. Ask for the pathology review to state whether any dysplasia or carcinoma is present, and for a written schedule of follow-up nasal endoscopy and MRI. Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### Will surgery for a sinus tumour involve the brain or the eye? URL: https://www.entliu.com/conditions/sinonasal-cancer/skull-base-surgery/ Cluster: Treatment **Answer:** Many sinonasal tumours can now be removed entirely through the nose using endoscopic skull-base surgery, without an external incision. Tumours involving the dura, brain, orbit or extensive facial soft tissue may still require a combined craniofacial approach with neurosurgery, ophthalmology and reconstructive flaps. Ask specifically about the plan for the skull-base defect (vascular flap reconstruction), risk of cerebrospinal fluid leak, whether the eye can be preserved, and what the expected changes in smell, vision and appearance will be. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What does sinonasal cancer treatment cost in China? URL: https://www.entliu.com/conditions/sinonasal-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** Illustrative planning ranges are ¥50,000–¥130,000 (about US$7,000–18,000) for endoscopic resection and ¥130,000–¥280,000 for combined craniofacial resection with reconstruction and adjuvant radiotherapy. Proton therapy and immunotherapy are billed separately. These figures are not a quotation. Because histology drives treatment, obtain a pathology review and a written staging report before comparing prices. Rare subtypes may require drugs or radiation techniques that are only available in a limited number of centres. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Head and Neck Cancer of Unknown Primary URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/ Also known as: Occult primary; Cervical metastasis of unknown primary; CUP of the head and neck; HPV-related unknown primary Classification: ICD-10 C79.8 / C80 (metastatic cervical node, primary unidentified) Quick answer: Head and neck cancer of unknown primary means a malignant cervical lymph node is found but no primary tumour can be seen after the initial examination. In North America and Northern Europe this presentation has become more common because small HPV-positive tonsil or base-of-tongue cancers hide in crypts. p16/HPV and EBV testing on the node aspirate usually points to the tissue of origin. A painless neck lump in an adult is cancer until proven otherwise. The work-up aims to find a hidden primary in the tonsil, base of tongue, nasopharynx, hypopharynx, thyroid, salivary gland or skin. When HPV-driven oropharyngeal cancer is common — as in the US, UK and Scandinavia — an HPV-positive, cystic upper-neck node with no visible lesion is now a recognisable clinical entity rather than a mystery. Finding the primary changes treatment: it can allow a smaller radiation field, transoral surgical resection and less long-term toxicity. Modern work-up therefore adds PET-CT, p16 and HPV/EBV testing, examination under anaesthesia, palatine tonsillectomy and transoral robotic base-of-tongue mucosectomy to the traditional endoscopic evaluation. **Global burden (2022):** about 2–5% of head and neck squamous cell carcinoma presentations (no separate global ASR — cases are coded to the metastatic site, not the hidden primary). The proportion of unknown-primary cases that are HPV/p16-positive has risen sharply in high-income countries alongside the HPV-related oropharyngeal cancer epidemic. **Where it is common** - North America: Oropharyngeal cancer makes up 43.8% of the region’s lip/oral/pharyngeal burden and about 70% of US oropharyngeal cancers are HPV-positive — the main reason occult tonsil/base-of-tongue primaries are frequently encountered. - Northern Europe & UK: High HPV-attributable fractions (52–77%) produce the same pattern of small, node-positive, visually occult primaries in younger non-smokers. - South-East Asia & North Africa: Nasopharyngeal carcinoma is the hidden primary to exclude; plasma EBV DNA, nasopharyngoscopy and MRI of the nasopharynx are essential. - Australia & New Zealand: Both HPV-related oropharyngeal cancer and UV-related head and neck skin cancer are common, so scalp, ear and facial skin must be examined as possible primaries. - South Asia: Oral cavity and hypopharyngeal cancers dominate; careful oral and panendoscopic examination is needed to exclude a small mucosal primary. **Risk factors** - Persistent high-risk HPV-16 infection (HPV-related occult oropharyngeal primary) - Tobacco and heavy alcohol use (HPV-negative mucosal primary) - EBV infection in endemic regions (occult nasopharyngeal primary) - Cumulative UV exposure and prior skin cancer (occult cutaneous primary) - Male sex and age 40–65 for HPV-related disease - Prior incomplete excision of a neck mass before proper work-up **Signs and symptoms** - A painless, firm or cystic lump in the upper or mid neck, present for weeks - No visible sore or lump in the mouth, throat or nose - Normal-looking tonsils or an asymmetric tonsil on close inspection - Occasionally unilateral ear pain, mild throat discomfort or a sensation of a lump in the throat - Skin lesions on the scalp, ear or face that the patient has not mentioned - Rarely, hoarseness, swallowing change or weight loss from a deeper primary **Diagnosis and staging** - Fine-needle aspiration (FNA) or core biopsy of the neck node — never an open excisional biopsy as the first step - p16 immunohistochemistry and confirmatory HPV DNA/RNA testing on the node specimen; EBER/EBV testing when NPC is possible - Complete head and neck examination including flexible nasopharyngolaryngoscopy, oral cavity, scalp, ear and skin - Contrast CT and/or MRI of the neck; FDG PET-CT before or after examination under anaesthesia - Examination under anaesthesia with panendoscopy, bilateral palatine tonsillectomy and/or TORS base-of-tongue mucosectomy - Thyroid, salivary gland and cutaneous assessment when histology is not squamous cell carcinoma When the primary remains occult, staging is based on nodal burden (number, size, laterality), p16/HPV or EBV status and distant metastasis. Under AJCC 8, p16-positive node-positive disease without an identified primary is generally managed along the HPV-mediated oropharyngeal pathway rather than as a generic metastatic cancer. **Treatment options** - If a primary is found (often in the tonsil or tongue base): site-directed surgery or radiotherapy following the relevant site guideline - If no primary is found: neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy, or definitive chemoradiotherapy to the neck and likely mucosal sites - HPV/p16-positive disease may be treated with a more limited or de-escalated approach — only within defined protocols or clinical trials - Adjuvant concurrent chemoradiotherapy for extranodal extension or positive margins - Immunotherapy/chemotherapy for distant metastatic disease; structured skin, thyroid and nasopharyngeal surveillance at follow-up - Avoid "diagnostic excision" of the node before imaging and FNA — it increases nodal recurrence and complicates later neck dissection **Prognosis** HPV/p16-positive unknown-primary disease has a markedly better prognosis than HPV-negative disease, reflecting the excellent outcomes of HPV-associated oropharyngeal cancer (about 85% five-year survival in published cohorts). Prognosis worsens with bulky N3 nodes, extranodal extension, supraclavicular nodes, EBV-positive nasopharyngeal origin or distant metastasis. **Prevention** - HPV vaccination according to national schedules (most effective before exposure) - Stop smoking and heavy alcohol use - Sun protection and regular skin checks for scalp, ear and face - Prompt FNA of any persistent adult neck lump rather than repeated antibiotics - In NPC-endemic regions, consider plasma EBV DNA and nasopharyngoscopy as part of the work-up **Treatment in China** A Chinese head and neck centre can repeat the FNA or review the cell block, perform p16/HPV and EBER testing, complete PET-CT and MRI staging, and carry out examination under anaesthesia with tonsillectomy or transoral tongue-base mucosectomy to look for the hidden primary before any treatment is started. - Bring the original FNA slides/cell block, pathology report, CT/MRI/PET-CT on DICOM, and photographs of the neck mass. - Ask that p16, HPV DNA/RNA and EBV (EBER) studies be performed or repeated before the tumour board decides the radiation field. - Request a written statement of whether a primary was found, where, and how the treatment field was chosen. - Do not allow an open excision of the node as the first procedure; ask for FNA or core biopsy instead. Cost guidance: As an illustrative planning range, diagnostic work-up with PET-CT, endoscopy under anaesthesia and pathology review is commonly budgeted at ¥15,000–¥40,000 (about US$2,100–5,600); neck dissection with adjuvant radiotherapy ¥90,000–¥190,000. These are budgeting figures, not a quotation. ### All 13 questions about Head and Neck Cancer of Unknown Primary #### What is head and neck cancer of unknown primary? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/what-is-it/ Cluster: Understanding the disease **Answer:** Head and neck cancer of unknown primary means a malignant cervical lymph node is found but no primary tumour can be seen after the initial examination. In North America and Northern Europe this presentation has become more common because small HPV-positive tonsil or base-of-tongue cancers hide in crypts. p16/HPV and EBV testing on the node aspirate usually points to the tissue of origin. A painless neck lump in an adult is cancer until proven otherwise. The work-up aims to find a hidden primary in the tonsil, base of tongue, nasopharynx, hypopharynx, thyroid, salivary gland or skin. When HPV-driven oropharyngeal cancer is common — as in the US, UK and Scandinavia — an HPV-positive, cystic upper-neck node with no visible lesion is now a recognisable clinical entity rather than a mystery. Finding the primary changes treatment: it can allow a smaller radiation field, transoral surgical resection and less long-term toxicity. Modern work-up therefore adds PET-CT, p16 and HPV/EBV testing, examination under anaesthesia, palatine tonsillectomy and transoral robotic base-of-tongue mucosectomy to the traditional endoscopic evaluation. Sources: HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### Where in the world is head and neck cancer of unknown primary most common? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/where-is-it-common/ Cluster: Understanding the disease **Answer:** Head and Neck Cancer of Unknown Primary is not evenly distributed: the highest-burden regions are North America, Northern Europe & UK and South-East Asia & North Africa. In 2022 there were about 2–5% of head and neck squamous cell carcinoma presentations worldwide (no separate global ASR — cases are coded to the metastatic site, not the hidden primary), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from North America may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - North America: Oropharyngeal cancer makes up 43.8% of the region’s lip/oral/pharyngeal burden and about 70% of US oropharyngeal cancers are HPV-positive — the main reason occult tonsil/base-of-tongue primaries are frequently encountered. - Northern Europe & UK: High HPV-attributable fractions (52–77%) produce the same pattern of small, node-positive, visually occult primaries in younger non-smokers. - South-East Asia & North Africa: Nasopharyngeal carcinoma is the hidden primary to exclude; plasma EBV DNA, nasopharyngoscopy and MRI of the nasopharynx are essential. - Australia & New Zealand: Both HPV-related oropharyngeal cancer and UV-related head and neck skin cancer are common, so scalp, ear and facial skin must be examined as possible primaries. - South Asia: Oral cavity and hypopharyngeal cancers dominate; careful oral and panendoscopic examination is needed to exclude a small mucosal primary. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What are the risk factors for head and neck cancer of unknown primary? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for head and neck cancer of unknown primary are persistent high-risk HPV-16 infection (HPV-related occult oropharyngeal primary), tobacco and heavy alcohol use (HPV-negative mucosal primary) and EBV infection in endemic regions (occult nasopharyngeal primary). Risks differ by region: North America has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Persistent high-risk HPV-16 infection (HPV-related occult oropharyngeal primary) - Tobacco and heavy alcohol use (HPV-negative mucosal primary) - EBV infection in endemic regions (occult nasopharyngeal primary) - Cumulative UV exposure and prior skin cancer (occult cutaneous primary) - Male sex and age 40–65 for HPV-related disease - Prior incomplete excision of a neck mass before proper work-up Sources: HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What are the early signs of head and neck cancer of unknown primary? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a painless, firm or cystic lump in the upper or mid neck, present for weeks, no visible sore or lump in the mouth, throat or nose, normal-looking tonsils or an asymmetric tonsil on close inspection and occasionally unilateral ear pain, mild throat discomfort or a sensation of a lump in the throat. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A painless, firm or cystic lump in the upper or mid neck, present for weeks - No visible sore or lump in the mouth, throat or nose - Normal-looking tonsils or an asymmetric tonsil on close inspection - Occasionally unilateral ear pain, mild throat discomfort or a sensation of a lump in the throat - Skin lesions on the scalp, ear or face that the patient has not mentioned - Rarely, hoarseness, swallowing change or weight loss from a deeper primary Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### How is head and neck cancer of unknown primary diagnosed and staged? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. When the primary remains occult, staging is based on nodal burden (number, size, laterality), p16/HPV or EBV status and distant metastasis. Under AJCC 8, p16-positive node-positive disease without an identified primary is generally managed along the HPV-mediated oropharyngeal pathway rather than as a generic metastatic cancer. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Fine-needle aspiration (FNA) or core biopsy of the neck node — never an open excisional biopsy as the first step - p16 immunohistochemistry and confirmatory HPV DNA/RNA testing on the node specimen; EBER/EBV testing when NPC is possible - Complete head and neck examination including flexible nasopharyngolaryngoscopy, oral cavity, scalp, ear and skin - Contrast CT and/or MRI of the neck; FDG PET-CT before or after examination under anaesthesia - Examination under anaesthesia with panendoscopy, bilateral palatine tonsillectomy and/or TORS base-of-tongue mucosectomy - Thyroid, salivary gland and cutaneous assessment when histology is not squamous cell carcinoma Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What are the treatment options for head and neck cancer of unknown primary? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines if a primary is found (often in the tonsil or tongue base): site-directed surgery or radiotherapy following the relevant site guideline, if no primary is found: neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy, or definitive chemoradiotherapy to the neck and likely mucosal sites and HPV/p16-positive disease may be treated with a more limited or de-escalated approach — only within defined protocols or clinical trials. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - If a primary is found (often in the tonsil or tongue base): site-directed surgery or radiotherapy following the relevant site guideline - If no primary is found: neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy, or definitive chemoradiotherapy to the neck and likely mucosal sites - HPV/p16-positive disease may be treated with a more limited or de-escalated approach — only within defined protocols or clinical trials - Adjuvant concurrent chemoradiotherapy for extranodal extension or positive margins - Immunotherapy/chemotherapy for distant metastatic disease; structured skin, thyroid and nasopharyngeal surveillance at follow-up - Avoid "diagnostic excision" of the node before imaging and FNA — it increases nodal recurrence and complicates later neck dissection Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What is the prognosis for head and neck cancer of unknown primary? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/prognosis/ Cluster: Prognosis & follow-up **Answer:** HPV/p16-positive unknown-primary disease has a markedly better prognosis than HPV-negative disease, reflecting the excellent outcomes of HPV-associated oropharyngeal cancer (about 85% five-year survival in published cohorts). Prognosis worsens with bulky N3 nodes, extranodal extension, supraclavicular nodes, EBV-positive nasopharyngeal origin or distant metastasis. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### Can head and neck cancer of unknown primary be prevented? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for head and neck cancer of unknown primary are HPV vaccination according to national schedules (most effective before exposure), stop smoking and heavy alcohol use and sun protection and regular skin checks for scalp, ear and face. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - HPV vaccination according to national schedules (most effective before exposure) - Stop smoking and heavy alcohol use - Sun protection and regular skin checks for scalp, ear and face - Prompt FNA of any persistent adult neck lump rather than repeated antibiotics - In NPC-endemic regions, consider plasma EBV DNA and nasopharyngoscopy as part of the work-up Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### What is the first test for a persistent neck lump in an adult? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/first-test-for-neck-lump/ Cluster: Symptoms & diagnosis **Answer:** An ultrasound-guided fine-needle aspiration (FNA) or core biopsy, together with a complete head and neck endoscopic examination. An open excisional biopsy as the first step should be avoided: it can seed tumour cells, distort lymphatic drainage and make later neck dissection and radiotherapy more difficult. Ask the cytopathologist to perform p16 immunohistochemistry and, where relevant, HPV DNA/RNA or EBV (EBER) studies on the cell block. A cystic node in a middle-aged non-smoker that yields squamous cells and is p16-positive strongly suggests an occult tonsil or tongue-base primary. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet #### Why can a cancer be too small to see but already spread to the neck? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/why-primary-hidden/ Cluster: Understanding the disease **Answer:** The palatine tonsils and base of tongue are lined by crypt epithelium that is especially susceptible to HPV-16. A tumour only a few millimetres across can shed cells into lymphatic vessels very early, producing a large nodal metastasis while the primary remains invisible even on endoscopy and MRI. This differs from tobacco-related oral cancer, where the visible ulcer usually grows before nodes appear. It explains why the rise of HPV-associated oropharyngeal cancer in North America and Northern Europe has increased the number of "unknown primary" presentations. Sources: HPV & Oropharyngeal Cancer (US National Institute of Dental and Craniofacial Research, 2025) https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ #### How is a hidden primary tumour found? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/finding-the-primary/ Cluster: Symptoms & diagnosis **Answer:** After FNA, contrast CT/MRI and FDG PET-CT, the standard next step is examination under anaesthesia with directed biopsies, bilateral palatine tonsillectomy and, increasingly, transoral robotic (TORS) mucosectomy of the base of tongue. These procedures find a small primary in a substantial proportion of patients previously labelled "unknown". Identifying the primary allows the radiotherapy field to be narrowed and may permit surgical resection, reducing long-term dry mouth and swallowing difficulty. In EBV-endemic regions the nasopharynx must be examined and imaged with MRI as well. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | HPV Detection in Oropharyngeal Cancer: A Narrative Review (PubMed Central / peer-reviewed review, 2025) https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ #### What happens if no primary tumour is ever found? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/treatment-without-primary/ Cluster: Treatment **Answer:** Treatment still proceeds, usually with neck dissection followed by risk-adapted radiotherapy (with chemotherapy for extranodal extension or positive margins), or with definitive chemoradiotherapy covering the neck and the likely mucosal sites. HPV-positive disease may qualify for a more limited field within established protocols. The trade-off is between the risk of an untreated hidden mucosal site and the long-term toxicity of irradiating the whole pharynx. Ask the radiation oncologist to explain the target volumes and why the tonsil, tongue base and nasopharynx are or are not included. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf #### What does an unknown-primary work-up and treatment cost in China? URL: https://www.entliu.com/conditions/unknown-primary-neck-cancer/cost-in-china/ Cluster: Treatment in China **Answer:** As a planning range, the diagnostic work-up (PET-CT, MRI, endoscopy under anaesthesia, pathology review and biomarker studies) is commonly budgeted at ¥15,000–¥40,000 (about US$2,100–5,600); neck dissection with adjuvant radiotherapy ¥90,000–¥190,000. These are budgeting figures, not a quotation. Ask for a written estimate that separates diagnostics from treatment, and request all biomarker results in English — p16, HPV and EBV status will determine the radiation field and can be reused if you later continue care at home. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- ## Oral Potentially Malignant Disorders URL: https://www.entliu.com/conditions/oral-precancerous-conditions/ Also known as: Leukoplakia; Erythroplakia; Oral submucous fibrosis; Oral epithelial dysplasia; Actinic cheilitis; Oral lichen planus Classification: ICD-10 K13.2 / D00.0 (preinvasive lesions) Quick answer: Oral potentially malignant disorders are chronic mucosal changes — white patches (leukoplakia), red patches (erythroplakia), oral submucous fibrosis and dysplasia — that carry a raised but variable risk of progressing to oral cavity cancer. They are especially common in South Asia because of areca nut and smokeless tobacco use, and most can be managed by removing the exposure and structured surveillance. Not every white patch is precancerous, and not every precancerous lesion becomes cancer. Erythroplakia and non-homogeneous, speckled leukoplakia carry higher malignant-transformation risk than a thin homogeneous white patch; oral submucous fibrosis from areca nut causes progressive scarring and restricted mouth opening as well as cancer risk. Biopsy with a dysplasia grade is what separates a harmless keratosis from a lesion needing excision. In high-burden countries, visual oral examination by a trained clinician or dentist is a low-cost, evidence-based early-detection strategy. In low-incidence countries, the priority is targeted examination of people with tobacco, areca nut or heavy alcohol exposure rather than population-wide screening. **Global burden (2022):** no global case count — these are precancerous lesions, not registered cancers (prevalence of oral potentially malignant disorders varies from under 1% to over 5% in high-exposure adult populations). A 2022 estimate attributed more than 120,000 oral cancer cases (about 30% of the global total) to smokeless tobacco, areca nut or both. **Where it is common** - India: Very high prevalence of leukoplakia, oral submucous fibrosis and oral cancer. Tobacco and areca nut account for about 70–80% of the 143,759 oral cancer cases recorded in 2022. - Bangladesh, Pakistan, Sri Lanka, Nepal: Widespread gutka, khaini, betel quid and areca nut use; smokeless tobacco consumption has been increasing since 2000. - Papua New Guinea & Pacific Islands: Areca nut chewing is associated with the world’s highest female oral cavity cancer ASR (8.1/100,000) and high rates of oral mucosal disease. - Taiwan region of China & South-East Asian communities: Betel quid chewing is associated with oral submucous fibrosis, leukoplakia and buccal mucosa cancer; cessation programmes reduce risk over time. - Migrant communities worldwide: Areca nut and smokeless tobacco habits often continue after migration, so clinicians in Europe, North America and Australia should ask specifically about chewing products. **Risk factors** - Areca nut / betel quid chewing, with or without tobacco — IARC Group 1 carcinogen - Smokeless tobacco (gutka, khaini, zarda, snuff, toombak) - Cigarette, bidi or pipe smoking and heavy alcohol use - Chronic mechanical trauma from sharp teeth, rough restorations or ill-fitting dentures - Oral submucous fibrosis, oral lichen planus and prior oral cancer - Immunosuppression and, for actinic cheilitis, cumulative UV exposure **Signs and symptoms** - A white patch that cannot be scraped off and persists for more than two weeks (leukoplakia) - A velvety red patch, often with a speckled white–red appearance (erythroplakia — higher risk) - Burning sensation, stiffness and progressive inability to open the mouth (oral submucous fibrosis) - A non-healing ulcer, a small lump or an area of hardness in the mucosa - Lace-like white streaks of oral lichen planus, especially in erosive forms - Persistent dry, scaly, fissured lower lip (actinic cheilitis) **Diagnosis and staging** - Full oral examination under good light with palpation, measurement and clinical photography - Removal of possible irritants (sharp tooth, denture trauma) and a short period of review before deciding on biopsy - Incisional biopsy of red, speckled, ulcerated, indurated or persistent lesions, reported with a dysplasia grade - Assessment of mouth opening, tongue mobility and nutritional intake in oral submucous fibrosis - Documentation of tobacco, areca nut and alcohol exposure, with a written cessation plan - Risk-stratified recall schedule: site, size, appearance, histology and continued exposure determine the interval These lesions are not staged with TNM. They are risk-stratified by clinical appearance (homogeneous vs non-homogeneous, red vs white), size, site (floor of mouth, lateral tongue and soft palate are higher risk), histological dysplasia grade (mild / moderate / severe or carcinoma in situ) and whether the exposure continues. **Treatment options** - Complete cessation of areca nut, smokeless tobacco, smoking and heavy alcohol — the single most effective intervention - Elimination of mechanical trauma: smooth sharp teeth, adjust or replace dentures, treat candidiasis if present - Surgical excision, laser ablation or photodynamic therapy for high-grade dysplasia, erythroplakia or persistent non-homogeneous leukoplakia - Mouth-opening exercises, physiotherapy and nutritional support for oral submucous fibrosis; selected cases may need surgical release of fibrous bands - Topical or systemic therapy for symptomatic lichen planus, with regular surveillance of erosive lesions - Structured photographic and clinical follow-up, with repeat biopsy if the lesion changes **Prognosis** Most oral potentially malignant disorders never become cancer, and stopping the causative habit reduces risk. Transformation rates reported in the literature vary widely — from roughly 1–3% for unselected leukoplakia to much higher figures for erythroplakia, severe dysplasia and oral submucous fibrosis. Regular review matters precisely because the risk is real but unpredictable for an individual. **Prevention** - Never start areca nut or smokeless tobacco; cessation support for current users (counselling plus pharmacotherapy for tobacco) - Limit alcohol and stop smoking - Regular dental review and prompt smoothing of sharp teeth or dentures - Sun protection for the lips (SPF lip balm, hats) to prevent actinic cheilitis - Any oral patch, ulcer or lump lasting more than two to three weeks should be examined and, if indicated, biopsied **Treatment in China** For international patients the useful service here is usually a careful pathology review and a written surveillance plan, not surgery. Chinese oral and maxillofacial / ENT teams can re-read dysplasia slides, remove traumatic irritants and excise high-grade lesions, but the essential intervention remains stopping areca nut and tobacco. - Bring clear clinical photographs, the biopsy slides and written dysplasia grade, and a record of which chewing products you use. - Ask for a written risk stratification and recall interval rather than an automatic operation for every white patch. - If mouth opening is limited, ask about a structured exercise programme and nutritional assessment. - Request the pathology report in English, since dysplasia grading terminology differs between countries. Cost guidance: As an illustrative planning range, an outpatient specialist assessment with repeat biopsy is commonly budgeted at ¥3,000–¥10,000 (about US$400–1,400); laser excision or formal excision of a high-grade lesion ¥10,000–¥35,000. These are budgeting figures, not a quotation, and many patients need surveillance only. ### All 13 questions about Oral Potentially Malignant Disorders #### What is oral potentially malignant disorders? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/what-is-it/ Cluster: Understanding the disease **Answer:** Oral potentially malignant disorders are chronic mucosal changes — white patches (leukoplakia), red patches (erythroplakia), oral submucous fibrosis and dysplasia — that carry a raised but variable risk of progressing to oral cavity cancer. They are especially common in South Asia because of areca nut and smokeless tobacco use, and most can be managed by removing the exposure and structured surveillance. Not every white patch is precancerous, and not every precancerous lesion becomes cancer. Erythroplakia and non-homogeneous, speckled leukoplakia carry higher malignant-transformation risk than a thin homogeneous white patch; oral submucous fibrosis from areca nut causes progressive scarring and restricted mouth opening as well as cancer risk. Biopsy with a dysplasia grade is what separates a harmless keratosis from a lesion needing excision. In high-burden countries, visual oral examination by a trained clinician or dentist is a low-cost, evidence-based early-detection strategy. In low-incidence countries, the priority is targeted examination of people with tobacco, areca nut or heavy alcohol exposure rather than population-wide screening. Sources: Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Where in the world is oral potentially malignant disorders most common? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/where-is-it-common/ Cluster: Understanding the disease **Answer:** Oral Potentially Malignant Disorders is not evenly distributed: the highest-burden regions are India, Bangladesh, Pakistan, Sri Lanka, Nepal and Papua New Guinea & Pacific Islands. In 2022 there were no global case count — these are precancerous lesions, not registered cancers worldwide (prevalence of oral potentially malignant disorders varies from under 1% to over 5% in high-exposure adult populations), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens. The regional pattern matters clinically. A patient from India may present with a different risk-factor profile and a different stage distribution than a patient from a low-incidence country, which changes both the differential diagnosis and the pretreatment work-up. All incidence figures on this site are age-standardised rates or absolute case counts from GLOBOCAN 2022 and its subsite analyses. They describe populations, not individual risk. - India: Very high prevalence of leukoplakia, oral submucous fibrosis and oral cancer. Tobacco and areca nut account for about 70–80% of the 143,759 oral cancer cases recorded in 2022. - Bangladesh, Pakistan, Sri Lanka, Nepal: Widespread gutka, khaini, betel quid and areca nut use; smokeless tobacco consumption has been increasing since 2000. - Papua New Guinea & Pacific Islands: Areca nut chewing is associated with the world’s highest female oral cavity cancer ASR (8.1/100,000) and high rates of oral mucosal disease. - Taiwan region of China & South-East Asian communities: Betel quid chewing is associated with oral submucous fibrosis, leukoplakia and buccal mucosa cancer; cessation programmes reduce risk over time. - Migrant communities worldwide: Areca nut and smokeless tobacco habits often continue after migration, so clinicians in Europe, North America and Australia should ask specifically about chewing products. Sources: Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 (CA: A Cancer Journal for Clinicians, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ | Global Cancer Observatory (GLOBOCAN 2022) (International Agency for Research on Cancer / WHO, 2022) https://gco.iarc.who.int/today/en | Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) (American Cancer Society, 2024) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What are the risk factors for oral potentially malignant disorders? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/risk-factors/ Cluster: Prevention & risk **Answer:** The main recognised risk factors for oral potentially malignant disorders are areca nut / betel quid chewing, with or without tobacco — IARC Group 1 carcinogen, smokeless tobacco (gutka, khaini, zarda, snuff, toombak) and cigarette, bidi or pipe smoking and heavy alcohol use. Risks differ by region: India has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer. Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning. - Areca nut / betel quid chewing, with or without tobacco — IARC Group 1 carcinogen - Smokeless tobacco (gutka, khaini, zarda, snuff, toombak) - Cigarette, bidi or pipe smoking and heavy alcohol use - Chronic mechanical trauma from sharp teeth, rough restorations or ill-fitting dentures - Oral submucous fibrosis, oral lichen planus and prior oral cancer - Immunosuppression and, for actinic cheilitis, cumulative UV exposure Sources: Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What are the early signs of oral potentially malignant disorders? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/early-signs/ Cluster: Symptoms & diagnosis **Answer:** The common early signs are a white patch that cannot be scraped off and persists for more than two weeks (leukoplakia), a velvety red patch, often with a speckled white–red appearance (erythroplakia — higher risk), burning sensation, stiffness and progressive inability to open the mouth (oral submucous fibrosis) and a non-healing ulcer, a small lump or an area of hardness in the mucosa. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics. Early disease can be painless, which is why the "two-to-three-week rule" is used: a persistent lump, ulcer, hoarseness, unilateral ear pain, nasal obstruction or swallowing change should be examined with an endoscope by an ENT or head and neck specialist. Do not wait for pain. Pain is usually a later feature in head and neck oncology, and delay in diagnosis is one of the strongest modifiable predictors of stage at presentation. - A white patch that cannot be scraped off and persists for more than two weeks (leukoplakia) - A velvety red patch, often with a speckled white–red appearance (erythroplakia — higher risk) - Burning sensation, stiffness and progressive inability to open the mouth (oral submucous fibrosis) - A non-healing ulcer, a small lump or an area of hardness in the mucosa - Lace-like white streaks of oral lichen planus, especially in erosive forms - Persistent dry, scaly, fissured lower lip (actinic cheilitis) Sources: Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer (American Cancer Society, 2025) https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### How is oral potentially malignant disorders diagnosed and staged? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/how-is-it-diagnosed/ Cluster: Symptoms & diagnosis **Answer:** Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment. These lesions are not staged with TNM. They are risk-stratified by clinical appearance (homogeneous vs non-homogeneous, red vs white), size, site (floor of mouth, lateral tongue and soft palate are higher risk), histological dysplasia grade (mild / moderate / severe or carcinoma in situ) and whether the exposure continues. Before radiotherapy, guidelines recommend a dental assessment and extraction of teeth with a poor prognosis inside the radiation field. Ask for this early: it prevents osteoradionecrosis later. - Full oral examination under good light with palpation, measurement and clinical photography - Removal of possible irritants (sharp tooth, denture trauma) and a short period of review before deciding on biopsy - Incisional biopsy of red, speckled, ulcerated, indurated or persistent lesions, reported with a dysplasia grade - Assessment of mouth opening, tongue mobility and nutritional intake in oral submucous fibrosis - Documentation of tobacco, areca nut and alcohol exposure, with a written cessation plan - Risk-stratified recall schedule: site, size, appearance, histology and continued exposure determine the interval Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What are the treatment options for oral potentially malignant disorders? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/treatment-options/ Cluster: Treatment **Answer:** Treatment is stage- and site-specific, and usually combines complete cessation of areca nut, smokeless tobacco, smoking and heavy alcohol — the single most effective intervention, elimination of mechanical trauma: smooth sharp teeth, adjust or replace dentures, treat candidiasis if present and surgical excision, laser ablation or photodynamic therapy for high-grade dysplasia, erythroplakia or persistent non-homogeneous leukoplakia. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team. The decision is made by a tumour board including head and neck surgery, radiation oncology, medical oncology, radiology, pathology, dentistry, nutrition and speech/swallow rehabilitation. Functional outcome — speech, swallowing, breathing and appearance — is considered alongside cancer control. Ask your team explicitly whether the goal is curative, organ-preserving or palliative, and whether a clinical trial is available. NCCN and NCI patient guidelines are a useful checklist for these questions. - Complete cessation of areca nut, smokeless tobacco, smoking and heavy alcohol — the single most effective intervention - Elimination of mechanical trauma: smooth sharp teeth, adjust or replace dentures, treat candidiasis if present - Surgical excision, laser ablation or photodynamic therapy for high-grade dysplasia, erythroplakia or persistent non-homogeneous leukoplakia - Mouth-opening exercises, physiotherapy and nutritional support for oral submucous fibrosis; selected cases may need surgical release of fibrous bands - Topical or systemic therapy for symptomatic lichen planus, with regular surveillance of erosive lesions - Structured photographic and clinical follow-up, with repeat biopsy if the lesion changes Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) (US National Cancer Institute, 2025) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### What is the prognosis for oral potentially malignant disorders? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/prognosis/ Cluster: Prognosis & follow-up **Answer:** Most oral potentially malignant disorders never become cancer, and stopping the causative habit reduces risk. Transformation rates reported in the literature vary widely — from roughly 1–3% for unselected leukoplakia to much higher figures for erythroplakia, severe dysplasia and oral submucous fibrosis. Regular review matters precisely because the risk is real but unpredictable for an individual. Published survival figures are population averages from registry data. Your own outlook depends on stage, HPV or EBV status, margins, nodal involvement, general health, smoking status during treatment and response to the first treatment. Most recurrences occur within the first two to five years. Follow-up visits are frequent at first (every one to three months in year one) and become annual after year five, in line with NCCN survivorship guidance. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Can oral potentially malignant disorders be prevented? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/prevention/ Cluster: Prevention & risk **Answer:** Many cases are preventable. The most useful steps for oral potentially malignant disorders are never start areca nut or smokeless tobacco; cessation support for current users (counselling plus pharmacotherapy for tobacco), limit alcohol and stop smoking and regular dental review and prompt smoothing of sharp teeth or dentures. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use. There is no population screening programme for most head and neck cancers. A routine oral examination by a dentist or doctor, plus early assessment of persistent symptoms, is currently the most practical early-detection strategy for patients outside high-risk screening programmes. - Never start areca nut or smokeless tobacco; cessation support for current users (counselling plus pharmacotherapy for tobacco) - Limit alcohol and stop smoking - Regular dental review and prompt smoothing of sharp teeth or dentures - Sun protection for the lips (SPF lip balm, hats) to prevent actinic cheilitis - Any oral patch, ulcer or lump lasting more than two to three weeks should be examined and, if indicated, biopsied Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ #### Will an oral white patch turn into cancer? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/will-it-turn-into-cancer/ Cluster: Understanding the disease **Answer:** Usually no, but some do. Risk depends on appearance, site, size, histology and whether the exposure continues. Thin homogeneous leukoplakia has a low annual transformation rate, while erythroplakia, speckled lesions, lesions on the lateral tongue or floor of mouth, and severe dysplasia carry substantially higher risk and are generally excised or closely monitored. A biopsy is the only way to know whether dysplasia is present. Stopping areca nut and tobacco and removing local trauma can make some lesions regress, which is why clinicians often reassess after a short interval before deciding on surgery. Sources: IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 #### Does stopping betel quid and areca nut really lower my risk? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/areca-nut-cessation/ Cluster: Prevention & risk **Answer:** Yes. Areca nut and betel quid (with or without tobacco) are IARC Group 1 carcinogens, and continued exposure is the main driver of both oral submucous fibrosis progression and malignant transformation. Risk falls over time after cessation, although it does not return immediately to that of a never-user, so surveillance should continue. Areca nut is addictive, and arecoline produces dependence, so behavioural support and, where tobacco is involved, standard tobacco-cessation pharmacotherapy are appropriate. Tell your dentist or doctor explicitly what you chew — many patients do not consider it "tobacco". Sources: Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ #### Is oral cancer screening worthwhile for people who chew tobacco? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/screening-evidence/ Cluster: Prevention & risk **Answer:** Targeted visual oral examination by a trained clinician or dentist is worthwhile for high-risk users: it is inexpensive, detects lesions early and has been shown to reduce oral cancer mortality in high-risk populations. Whole-population screening in low-incidence countries is not generally recommended because most detected patches are harmless. The practical approach is a thorough look under good light with palpation, photographs for comparison, a written cessation plan, and prompt biopsy of any red, speckled, ulcerated or persistent lesion. Ask your dentist to record the exact site and size at each visit. Sources: Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison (ecancermedicalscience, 2026) https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison | Smokeless Tobacco and Oral Cancer in Global Perspective (New England Journal of Medicine, 2026) https://www.nejm.org/doi/full/10.1056/NEJMp2500631 #### Can limited mouth opening from oral submucous fibrosis be improved? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/mouth-opening-exercises/ Cluster: Side effects & recovery **Answer:** Mild to moderate limitation often improves with daily mouth-opening exercises, physiotherapy, nutritional support and complete areca nut cessation. Fibrotic bands that do not respond may require surgical release or laser treatment, but surgery without stopping the habit has a high recurrence rate. Improving mouth opening also makes dental care, oral examination and any future biopsy or cancer surgery much easier. Record the inter-incisal distance at each visit so progress is measurable. Sources: Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy (PubMed Central / peer-reviewed review, 2026) https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) (International Agency for Research on Cancer / WHO, 2024) https://monographs.iarc.who.int/ #### What does assessment of an oral precancerous lesion cost in China? URL: https://www.entliu.com/conditions/oral-precancerous-conditions/cost-in-china/ Cluster: Treatment in China **Answer:** As a planning range, a specialist outpatient assessment with repeat biopsy and pathology review is commonly budgeted at ¥3,000–¥10,000 (about US$400–1,400); laser or surgical excision of a high-grade lesion ¥10,000–¥35,000. Many patients need surveillance only, which costs far less. These figures are not a quotation. The most valuable output of a visit is a written risk stratification, dysplasia grade and recall interval in English — not an automatic operation. Bring your biopsy slides so the dysplasia grade can be re-reviewed before any irreversible treatment. Sources: NCCN Guidelines for Patients: Head and Neck Cancers (National Comprehensive Cancer Network, 2025) https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf --- # Part 4 — Treatment and care guides ## 10 Warning Signs of Head and Neck Cancer URL: https://www.entliu.com/guides/warning-signs/ Category: Symptoms & diagnosis Summary: A symptom-based checklist for patients and clinicians: which head and neck changes deserve an ENT examination, how long to wait, and what the first tests should be. Quick answer: Any head or neck symptom that persists for more than two to three weeks without an obvious cause should be examined by an ENT or head and neck specialist. The most important warning signs are a painless neck lump, a non-healing mouth ulcer, persistent hoarseness, one-sided nasal blockage or bleeding, difficulty swallowing, and unilateral ear pain with a normal ear examination. ### What is the two-to-three-week rule? Persistence, not severity, is the trigger for referral. Most head and neck cancers begin with symptoms that look like everyday problems: a cold that lingers, a mouth ulcer, a hoarse voice, a blocked ear or a tender tooth. Inflammatory conditions normally settle within two weeks. A symptom that is still present after two to three weeks needs direct visualisation with an endoscope and, if a lesion is seen, a biopsy. Pain is a poor guide. Early tumours are often painless, and pain usually appears only when the tumour invades deeper structures. Waiting for pain, or accepting repeated courses of antibiotics, steroids or antifungal treatment without an examination, is the commonest avoidable cause of late diagnosis. | Warning sign | Why it matters | First test | | --- | --- | --- | | Painless neck lump | Could be a nodal metastasis from tonsil, tongue base, nasopharynx, thyroid or skin | Ultrasound + fine-needle aspiration | | Mouth ulcer or white/red patch >2–3 weeks | Oral cavity cancer or a potentially malignant disorder | Oral examination + incisional biopsy | | Hoarseness >2–3 weeks | Classic early sign of glottic laryngeal cancer | Flexible laryngoscopy | | One-sided nasal blockage or nosebleeds | Sinonasal or nasopharyngeal tumour, especially in endemic regions | Nasal endoscopy + contrast MRI | | Unilateral "blocked ear" in an adult | Eustachian tube obstruction by a nasopharyngeal tumour | Nasopharyngoscopy + audiometry | | Difficulty or pain on swallowing | Hypopharyngeal, oropharyngeal, oesophageal or laryngeal lesion | Flexible endoscopy + contrast CT/MRI | | Ear pain with a normal ear exam | Referred pain from the throat or tongue base | Full head and neck endoscopy | | One tonsil larger, or a neck cyst | Occult HPV-positive oropharyngeal primary | FNA with p16/HPV testing + PET-CT | | Loose tooth or non-healing socket | Possible gingival or maxillary sinus tumour | Dental panoramic radiograph + biopsy | | Changing mole or non-healing facial/scalp sore | Melanoma, BCC or cutaneous SCC | Dermoscopy + excisional biopsy | Adapted from NCI, ACS and NCCN patient guidance. This is a screening checklist, not a diagnosis. ### What should I do if I have one of these signs? See a clinician who can look directly at the site — do not self-treat for weeks. - Book an appointment with an ENT / otolaryngologist, oral medicine specialist or dentist, stating the exact duration of the symptom. - Ask for flexible nasopharyngolaryngoscopy (a brief clinic procedure) and imaging if a neck mass is present. - Request fine-needle aspiration, not open excision, for a neck lump. - Stop tobacco, areca nut and alcohol while being assessed; this improves healing and lowers future risk regardless of the result. - Keep a dated photograph of any oral or skin lesion so change over time can be documented. ### Who should be especially alert? Risk is not evenly distributed. In North America and Northern Europe, a non-smoking man aged 40–60 with a cystic neck lump should be assessed for HPV-associated oropharyngeal cancer. In South Asia, any persistent cheek ulcer or restricted mouth opening in an areca nut or smokeless tobacco user needs biopsy. In South-East Asia and North Africa, unilateral nasal symptoms and a blocked ear should trigger nasopharyngoscopy for nasopharyngeal carcinoma. In Australia and New Zealand, a non-healing lip, ear or scalp lesion is a UV-related warning sign. Note (warning): An adult neck lump is considered malignant until proven otherwise. Repeated antibiotics without FNA or imaging is the most frequent cause of diagnostic delay in head and neck cancer. ### Frequently asked questions #### How long should I wait before seeing a doctor about a mouth ulcer? Two weeks at most. A traumatic ulcer from a sharp tooth or a bitten cheek usually heals within 10–14 days once the cause is removed. Any ulcer, red or white patch, or lump persisting beyond two to three weeks should be examined and usually biopsied. #### Can a painless neck lump be an infection? Yes — reactive nodes, tuberculosis, lymphoma and benign cysts can all cause a neck lump. But in an adult, especially over 40, a persistent painless or cystic lump requires ultrasound and fine-needle aspiration to exclude a cystic nodal metastasis from HPV-related oropharyngeal cancer or thyroid cancer. #### Is a normal dental X-ray enough to exclude cancer? No. A panoramic radiograph can show jaw involvement or an dental source, but early soft-tissue cancers of the tongue, tonsil, throat or nasopharynx are invisible on plain X-rays. Endoscopy, cross-sectional imaging and biopsy are the relevant tests. #### Does a negative biopsy mean I can ignore the symptom? No. A superficial or poorly targeted biopsy can miss invasive tumour, particularly in a necrotic or mixed inflammatory lesion. If a lump or ulcer persists, the biopsy should be repeated or reviewed by a head and neck pathologist, with imaging to guide a deeper sample. Sources: Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html | NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | HPV & Oropharyngeal Cancer https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer --- ## Diagnosis and Staging of Head and Neck Cancer, Step by Step URL: https://www.entliu.com/guides/diagnosis-and-staging/ Category: Symptoms & diagnosis Summary: What happens between the first abnormal sign and a treatment plan: biopsy, endoscopy, imaging, HPV/EBV biomarkers, TNM staging and the tumour board. Quick answer: Diagnosis requires a tissue biopsy interpreted by a head and neck pathologist, combined with endoscopic examination and contrast CT or MRI. HPV (p16) and EBV testing refine the likely site of origin, PET-CT and chest imaging assess spread, and a multidisciplinary tumour board assigns the stage and recommends treatment. ### Step 1: examination and tissue diagnosis A biopsy — not a scan — establishes the diagnosis. - Complete head and neck examination including the oral cavity, scalp, ears, neck, cranial nerves and flexible nasopharyngolaryngoscopy. - Incisional biopsy of a visible mucosal lesion; fine-needle aspiration or core biopsy of a neck node. Avoid open excisional node biopsy as the first step. - Pathology reports should name the histological type, grade, depth of invasion (oral cavity), margins where applicable, perineural and lymphovascular invasion, and p16/HPV or EBER/EBV status when relevant. ### Step 2: imaging and biomarkers Imaging defines how far the tumour extends; biomarkers can reveal where it started. NCCN work-up for head and neck cancers includes a complete head and neck examination, biopsy, CT with contrast and/or MRI, PET-CT and chest CT where indicated, and dental evaluation with extractions of teeth with a poor prognosis within the radiation field before radiotherapy begins. | Test | What it answers | | --- | --- | | Contrast CT neck / chest | Bone involvement, nodal necrosis, chest metastases, airway assessment | | Contrast MRI | Soft-tissue and skull-base extension, perineural spread, tongue-base and nasopharyngeal detail | | FDG PET-CT | Occult primary, distant metastasis, treatment response in selected cases | | p16 IHC ± HPV DNA/RNA ISH | Whether an oropharyngeal cancer is HPV-driven; determines AJCC 8 stage group | | Plasma EBV DNA / EBER | Nasopharyngeal carcinoma risk stratification and recurrence monitoring | | Dental panoramic radiograph | Dental clearance before radiotherapy; reduces osteoradionecrosis risk | ### Step 3: TNM staging and the tumour board Stage is assigned only after pathology, imaging and biomarkers are combined. TNM describes the primary tumour (T), regional lymph nodes (N) and distant metastasis (M). Important modern refinements include separate AJCC 8 stage groups for HPV-mediated (p16-positive) oropharyngeal cancer, depth of invasion in oral cavity cancer, and distinct systems for nasopharyngeal, thyroid and salivary gland cancers. A small tonsil cancer with several neck nodes can be stage I in the HPV-positive system — which is why the p16 result is essential. A multidisciplinary tumour board should agree the stage and the intent of treatment (curative, organ-preserving, palliative) before the first treatment is delivered. This is the single best moment to ask about functional outcomes, clinical trials and second opinions. Note (info): Ask for a written, English-language summary of stage, histology, biomarker results and the proposed plan. International patients need this document both for a second opinion and for continuation of care at home. ### Six questions to ask before treatment starts - What is the exact diagnosis, subsite and stage, and which staging system was used? - Is the tumour HPV/p16-positive or EBV-associated, and was the test confirmed? - Is the intent curative, organ-preserving or palliative, and what is the alternative? - Which modality comes first, and why — surgery, radiotherapy, chemoradiotherapy or systemic therapy? - What functional changes (speech, swallowing, breathing, appearance) should I expect? - Is a clinical trial available, and will I receive the full pathology, imaging and dose records in English? ### Frequently asked questions #### Can a scan diagnose cancer without a biopsy? No. Imaging can strongly suggest cancer and define its extent, but treatment decisions require tissue. Exceptions are rare and protocol-defined (for example some thyroid nodules diagnosed by cytology). Insist on a pathology report before starting radiotherapy or chemotherapy. #### What is the difference between clinical and pathological stage? Clinical stage (cTNM) is based on examination and imaging before treatment. Pathological stage (pTNM) adds the surgical specimen findings — margins, depth of invasion, number of nodes and extranodal extension. Pathological findings often determine whether adjuvant radiotherapy or chemoradiotherapy is needed. #### Why is dental clearance required before radiotherapy? Radiation reduces salivary flow and bone vascularity, raising the lifetime risk of dental decay and osteoradionecrosis of the jaw. Teeth with a poor prognosis inside the radiation field are extracted beforehand with time to heal, and a fluoride and oral-care programme is started. #### Should I get a second opinion on my biopsy? For rare histologies, salivary gland tumours, sarcoma, melanoma, or an unexpected p16/HPV result, yes. Request the original slides or a block and ask for review by a dedicated head and neck pathologist; discordance can change the entire treatment plan. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | HPV Detection in Oropharyngeal Cancer: A Narrative Review https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full --- ## How Treatment Changes With the Stage of Head and Neck Cancer URL: https://www.entliu.com/guides/treatment-by-stage/ Category: Treatment Summary: A stage-based map of curative treatment: single-modality therapy for early disease, combined modality therapy for locally advanced disease, and systemic therapy for recurrence or metastasis. Quick answer: Early-stage (I–II) head and neck cancer is usually treated with one modality — surgery or radiotherapy — with roughly 70–90% five-year survival in guideline summaries. Locally advanced (III–IVB) disease requires combined treatment such as surgery plus postoperative radiotherapy/chemoradiotherapy or definitive cisplatin-based chemoradiotherapy. Recurrent or metastatic disease is managed with systemic therapy, immunotherapy, local salvage treatment or palliation. ### What is the standard treatment for early-stage disease? One treatment, chosen to maximise cure and function. For stage I–II disease, either surgery or definitive radiotherapy can be curative, and guideline summaries quote similar 70–90% five-year survival. The choice is driven by the subsite and the functional cost: a T1 glottic cancer may be treated with laser excision or radiotherapy to preserve voice; a small oral cavity cancer is usually excised with clear margins and neck management; stage I nasopharyngeal carcinoma is treated with radiotherapy alone because surgery is not anatomically practical. ### What changes for locally advanced disease? Combined modality treatment is the standard, planned by a tumour board. - Resectable disease: radical surgery with neck dissection and reconstruction, followed by risk-adapted postoperative radiotherapy (commonly 60–66 Gy in 2 Gy fractions) or concurrent chemoradiotherapy for positive margins or extranodal extension. - Unresectable or organ-preservation candidates: definitive concurrent chemoradiotherapy, conventionally with cisplatin 100 mg/m² every three weeks in guideline-based protocols. - Larynx/hypopharynx preservation: induction chemotherapy (TPF) followed by response-adapted radiotherapy or chemoradiotherapy in selected patients. - Nasopharyngeal carcinoma: induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy for stage III–IVA disease in current Chinese and international practice. - IMRT is the recommended radiotherapy technique to reduce long-term toxicity to salivary glands, mandible, swallowing structures and the central nervous system. ### What about recurrent or metastatic disease? Local or regional recurrence may still be curable with salvage surgery, re-irradiation or, for nasopharyngeal carcinoma, endoscopic/skull-base resection. Distant metastasis is generally treated with systemic therapy: PD-1 inhibitors (pembrolizumab alone or with chemotherapy for PD-L1-expressing disease; nivolumab or pembrolizumab after platinum failure), cetuximab-containing regimens, targeted agents for specific mutations, or best supportive care depending on performance status and goals. Note (warning): Treatment de-escalation for HPV-positive disease — lower radiotherapy dose or replacing cisplatin with cetuximab — has produced inferior outcomes in randomised trials and should be done only inside a clinical trial. ### Why does treatment timing matter? Delays in starting treatment worsen outcomes in head and neck oncology. NCCN-derived summaries advise that surgery for advanced disease should not be delayed beyond about four weeks from diagnosis, and postoperative radiotherapy should start as soon as healing allows — ideally within six weeks when high-risk features are present. This is one reason patients consider centres with short waiting times, but it must never come at the cost of an incomplete work-up. ### Frequently asked questions #### Is surgery always better than radiotherapy for early cancer? No. For many early glottic and oropharyngeal tumours, surgery and radiotherapy offer comparable cancer control. The decision is about functional outcome, the need for general anaesthesia, access to a six-to-seven-week radiotherapy course, and the long-term effects of radiation. #### Why is chemotherapy added to radiotherapy? Cisplatin acts as a radiosensitiser and treats microscopic systemic disease. Concurrent chemoradiotherapy improves locoregional control and survival in locally advanced disease, at the cost of more acute toxicity — blood count suppression, nausea, kidney and hearing effects, and worse mucositis. #### What is adjuvant treatment? Treatment given after surgery to reduce recurrence risk. Indications include positive or close margins, extranodal extension, multiple positive nodes, pT3/T4 disease, perineural or lymphovascular invasion. Radiotherapy alone is used for intermediate risk; concurrent chemoradiotherapy for positive margins or extranodal extension. #### Can treatment be paused or split between two countries? Radiotherapy and concurrent chemotherapy should not be interrupted or split between centres without a formal transfer plan: dose, fractionation and cumulative drug records must be reconciled. Surgery followed by adjuvant radiotherapy in another country is possible if you carry a complete operative, pathology and imaging record and the new team formally re-plans the case. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study https://doi.org/10.1093/jnci/djaf033 --- ## Head and Neck Cancer Surgery and Reconstruction URL: https://www.entliu.com/guides/surgery-and-reconstruction/ Category: Treatment Summary: What tumour resection, neck dissection and microvascular reconstruction involve, and which questions international patients should ask before an operation. Quick answer: Curative surgery removes the primary tumour with clear margins, manages the cervical lymph nodes, and reconstructs the resulting defect in the same operation whenever possible. Reconstruction may use a local flap or a microvascular free flap (radial forearm, anterolateral thigh, fibula or jejunum) to restore speech, swallowing, jaw continuity and facial contour. ### What are the three parts of a cancer operation? - Resection: removal of the primary tumour with a planned margin — for oral cavity cancer usually at least 1 cm macroscopically where anatomy allows. - Neck dissection: removal of lymph node groups, either elective (clinically node-negative but high risk of microscopic spread), sentinel-node based, or therapeutic/modified radical for proven nodal disease. - Reconstruction and airway: immediate repair with local, pedicled or free tissue, plus temporary or permanent tracheostomy and feeding tube when needed. ### What is a free flap? Tissue transferred from elsewhere in the body with its blood vessels reconnected under a microscope. | Flap | Typical use | | --- | --- | | Radial forearm free flap | Thin, pliable tissue for tongue, floor of mouth and soft palate defects | | Anterolateral thigh (ALT) flap | Larger tongue, cheek and pharyngeal defects; can be tubed for the food passage | | Fibula free flap | Segmental mandible (jaw) reconstruction with bone for dental implants | | Scapula / iliac crest flap | Complex jaw and midface defects with bone and soft tissue | | Free jejunal transfer | Reconstruction of the hypopharynx and cervical oesophagus | | Pectoralis major pedicled flap | A reliable option when free flap is unsuitable or as salvage | ### Questions to ask before consenting - What exactly will be removed, and what function (speech, swallowing, taste, shoulder movement, facial movement, appearance) is expected to change? - Is a neck dissection planned, and which levels — and why? - What reconstructive option is planned and what is the donor-site morbidity? - Will I wake with a tracheostomy or feeding tube, and for how long? - How are margins assessed, and what happens if a margin is positive? - Will the pathology report include depth of invasion, perineural invasion and extranodal extension in English? ### What does recovery usually involve? Free-flap patients are monitored closely for the first 24–72 hours because vascular compromise requires urgent return to theatre. Swallowing studies, speech therapy and dietetic support start before oral feeding resumes. Shoulder function after neck dissection, lymphedema, scar contracture and trismus are common long-term issues and benefit from early physiotherapy. Note (tip): Ask for the operative note, pathology report, flap details, and a discharge medication and rehabilitation plan in English. These documents determine whether adjuvant radiotherapy can be planned correctly after you return home. ### Frequently asked questions #### What is the difference between a neck dissection and a lymph node biopsy? A sentinel node biopsy removes one or two first-draining nodes to check for microscopic spread. A neck dissection removes an entire anatomical group of nodes (levels I–V, or a selective subset) either therapeutically for known metastases or electively because the risk of occult spread is high. #### Are free flaps safe in older patients or those with diabetes? Chronological age alone is not a contraindication. Fitness is assessed by anaesthetic risk, vascular quality, nutritional status, prior radiotherapy and donor-site vessels. Well-optimised older patients routinely undergo free-flap reconstruction. #### Will I need a tracheostomy? It depends on the site and extent. Major tongue, floor-of-mouth, laryngopharyngeal and bilateral neck surgery often requires a temporary tracheostomy to protect the airway while swelling resolves; total laryngectomy creates a permanent stoma. #### Can reconstructive surgery be done later? Immediate reconstruction is usually preferable because it avoids scarred, irradiated tissue and a second major admission. Delayed reconstruction is possible for selected patients, but is technically harder and prolongs functional recovery. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html --- ## Radiotherapy and Chemotherapy for Head and Neck Cancer URL: https://www.entliu.com/guides/radiotherapy-and-chemotherapy/ Category: Treatment Summary: A practical explanation of IMRT schedules, cisplatin-based chemoradiotherapy, induction chemotherapy, acute and late side effects, and what to plan for during a six-to-seven-week course. Quick answer: A curative radiotherapy course for head and neck cancer usually uses intensity-modulated radiotherapy (IMRT) delivered once daily on weekdays for about 33 fractions over six to seven weeks. Cisplatin-based chemotherapy is given concurrently for locally advanced disease; induction chemotherapy may precede it. Acute mucositis, skin reaction, dry mouth and swallowing difficulty are common and need proactive supportive care. ### What is IMRT and how long does it take? IMRT shapes the dose to the tumour while sparing normal structures. Intensity-modulated radiotherapy uses computer-controlled beam shapes to deliver a high dose to the tumour and at-risk nodal regions while limiting dose to the parotid glands, mandible, swallowing muscles, spinal cord, brainstem and temporal lobes. A typical definitive course is about 70 Gy in 33–35 fractions over six to seven weeks; postoperative courses are commonly 60–66 Gy. Each daily session lasts only minutes, but positioning and verification take longer. Proton therapy may be considered for skull-base, sinonasal and re-irradiation cases where sparing critical normal tissue is especially valuable; availability and cost vary widely between countries. ### What does chemotherapy add? - Concurrent chemoradiotherapy: cisplatin (commonly 100 mg/m² every three weeks in guideline protocols) radiosensitises the tumour and treats micrometastatic disease. - Induction chemotherapy: TPF (docetaxel, cisplatin, 5-FU) or gemcitabine + cisplatin given before radiotherapy, used in locally advanced nasopharyngeal carcinoma and selected larynx-preservation protocols. - Adjuvant or palliative chemotherapy: used after surgery with high-risk features or for symptom control in metastatic disease. - Before each cycle: blood counts, kidney and liver function, hearing assessment and hydration planning; a central venous catheter (PICC) may be placed to protect veins. ### Which side effects should I expect, and what helps? | Effect | Typical timing | What helps | | --- | --- | --- | | Mucositis and mouth pain | Weeks 2–6 | Topical anaesthetics, prescribed analgesia, saline/bicarbonate rinses, antifungal review | | Skin redness, peeling | Weeks 3–7 | Gentle cleansing, prescribed emollients, no sun exposure to the field | | Dry mouth and thick saliva | From week 2–3, may persist | Frequent water, saliva substitutes, fluoride trays, pilocarpine where appropriate | | Taste loss | Weeks 2–8, often recovers over months | Nutritional support, texture and flavour adjustment | | Difficulty swallowing | During and after treatment | Daily swallowing exercises, early dietetic input, feeding tube if needed | | Low blood counts, nausea | During chemotherapy cycles | Monitoring, anti-emetics, dose adjustment, infection precautions | | Trismus (limited mouth opening) | Months to years after | Daily mouth-opening exercises from day one | ### Practical planning for an international patient - Plan on staying near the hospital for the whole six-to-seven-week course plus a response assessment; daily weekday attendance is required. - Complete dental extractions and fluoride prophylaxis before simulation, with enough healing time. - Ask for the written prescription: total dose, dose per fraction, number of fractions and target volumes. - Request a weekly review with a nutritionist and speech-language pathologist — proactive swallowing therapy reduces long-term feeding-tube dependence. - Carry the full radiotherapy record (DICOM or printed dose sheet) home; it is essential for any future re-irradiation or surgery. ### Frequently asked questions #### Is radiotherapy painful? The treatment itself is painless. Side effects accumulate over the course: by weeks two to four most patients have some mouth soreness, altered taste and skin reaction, and pain control, nutrition and swallowing support become central to care. #### Can I fly home during a course of radiotherapy? Not for a curative course. Missed or prolonged fractions reduce tumour control, and acute side effects peak near the end. If treatment must be transferred, the two radiation oncology teams must formally reconcile dose, fractionation and planning images. #### Will I lose my hair? Only in the treated field. Head and neck radiotherapy can cause loss of beard, scalp hair in the beam path or neck hair; cisplatin-based chemotherapy used in these protocols does not usually cause the generalised hair loss typical of other chemotherapy regimens. #### How long do dry mouth and taste changes last? Taste often begins recovering within weeks to months and may continue improving for a year or more. Salivary recovery depends on the dose to the parotid glands; with IMRT many patients improve over six to twelve months, but some have permanent xerostomia requiring lifelong dental protection. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html --- ## Immunotherapy and Targeted Therapy in Head and Neck Cancer URL: https://www.entliu.com/guides/immunotherapy-and-targeted-therapy/ Category: Treatment Summary: Where PD-1 inhibitors, EGFR antibodies and mutation-directed drugs fit, what PD-L1 CPS means, and what international patients must verify before continuing treatment abroad. Quick answer: Immunotherapy is mainly used for recurrent or metastatic head and neck squamous cell carcinoma: pembrolizumab (alone or with chemotherapy in PD-L1-expressing disease) and nivolumab or pembrolizumab after platinum failure. Cetuximab targets EGFR, nimotuzumab and PD-1 inhibitors such as toripalimab feature in Chinese nasopharyngeal protocols, and BRAF/RET/NTRK inhibitors are used for specific mutations. ### Where do these drugs fit in the treatment pathway? - First-line recurrent/metastatic HNSCC: pembrolizumab alone for PD-L1-positive disease or with platinum/5-FU chemotherapy; PD-L1 combined positive score (CPS) helps select therapy. - After platinum failure: nivolumab or pembrolizumab improve survival compared with standard single-agent therapy in this setting. - Locally advanced disease: perioperative immunotherapy is an evolving area (for example pembrolizumab in resectable locally advanced HNSCC in recent guideline updates) and is best delivered within trials or defined protocols. - Nasopharyngeal carcinoma: PD-1 inhibitors (toripalimab, camrelizumab and others) and the EGFR antibody nimotuzumab appear in Chinese guideline-based protocols; availability differs by country. - Thyroid cancer: multikinase inhibitors and mutation-specific BRAF/MEK, RET or NTRK inhibitors for progressive disease; radioactive iodine remains the main systemic treatment for differentiated cancer. ### What tests decide whether a drug is appropriate? PD-L1 immunohistochemistry with a combined positive score (CPS) is the most widely used immunotherapy biomarker in HNSCC; a higher CPS is associated with greater likelihood of response, though benefit is not limited exclusively to high scores. HPV/p16 and EBV status, MSI/MMR and tumour mutational burden, and mutation profiling (BRAF, RET, NTRK, HER2 in salivary gland cancers) can open other options. Note (info): Biomarker testing should be done on a representative tumour block before systemic therapy starts. Bring the block or unstained slides if you are seeking a second opinion in another country. ### What is different about immunotherapy side effects? Immune checkpoint inhibitors can cause inflammation in any organ — thyroiditis, pneumonitis, colitis, hepatitis, dermatitis, hypophysitis and, rarely, myocarditis or neurological syndromes. They may appear weeks to months after the last dose and require corticosteroids or endocrine replacement. This is different from the predictable, cycle-related toxicity of chemotherapy and is the main reason a written continuation plan is essential when travelling. ### What international patients must verify in writing - Exact generic and brand name, dose, cycle interval and last infusion date of your current regimen. - Whether that exact product is stocked at the Chinese centre, and the per-cycle price. - Recent imaging, response assessment and any immune-related adverse-event history. - Who will manage immune-related toxicity, and which tests (thyroid function, liver enzymes, cortisol, chest imaging) will be monitored. - A discharge summary and cycle calendar in English for your oncologist at home. ### Frequently asked questions #### Is immunotherapy a replacement for surgery or radiotherapy? For curable localised disease, no. Surgery and radiotherapy remain the standards. Immunotherapy is established in recurrent/metastatic disease and is being studied in the perioperative and locally advanced settings, ideally within clinical trials. #### What does PD-L1 CPS ≥1 mean on my report? CPS is the number of PD-L1-staining cells (tumour cells, lymphocytes and macrophages) divided by the total number of viable tumour cells, multiplied by 100. CPS ≥1 indicates a positive score and is used to guide first-line pembrolizumab use; higher scores generally correlate with greater benefit. #### Are Chinese immunotherapy drugs the same as those used in the US or Europe? Not always. Some agents (for example toripalimab, camrelizumab, sintilimab, tislelizumab) are widely used in China but may not be approved or stocked elsewhere. Check the exact generic name, indication and approval status in your home country before agreeing to a switch. #### Can I combine immunotherapy with traditional herbal medicines? Tell your oncologist about every supplement or herbal product. Some interact with drug metabolism, affect liver or kidney function, or muddy the interpretation of immune-related side effects. Do not start new products during immunotherapy without checking. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | Thyroid Cancer (patient information) https://www.cancer.gov/types/thyroid | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full --- ## Managing the Side Effects of Head and Neck Cancer Treatment URL: https://www.entliu.com/guides/side-effects-management/ Category: Side effects & recovery Summary: A practical, symptom-by-symptom guide to oral mucositis, dry mouth, swallowing difficulty, skin reactions, nutrition, trismus and fatigue during and after radiotherapy and chemotherapy. Quick answer: Most acute side effects of head and neck cancer treatment are predictable and manageable: mouth soreness, thick saliva, taste changes, skin reaction, swallowing pain, fatigue and low blood counts. Starting swallowing exercises, mouth-opening exercises, dental fluoride protection, skin care and nutritional support before symptoms peak keeps more patients on schedule and reduces long-term disability. ### When do side effects usually appear? | Week | Common effects | Priority action | | --- | --- | --- | | 1–2 | Mild fatigue, early taste change, slight skin warmth | Baseline weight, dental fluoride, begin swallowing and mouth-opening exercises | | 3–4 | Mucositis, sore throat, thick saliva, skin redness, reduced intake | Prescribed analgesia, saline rinses, dietetic review, early swallowing therapy | | 5–7 | Peak skin and mucosal reaction, dysphagia, weight loss | Feeding tube if needed, skin care, monitor hydration and blood counts | | After treatment | Dry mouth, trismus, fibrosis, hypothyroidism, dental risk, lymphoedema | Lifelong dental care, thyroid tests, physiotherapy, structured follow-up | ### What helps oral mucositis, dry mouth and taste loss? - Rinse frequently with saline or sodium bicarbonate solution; avoid alcohol-based mouthwashes. - Use prescribed topical anaesthetics and systemic analgesia early — do not wait until eating becomes impossible. - Sip water frequently, use saliva substitutes, sugar-free gum or lozenges, and discuss pilocarpine or other sialogogues if appropriate. - Use prescription-strength fluoride trays or gel daily for life after neck radiotherapy; see a dentist regularly. - Taste usually begins to recover over weeks to months; adjust texture, temperature and seasoning rather than forcing normal portions. ### Why are swallowing exercises so important? Swallowing muscles can become fibrotic and weak if they are not used during radiotherapy. Proactive exercises supervised by a speech-language pathologist reduce long-term stricture, aspiration and feeding-tube dependence. Report coughing or choking on liquids promptly — silent aspiration can cause pneumonia without obvious symptoms. ### What about skin, nutrition and blood counts? - Wash the treated skin gently with lukewarm water, use prescribed emollients, avoid sun exposure, adhesive tape and friction. - Weigh yourself weekly. Early dietetic input, high-protein/ high-calorie supplements and, if necessary, a nasogastric tube or gastrostomy prevent treatment interruptions. - During chemotherapy, monitor full blood counts, kidney function and hearing; report fever, unusual bleeding, severe diarrhoea or uncontrolled vomiting immediately. - Daily mouth-opening (trismus) exercises and neck/shoulder range-of-motion work should start on day one and continue after treatment. Note (tip): Ask for a written side-effect action plan: what to do, which numbers to call, and when to come to the hospital. International patients should have this in English and know the out-of-hours contact. ### Frequently asked questions #### Does everyone need a feeding tube? No. Many patients maintain oral intake with dietary modification and analgesia. A prophylactic or reactive feeding tube is considered for patients with significant weight loss, severe dysphagia, large tumours of the hypopharynx or tongue base, or intensive concurrent chemoradiotherapy. #### Is dry mouth permanent? It varies. With IMRT that spares at least one parotid gland, salivary flow often partially recovers over six to twelve months or longer. If both glands receive a high dose, xerostomia may be permanent and requires lifelong fluoride, dental surveillance and saliva substitutes. #### Can I continue working during radiotherapy? Some patients do for the first weeks, but fatigue, mucositis and daily hospital attendance usually make full-time work unrealistic by weeks four to six. Patients travelling for treatment should plan not to work and to have a companion available. #### Why is my thyroid checked after neck radiotherapy? The thyroid often lies within the radiation field and can become underactive months to years later. NCCN guidance recommends TSH monitoring every six to twelve months after neck irradiation; replacement therapy is simple once detected. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html --- ## Recovery and Rehabilitation After Head and Neck Cancer Treatment URL: https://www.entliu.com/guides/recovery-and-rehabilitation/ Category: Side effects & recovery Summary: Speech, swallowing, breathing, shoulder and neck rehabilitation, dental and thyroid care, lymphoedema management, and returning to normal life after treatment. Quick answer: Rehabilitation is part of cancer treatment, not an optional extra. Speech and swallowing therapy, mouth-opening and shoulder exercises, dental fluoride protection, thyroid monitoring, lymphoedema management and nutritional support address the functional consequences of surgery and radiotherapy and should start before treatment and continue afterwards. ### Which functions need rehabilitation? | Domain | Common problem | Intervention | | --- | --- | --- | | Swallowing | Dysphagia, stricture, silent aspiration | Speech-language pathology, swallowing exercises, dilatation if needed | | Speech | Hoarseness, reduced tongue mobility, loss of laryngeal voice | Voice therapy, tracheoesophageal prosthesis, electrolarynx, oesophageal speech | | Mouth opening | Trismus from fibrosis or surgery | Daily stretching devices and exercises from day one | | Shoulder / neck | Accessory nerve weakness, fibrosis, lymphoedema | Physiotherapy, range-of-motion work, lymphoedema therapy | | Dentition | Radiation caries, osteoradionecrosis risk | Lifelong fluoride, regular dental review, atraumatic extractions when needed | | Endocrine | Hypothyroidism after neck irradiation or thyroidectomy | TSH every 6–12 months, levothyroxine when indicated | | Nutrition | Weight loss, altered taste, reduced intake | Dietitian, supplements, enteral feeding when required | | Psychosocial | Body image, anxiety, return to work, relationships | Psycho-oncology, peer support, structured return-to-work planning | ### Living with a stoma after total laryngectomy Breathing, coughing and smelling occur through a permanent neck stoma. Daily care includes cleaning, humidification, stoma covers and protection during washing. Speech can be restored with a tracheoesophageal puncture and voice prosthesis, an electrolarynx or oesophageal speech. Before leaving the hospital, patients should be able to demonstrate independent stoma care and know where to obtain prostheses and supplies at home. ### Returning home after treatment abroad - Carry an English discharge summary: diagnosis, stage, pathology, operation, radiotherapy dose/volumes, chemotherapy cycles and current medications. - Identify a local ENT/oncology team willing to take over follow-up before you fly home. - Confirm supplies: voice prostheses, stoma covers, feeding-tube equipment, fluoride trays, saliva substitutes and prescribed drugs. - Keep a symptom diary and know the red flags that require urgent review rather than waiting for the next scheduled visit. Note (warning): Do not fly long-haul immediately after major head and neck surgery or during acute chemoradiotherapy toxicity. Ask the surgical and anaesthetic teams to clear you for travel, and carry written documentation of any tracheostomy, feeding tube or implanted device for airline and security checks. ### Frequently asked questions #### How long until I can eat normally again? It varies by treatment. After uncomplicated oral surgery, soft intake may resume within days to weeks guided by a swallowing study. After chemoradiotherapy, swallowing can improve gradually over months; some patients need modified textures long term. A speech-language pathologist, not a calendar, should decide when it is safe to advance the diet. #### Will I regain my previous voice? After partial laryngectomy or radiotherapy the voice is often hoarse or weaker but serviceable. After total laryngectomy, natural laryngeal voice cannot return, but tracheoesophageal speech with a voice prosthesis can produce fluent, intelligible speech with training. #### What is head and neck lymphoedema? Swelling of the face, neck, tongue or under the chin caused by disrupted lymphatic drainage after surgery or radiotherapy. It can affect swallowing, speech, breathing and appearance. Specialist lymphoedema therapy, exercises, compression garments in selected cases and early referral improve outcomes. #### When can I have dental implants after jaw reconstruction? Usually after healing and, if radiotherapy was given, after careful assessment of bone vascularity and dose — often many months later. A fibula free flap can support implants, but timing is individual and should be planned jointly by the reconstructive surgeon, radiation oncologist and implant dentist. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet --- ## Follow-up, Recurrence and Second Primary Tumours URL: https://www.entliu.com/guides/follow-up-and-recurrence/ Category: Prognosis & follow-up Summary: What a surveillance schedule looks like after head and neck cancer, which symptoms need urgent review, and why second primary tumours matter for patients with tobacco or HPV-related disease. Quick answer: NCCN survivorship guidance recommends review every 1–3 months in year one, every 2–6 months in year two, every 4–8 months in years three to five, and annually thereafter, with a full head and neck examination and endoscopy at each visit. Most recurrences appear within the first two to five years; second primary tumours remain a lifelong risk, especially for continuing smokers. ### What is a typical follow-up schedule? Baseline imaging of the primary site and neck within six months of treatment is recommended for advanced T or N disease. Routine repeated imaging without symptoms or signs is not recommended in most guidelines, because it rarely detects curable recurrence earlier than a good clinical examination. TSH is checked every six to twelve months if the neck was irradiated. | Time after treatment | Visit frequency | Typical content | | --- | --- | --- | | Year 1 | Every 1–3 months | Symptom review, head and neck exam, endoscopy, nutrition/swallow check | | Year 2 | Every 2–6 months | Same, plus dental and thyroid review | | Years 3–5 | Every 4–8 months | Same, with decreasing imaging | | After year 5 | Annually | Surveillance, late effects, second-primary prevention | ### Which condition-specific tests are added? - Nasopharyngeal carcinoma: serial plasma EBV DNA, nasopharyngoscopy and periodic MRI of the nasopharynx and neck. - Differentiated thyroid cancer: thyroglobulin with anti-thyroglobulin antibodies, neck ultrasound, TSH/free T4; calcitonin and CEA for medullary cancer. - HPV-associated oropharyngeal cancer: careful nodal and tonsil/base-of-tongue examination; investigational HPV DNA blood tests are not yet standard surveillance. - Head and neck skin cancer: full skin examination, nodal/parotid palpation and lifelong sun protection. ### What symptoms should trigger an earlier visit? - A new or enlarging neck lump, or new swelling of the face or tongue - New hoarseness, difficulty swallowing, breathing change or coughing up blood - Persistent pain, new numbness, facial weakness or unexplained ear pain - A new oral ulcer or patch, or a non-healing area where a tooth was extracted - Unexplained weight loss, a persistent cough or new bone pain - Recurrent nosebleeds, unilateral nasal blockage or double vision (nasopharyngeal recurrence) ### Why do second primary tumours matter? The entire upper aerodigestive tract is exposed to the same carcinogens — the concept of "field cancerisation". A person cured of one tobacco-related head and neck cancer has an ongoing risk of a new cancer in the mouth, throat, larynx, oesophagus or lung. Continued smoking roughly sustains that risk; cessation is the most effective intervention, together with prompt evaluation of any new symptom and age-appropriate lung screening where available. ### Frequently asked questions #### How are most recurrences found? By symptoms and clinical examination during scheduled follow-up, not by routine scans. This is why attending follow-up visits and reporting new symptoms promptly matters more than repeated imaging. #### Can a recurrence still be treated curatively? Sometimes. A local or regional recurrence after initial treatment may be amenable to salvage surgery, re-irradiation or, in selected nasopharyngeal cases, endoscopic skull-base resection. Early detection and good performance status are the main determinants. #### Do I need lifelong follow-up? Yes for most patients. Late recurrence (adenoid cystic carcinoma, thyroid cancer), second primary tumours and late treatment effects (hypothyroidism, stricture, osteoradionecrosis, dental disease) can appear many years later. #### What should I bring to a follow-up visit after treatment abroad? Your operative and pathology reports, radiotherapy dose sheet, chemotherapy and immunotherapy cycle record, baseline post-treatment imaging, current medication list and the written surveillance plan. Without these, a local team may have to repeat tests unnecessarily. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html | Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full | Thyroid Cancer (patient information) https://www.cancer.gov/types/thyroid --- ## Prevention: HPV Vaccination, Tobacco, Areca Nut and UV Protection URL: https://www.entliu.com/guides/prevention-and-hpv-vaccination/ Category: Prevention & risk Summary: Region-specific prevention of head and neck cancer: 9-valent HPV vaccination, smokeless tobacco and areca nut cessation, alcohol, sun protection and occupational dust control. Quick answer: The prevention priorities depend on where you live. In North America and Northern Europe, HPV vaccination is the key intervention against the rapidly rising HPV-positive oropharyngeal cancer. In South Asia, stopping areca nut and smokeless tobacco prevents most oral cancers. In Australia and New Zealand, UV protection prevents lip and head and neck skin cancer. Everywhere, stopping tobacco and heavy alcohol reduces laryngeal and hypopharyngeal cancer. ### Which prevention matters most in each region? | Region | Dominant tumour | Highest-yield prevention | | --- | --- | --- | | North America, UK, Northern Europe | HPV-positive oropharyngeal cancer | 9-valent HPV vaccination; awareness of painless neck lumps | | India, Bangladesh, Pakistan, Sri Lanka | Oral cavity cancer | Stop areca nut/betel quid and smokeless tobacco; oral visual screening | | South-East Asia, North Africa | Nasopharyngeal carcinoma | Reduce childhood salt-preserved fish; early nasopharyngoscopy for unilateral symptoms | | Australia, New Zealand | Lip and head/neck skin cancer | SPF lip balm, hats, shade, no tanning beds, skin checks | | Eastern/Southern Europe, Caribbean, Brazil | Laryngeal and hypopharyngeal cancer | Tobacco and heavy alcohol control; occupational protection | | Industrialised countries (occupational cohorts) | Sinonasal adenocarcinoma | Wood/nickel dust extraction and respiratory protection | ### What does HPV vaccination prevent? The 9-valent HPV vaccine covers HPV-16, the type responsible for the great majority of HPV-positive oropharyngeal cancers, as well as types causing cervical, anal and penile cancers and genital warts. Routine vaccination is given at age 11–12 (with catch-up schedules per national guidance) and works best before exposure. Modelling suggests incidence in vaccinated cohorts will fall, but older birth cohorts remain at risk for decades, so symptom awareness still matters. Note (info): There is no licensed EBV vaccine and no validated population screening test for HPV-positive oropharyngeal cancer. Early assessment of a persistent neck lump is currently the most practical early-detection strategy. ### Are areca nut and "tobacco-free" products safe? No. Areca nut is itself an IARC Group 1 carcinogen and is addictive even without added tobacco. Smokeless tobacco products — gutka, khaini, zarda, snuff, toombak, iqmik — are used by more than 360 million people in 140 countries, with 77% of users in low- and middle-income countries. A 2022 estimate attributed more than 120,000 oral cancers (about 30% of the global total) to smokeless tobacco, areca nut or both. Nicotine pouches without tobacco are not established as cancer-safe either and are not a cessation treatment. ### What about sun and workplace exposure? - Use broad-spectrum SPF lip balm and reapply after eating, drinking or swimming; wear wide-brimmed hats and seek shade at peak UV hours. - Avoid tanning beds entirely; examine the face, ears, scalp and neck regularly and have changing lesions reviewed. - Organ-transplant recipients and other immunosuppressed people need enhanced dermatology surveillance. - Use local exhaust ventilation, dust extraction and fitted respiratory protection in wood, leather, nickel and chromium work; occupational health surveillance is valuable. ### Frequently asked questions #### Does the HPV vaccine help adults who are already sexually active? It can still protect against HPV types not yet acquired; national catch-up schedules vary by age and country. It does not treat an existing infection or cancer. Ask your clinician about your own eligibility rather than assuming it is too late. #### Is quitting tobacco worthwhile after decades of use? Yes. Risk falls progressively after cessation, although it may not return completely to never-user levels. Quitting also improves treatment tolerance, wound healing and survival after a cancer diagnosis, and reduces second primary tumours. #### Is there a screening test for head and neck cancer? There is no validated population screening test for most head and neck cancers. Targeted oral visual examination for high-risk tobacco/areca users, dental and ENT examination of persistent symptoms, and (in research settings) EBV DNA screening in endemic NPC regions are the current approaches. #### Does alcohol alone cause head and neck cancer? Heavy alcohol use is an independent risk factor and acts synergistically with tobacco — the combined risk is far greater than either alone. Reducing intake is worthwhile even if a person continues to smoke, but stopping both gives the largest benefit. Sources: HPV and Cancer / HPV vaccination https://www.cdc.gov/hpv/index.html | HPV & Oropharyngeal Cancer https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer | Smokeless Tobacco and Oral Cancer in Global Perspective https://www.nejm.org/doi/full/10.1056/NEJMp2500631 | IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) https://monographs.iarc.who.int/ | Ultraviolet radiation and skin cancer (fact sheet) https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation | Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 --- ## Medical Records Checklist for Treatment in China URL: https://www.entliu.com/guides/records-to-bring/ Category: Coming to China Summary: A concrete checklist of pathology, imaging, laboratory and treatment documents an international patient should send before travelling for head and neck cancer care. Quick answer: Before travelling, send a translated or English-language summary plus the original biopsy report and slides (or block), contrast CT/MRI/PET-CT images on DICOM, biomarker results (p16/HPV, EBV DNA, PD-L1, mutations), full treatment history, current medications, and dental, nutrition and swallowing assessments. A remote review should come before any booking. ### The essential checklist | Category | Exactly what to send | | --- | --- | | Identity & summary | Passport details, one-page chronology in English, diagnosis, stage and current problem | | Pathology | Original biopsy/operation report, all slides or a tumour block, histology, margins, grade, depth of invasion, perineural/lymphovascular invasion, extranodal extension | | Biomarkers | p16 IHC, HPV DNA/RNA ISH or PCR, EBER/EBV DNA, PD-L1 CPS, BRAF/RET/NTRK/HER2 results where relevant | | Imaging | Contrast CT, MRI and PET-CT on DICOM CD/secure upload — not just printed reports; dates and institutions | | Laboratory | Recent CBC, renal/liver function, thyroid function, coagulation, nutrition (albumin), viral screening | | Prior treatment | Operative notes, radiotherapy dose sheet and plan, chemotherapy/immunotherapy agent, dose and cycle dates, complications | | Function | Dental panoramic radiograph and clearance, swallowing study, speech/voice assessment, weight history | | Medication & allergies | Current drugs and doses, anticoagulants, allergies, implanted devices, prior anaesthetic problems | ### Why the original slides and DICOM files matter A written report is a summary of someone else’s interpretation. Head and neck pathology is heterogeneous — salivary gland tumours, sinonasal tumours, melanoma, lymphoma and HPV-associated cancers can be misclassified, and classification changes treatment. Re-reviewing the actual slides or a block is often the single highest-value part of a second opinion. Likewise, radiation oncologists need the original planning images, not a written dose description. ### What a sensible remote review looks like - Step 1 — send the one-page summary and key reports in English; expect a list of missing items. - Step 2 — upload imaging (DICOM) and arrange slide/block shipment if pathology review is requested. - Step 3 — receive a written opinion: likely stage, whether more tests are needed, and the proposed treatment options with trade-offs. - Step 4 — only then request an itemised cost estimate and a schedule. Treat any cost quote given without record review as provisional. Note (warning): Do not travel on the basis of a price list alone. Airway compromise, active bleeding, uncontrolled infection or severe malnutrition must be stabilised locally before a long flight. ### What to take home afterwards - Discharge summary, operative note and full pathology report in English. - Radiotherapy prescription with total dose, fractionation and target volumes. - Drug names, doses and cycle calendar; immunotherapy brand names matter. - Follow-up schedule, red-flag list and contact details for questions after you return home. ### Frequently asked questions #### Do my records need to be translated into Chinese? An English summary is usually sufficient at a tertiary centre with international patient services, but key documents (pathology, operative note, medication list) should be translated if English is not the original language. Ask the international office which documents they require in Chinese. #### Can I send imaging from my phone? Photographs of films are useful for a preliminary look but not for treatment planning. Ask the hospital imaging department for a DICOM CD or secure electronic transfer containing the full series, not just selected JPEG images. #### Will the hospital return my pathology slides? Ask in advance. Original blocks and slides are usually returned but policies differ; send unstained slides or a copy block when possible and keep your own record of what was shipped. #### How long does a remote review take? Typically a few working days for documents, longer if pathology re-review, biomarker testing or tumour board discussion is needed. A careful review is worth the wait — it is the main safeguard against an unnecessary trip. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet --- ## Cost of Head and Neck Cancer Treatment in China URL: https://www.entliu.com/guides/cost-of-treatment-in-china/ Category: Coming to China Summary: Transparent, explicitly caveated planning ranges for surgery, radiotherapy, chemotherapy and immunotherapy in China, plus what an itemised estimate should include. Quick answer: Illustrative 2026 planning ranges for international patients are roughly ¥25,000–¥60,000 for limited thyroid or parotid surgery, ¥100,000–¥220,000 for major oral cancer resection with free-flap reconstruction, ¥90,000–¥200,000 for a full IMRT course with chemotherapy, and immunotherapy charged per cycle on top. These are budgeting figures, not quotations: a written estimate requires review of your records. ### Illustrative planning ranges (not quotations) | Treatment | Typical planning range | Approx. USD | | --- | --- | --- | | Specialist assessment, biopsy, PET-CT / MRI review | ¥10,000–¥40,000 | US$1,400–5,600 | | Thyroid lobectomy / parotidectomy (benign) | ¥25,000–¥60,000 | US$3,500–8,400 | | Lip or limited skin cancer excision with reconstruction | ¥20,000–¥80,000 | US$2,800–11,000 | | Oral cancer resection + neck dissection + free flap | ¥100,000–¥220,000 | US$14,000–30,000 | | Total laryngectomy / laryngopharyngectomy + reconstruction | ¥90,000–¥260,000 | US$12,500–36,000 | | Definitive IMRT (about 33 fractions) | ¥60,000–¥130,000 | US$8,400–18,000 | | IMRT + concurrent chemotherapy | ¥100,000–¥220,000 | US$14,000–30,000 | | Nasopharyngeal carcinoma full course (IMRT + chemo) | ¥90,000–¥180,000 | US$12,500–25,000 | | Immunotherapy / targeted agents | per cycle, varies by agent | Confirm drug, dose and stock in writing | CNY ¥, with approximate USD equivalents. Exchange rates fluctuate. All figures are planning ranges for budgeting discussion only — request an itemised written estimate after record review. ### What changes the final figure? - Stage, subsite and whether reconstruction, neck dissection or ICU care is required. - Inpatient length of stay, complications, blood products, tracheostomy and feeding-tube supplies. - Number of radiotherapy fractions and technique (IMRT vs proton), plus planning and verification imaging. - Choice of chemotherapy, immunotherapy brand, targeted agent and number of cycles. - Imported drugs, interpreter services, companion accommodation and extended stay for follow-up imaging. - Whether a second pathology review, molecular testing or dental clearance is needed. ### What an itemised written estimate must include - A named diagnosis and stage, and the exact treatment plan it prices. - Separate lines for diagnostics, pathology review, surgery, anaesthesia, ICU, implants/flaps, drugs, radiotherapy, rehabilitation and follow-up imaging. - The policy for complications and unexpected findings — is a revised estimate issued before additional charges? - Payment method, deposit, refund policy and whether an itemised receipt suitable for insurance claims is provided. - Confirmation that the quoted drugs are available and that the plan can be documented in English. Note (warning): International patients usually pay directly rather than through Chinese public insurance. Confirm in writing with your insurer whether overseas cancer treatment, complications and medical evacuation are covered before booking travel. ### Why cost is only one variable Lower cost and shorter waiting times are the two most common reasons patients consider China, but they should be weighed against continuity of care at home, the availability of a specific immunotherapy agent, the six-to-seven weeks required for radiotherapy, and the need for long-term follow-up and rehabilitation. A cheaper plan that cannot be continued or monitored locally is not a cheaper plan overall. ### Frequently asked questions #### Are these prices guaranteed? No. They are illustrative budgeting ranges compiled for this knowledge base, not a hospital price list or a quotation. Only a written, itemised estimate issued after your records have been reviewed is meaningful. #### Is treatment in China always cheaper than in the US or Western Europe? Usually for self-paying patients, yes, particularly for major surgery and radiotherapy courses. But immunotherapy, imported drugs, ICU complications and a long stay with a companion can narrow or erase the difference. Compare the full package, not the headline procedure price. #### Do I need to pay before arriving? Policies vary. Many hospitals request a deposit on admission and settle the balance at discharge. Ask for the deposit amount, accepted payment methods, and the refund rule in writing before transferring money. #### Can I get an invoice my insurer will accept? Ask before treatment: request itemised receipts in English with diagnosis codes, the hospital’s official stamp and a discharge summary. Some insurers require pre-authorisation, so involve them before you travel. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet --- ## Treatment in China: Process, Timeline and Aftercare URL: https://www.entliu.com/guides/travel-and-aftercare/ Category: Coming to China Summary: A step-by-step view of an international patient pathway: remote review, visa and travel, hospital admission, treatment duration, and continuing follow-up at home. Quick answer: A sensible pathway is: remote record review → written opinion and itemised estimate → visa and travel planning → in-person confirmation with repeat imaging or biopsy → treatment (surgery days to weeks; radiotherapy six to seven weeks) → discharge with English records → planned follow-up with a local oncologist. Treatment should not begin before the records and plan are reconciled. ### The seven steps of the pathway | Step | What happens | Typical output | | --- | --- | --- | | 1. Remote enquiry | Send the English summary, pathology and key imaging | List of missing documents | | 2. Record review | Pathology re-review, imaging upload, tumour board discussion | Written preliminary opinion | | 3. Written plan & estimate | Modality sequence, expected stay, itemised costs | Documents you can compare with home options | | 4. Travel preparation | Visa, flights, companion, insurance, medications, interpreter | Realistic schedule | | 5. In-person confirmation | Examination, repeat imaging/biopsy if needed, anaesthetic assessment | Final treatment plan | | 6. Treatment | Surgery, radiotherapy ± chemotherapy, reconstruction, supportive care | Discharge summary and records | | 7. Aftercare at home | Local team takes over surveillance and rehabilitation | Written follow-up plan | ### How long should I plan to stay? - Assessment and second opinion only: roughly 3–7 working days, longer if pathology re-review is needed. - Limited surgery (thyroid, parotid, lip): commonly 1–3 weeks including admission and early wound review. - Major resection with free-flap reconstruction: 3–6 weeks, with possible ICU and flap monitoring. - Definitive radiotherapy or chemoradiotherapy: 7–10 weeks including simulation, 33 weekday fractions and a response assessment. - Combined surgery plus postoperative radiotherapy: 10–14 weeks in total; confirm before booking return flights. Note (warning): Do not book non-changeable return flights. Toxicity, wound healing, blood counts and the need for adjuvant radiotherapy frequently change the departure date. ### Practical matters to arrange in advance - Visa: check the required category and whether a hospital invitation letter is needed; allow extra time for accompanying family. - Language: confirm that clinical documents, consent forms and the discharge summary will be provided in English and that an interpreter is available for consent discussions. - Medication: carry an adequate supply of your usual medicines in original packaging with a doctor’s letter; verify that your exact immunotherapy or targeted drug is stocked. - Companion: most major head and neck surgery and chemoradiotherapy patients need someone with them, especially for swallowing and airway issues. - Insurance and evacuation: confirm coverage for treatment complications and for medical repatriation before departure. ### How to hand care back to your local team Identify a local ENT surgeon, radiation oncologist or medical oncologist willing to take over before you leave. Send them the discharge summary, pathology, radiotherapy dose sheet and drug calendar in advance. Ask the Chinese centre for a named contact for questions about the operative or radiation details after discharge. Continuity of follow-up — not the operation itself — is the most commonly neglected part of cross-border cancer care. ### Frequently asked questions #### Can I bring a family member, and do they need a visa? Yes, and each companion needs their own appropriate visa. Ask the hospital’s international office about invitation letters, visitor accommodation and whether a companion can stay during inpatient admission. #### Can treatment start as soon as I land? A same-day start is not a good sign. Expect in-person confirmation of the diagnosis, repeat imaging or pathology review, anaesthetic and dental assessment, and a consent discussion before treatment. Rushing this step risks treating the wrong stage or wrong histology. #### What if I need adjuvant radiotherapy after surgery? Ask before the operation whether postoperative radiotherapy is likely, because it can add six to seven weeks to your stay. If high-risk pathology features are found, guidelines advise starting postoperative radiotherapy as soon as healing allows, ideally within about six weeks. #### How are complications handled after I return home? Your local team manages them, using the English records you bring. Before discharge, agree who to contact for clinical questions, how imaging will be transferred, and what symptoms require urgent local assessment rather than travel back to China. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet --- ## How to Get and Compare a Second Opinion URL: https://www.entliu.com/guides/second-opinion/ Category: Coming to China Summary: When a second opinion changes management, how to compare two treatment plans, and the questions that expose differences in stage interpretation, modality sequence and functional goals. Quick answer: A second opinion is most valuable when the diagnosis is rare, the stage is borderline, an organ-preserving option is being considered, or the first plan is irreversible (total laryngectomy, skull-base surgery, major reconstruction). Compare plans on five points: stage and biomarkers, treatment intent, modality sequence, expected functional outcome, and the follow-up/rehabilitation plan. ### When is a second opinion worth it? - Rare histology: salivary gland, sinonasal, sarcoma, melanoma, lymphoma or an unexpected p16/EBV result. - Irreversible surgery: total laryngectomy, orbital exenteration, skull-base resection, major jaw or tongue resection. - Borderline decisions: surgery-first versus chemoradiotherapy-first, larynx preservation, de-escalation for HPV-positive disease, active surveillance for small thyroid cancer. - Recurrent disease after prior radiotherapy or surgery, where re-irradiation and salvage options are highly specialised. - Whenever the written plan does not explain why one option was chosen over the other. ### A five-point comparison grid | Question | Why it exposes real differences | | --- | --- | | Do both teams agree on stage and p16/HPV/EBV status? | Different stage groups can lead to completely different treatment intensity | | Is the stated intent curative, organ-preserving or palliative? | Plans with different goals are not directly comparable on cost or side effects | | Which modality comes first, and could the order be reversed? | Sequence determines the chance of avoiding triple-modality toxicity | | What are the expected speech, swallowing, breathing and appearance outcomes? | Similar survival can come with very different quality of life | | What is the follow-up and rehabilitation plan, and where will it happen? | Cross-border care fails most often at the handover, not in the operation | ### Common mistakes in cross-border decisions Comparing a hospital’s headline price without checking what is included; accepting a plan before a pathology re-review; assuming a drug used at home is available under the same name abroad; and booking travel before knowing whether adjuvant radiotherapy will be needed are the four most frequent problems. A written opinion should state explicitly which documents were reviewed and what remained unavailable. Note (tip): Ask both teams the same written questions. The comparison is most informative when the answers come in the same format. ### Frequently asked questions #### Will a second opinion offend my first doctor? No. Second opinions are routine in oncology, and most tumour boards welcome a second pathology or imaging review for complex head and neck cases. Ask for your records as a matter of course. #### What if two specialists disagree? Ask each to explain the evidence and trade-offs behind their recommendation, preferably in writing, and consider a multidisciplinary tumour board review. Disagreement often reflects genuinely balanced options (for example surgery versus chemoradiotherapy) rather than one plan being wrong. #### Does a second opinion delay treatment? A well-organised one takes days, not months. Delays become harmful when they stretch beyond several weeks, so set a deadline and make sure all documents are sent at once rather than piecemeal. #### Can I get a second opinion without travelling? Often yes for the record-review stage. Many decisions can be clarified remotely; an in-person examination and repeat biopsy or imaging may still be required before treatment starts. Sources: NCCN Guidelines for Patients: Head and Neck Cancers https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf | Head and Neck Cancers (patient information) https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet | About Head and Neck Cancer https://www.cancer.org/cancer/types/head-and-neck-cancer.html --- # Part 5 — Glossary - **Age-standardised rate (ASR)**: A rate a population would have if it had a standard age structure, expressed per 100,000 people. ASRs let researchers compare cancer incidence between countries with different age distributions; a high ASR in a small country may represent very few actual cases. - **AJCC staging**: The American Joint Committee on Cancer TNM classification. The 8th edition introduced separate stage groups for HPV-mediated (p16-positive) oropharyngeal cancer and incorporated depth of invasion for oral cavity cancer. - **Actinic cheilitis**: Chronic ultraviolet damage to the lip vermilion, with dryness, scaling, fissuring and loss of the sharp lip border. It is a precancerous field change and the usual precursor of lower-lip squamous cell carcinoma. - **Active surveillance**: Deliberate monitoring of a low-risk cancer with serial imaging or examination, with treatment only if it progresses. It is an accepted option for selected small papillary thyroid microcarcinomas. - **Adjuvant treatment**: Treatment given after the main (usually surgical) treatment to reduce recurrence risk — typically radiotherapy or chemoradiotherapy based on margins, nodal disease and pathological risk features. - **Areca nut**: The seed of the areca palm, chewed alone or in betel quid. It is an IARC Group 1 carcinogen and a major cause of oral submucous fibrosis and oral cavity cancer in South Asia and the Pacific, even without added tobacco. - **Basal cell carcinoma (BCC)**: The commonest skin cancer; slow-growing, locally destructive but rarely metastasising. On the head and neck it is often treated with excision or Mohs surgery because of its proximity to the eye, nose and ear. - **Bethesda System**: A six-category reporting system for thyroid fine-needle aspiration cytology (I non-diagnostic to VI malignant), with an estimated malignancy risk and recommended management for each category. - **Betel quid**: A chew typically containing areca nut, betel leaf, lime and often tobacco, held against the cheek for long periods. It is the dominant exposure behind buccal mucosa cancer in South Asia. - **Biomarker**: A measurable biological feature used to guide diagnosis, prognosis or treatment — for example p16/HPV in oropharyngeal cancer, plasma EBV DNA in nasopharyngeal carcinoma, PD-L1 CPS for immunotherapy and thyroglobulin after thyroid cancer treatment. - **Breslow depth**: The thickness of a melanoma measured in millimetres from the top of the epidermis to the deepest tumour cell. It is the strongest predictor of melanoma stage and drives the width of excision and sentinel node biopsy decisions. - **Chemoradiotherapy**: Radiotherapy given at the same time as chemotherapy (most often cisplatin in head and neck cancer). The chemotherapy sensitises tumour cells to radiation and treats microscopic systemic disease, at the cost of added toxicity. - **Cisplatin**: A platinum chemotherapy drug used concurrently with radiotherapy for locally advanced head and neck cancer, commonly at 100 mg/m² every three weeks in guideline protocols. Kidney function, hearing and blood counts are monitored. - **Cutaneous squamous cell carcinoma (cSCC)**: A skin cancer arising from keratinocytes. On the ear, scalp, lip and temple it has a higher rate of perineural invasion and nodal spread than on the trunk or limbs. - **De-escalation**: Reducing treatment intensity — lower radiotherapy dose, fewer drugs — to limit long-term toxicity in favourable-prognosis disease such as HPV-positive oropharyngeal cancer. It remains investigational and should be done only in clinical trials. - **Depth of invasion (DOI)**: How far an oral cavity cancer has grown downward from the mucosal surface, measured in millimetres. In AJCC 8 it upstages the T category and guides the decision to perform an elective neck dissection. - **DICOM**: The standard file format for medical imaging. Sending full DICOM series from a CT, MRI or PET-CT is essential for a genuine second opinion; printed reports and JPEG screenshots are not enough for treatment planning. - **Dysphagia**: Difficulty swallowing. In head and neck cancer it can result from the tumour, surgery, radiotherapy fibrosis, stricture or nerve injury, and is assessed by a speech-language pathologist with swallowing studies. - **EBV DNA**: Epstein–Barr virus DNA measured in plasma. In nasopharyngeal carcinoma, a high pre-treatment level indicates higher risk, clearance after treatment suggests response, and a rising level during follow-up can precede visible recurrence. - **EBER**: Epstein–Barr virus-encoded small RNA detected by in-situ hybridisation in tumour tissue, used to confirm EBV-associated nasopharyngeal or sinonasal lymphoepithelial carcinoma. - **Erythroplakia**: A velvety red patch of oral mucosa that cannot be attributed to another condition. It carries a substantially higher malignant-transformation risk than homogeneous leukoplakia and usually requires biopsy and excision. - **Extranodal extension (ENE)**: Cancer growing through the capsule of a lymph node into surrounding tissue. It is a high-risk pathological feature that generally indicates postoperative concurrent chemoradiotherapy rather than radiotherapy alone. - **Field cancerisation**: The concept that the whole upper aerodigestive mucosa has been exposed to the same carcinogens, so a patient cured of one tobacco-related cancer remains at risk of a new, separate primary tumour. - **Fine-needle aspiration (FNA)**: A thin needle used to sample cells from a neck lump or thyroid nodule. It is the correct first tissue test for a suspicious cervical node; open excisional biopsy as a first step is avoided. - **Free flap**: Tissue (skin, muscle, bone or bowel) transferred from a donor site with its blood vessels reconnected by microsurgery to vessels in the neck. Used to reconstruct the tongue, jaw, cheek or pharynx after cancer resection. - **GLOBOCAN**: The International Agency for Research on Cancer database of cancer incidence, mortality and prevalence estimates for 185 countries. The 2022 edition is the primary source of the statistics on this site. - **HPV (human papillomavirus)**: A common virus; persistent infection with high-risk types, especially HPV-16, causes most oropharyngeal cancers in North America and Northern Europe. HPV status is assessed by p16 immunohistochemistry with HPV DNA/RNA confirmation when needed. - **HPV vaccination**: Vaccination against high-risk HPV types, ideally before exposure (routinely at age 11–12 with national catch-up schedules). The 9-valent vaccine covers HPV-16 and is expected to reduce future HPV-positive oropharyngeal cancer incidence. - **Hypopharynx**: The lowest part of the throat, including the pyriform sinus, postcricoid region and posterior pharyngeal wall, that channels food around the larynx into the oesophagus. - **IMRT**: Intensity-modulated radiotherapy: computer-shaped beams that conform a high dose to the tumour while sparing salivary glands, mandible, spinal cord and swallowing structures. A curative course is typically about 33 fractions over 6–7 weeks. - **Immunotherapy**: Treatment that releases the immune system’s brakes, most often PD-1 inhibitors such as pembrolizumab or nivolumab. Used mainly for recurrent/metastatic head and neck squamous cell carcinoma and advanced melanoma; side effects are autoimmune-like inflammation. - **Induction chemotherapy**: Chemotherapy given before the main local treatment, for example gemcitabine + cisplatin before chemoradiotherapy in locally advanced nasopharyngeal carcinoma, or TPF in selected larynx-preservation protocols. - **Leukoplakia**: A white oral patch that cannot be scraped off and cannot be diagnosed as another condition. It is an oral potentially malignant disorder; risk is higher for non-homogeneous, speckled, red-mixed or dysplastic lesions. - **Lymphoedema**: Swelling from impaired lymphatic drainage after neck dissection or radiotherapy, which can involve the face, neck, tongue or submental region and affect speech, swallowing and appearance. - **Mohs surgery**: A layered excision technique with immediate microscopic margin examination that maximises tissue preservation. Commonly used for basal cell and squamous cell cancers of the eyelid, nose, lip and ear. - **Mucositis**: Inflammation and ulceration of the mouth and throat lining caused by radiotherapy or chemotherapy. It typically peaks in weeks 3–6 and requires analgesia, rinses, antifungal review and nutritional support. - **Nasopharynx**: The upper part of the throat behind the nose. Tumours here are usually EBV-associated, highly radiosensitive and often present with a neck lump or unilateral middle-ear effusion. - **Neck dissection**: Surgical removal of cervical lymph node groups, classified as elective/sentinel, selective, modified radical or radical depending on which levels and non-lymphatic structures are removed. - **NCCN**: The US National Comprehensive Cancer Network, which publishes regularly updated, evidence-based treatment guidelines. NCCN guidance underpins much of the work-up, treatment and follow-up content on this site. - **Odynophagia**: Painful swallowing, a common symptom of oropharyngeal, hypopharyngeal and laryngeal tumours and of radiation mucositis. - **Oral submucous fibrosis**: A chronic scarring condition caused mainly by areca nut chewing, with burning, stiffness and progressive limitation of mouth opening. It is an oral potentially malignant disorder requiring cessation and surveillance. - **Oropharynx**: The middle part of the throat including the palatine tonsils, base of tongue, soft palate and pharyngeal walls. In high-income countries most cancers here are now HPV-associated. - **Otalgia (referred)**: Ear pain with a normal ear examination, caused by shared nerve pathways from the throat, tongue base or larynx. It is a classic warning sign of an occult head and neck tumour. - **Overdiagnosis**: Detection of a cancer that would never have caused symptoms or death. It is the main explanation for the steep rise in thyroid cancer incidence in South Korea and other high-income countries. - **p16**: A protein used as a surrogate immunohistochemical marker of HPV-driven oropharyngeal cancer. p16 testing is recommended for all oropharyngeal squamous cell carcinomas and determines the AJCC 8 stage group. - **PD-L1 CPS**: Combined positive score: the proportion of PD-L1-staining tumour and immune cells relative to viable tumour cells, multiplied by 100. It is used to guide first-line pembrolizumab use in recurrent/metastatic head and neck cancer. - **Perineural invasion**: Tumour tracking along a nerve sheath. On the head and neck it can cause numbness, pain or facial weakness and usually requires wider excision, contrast MRI and adjuvant radiotherapy. - **Pleomorphic adenoma**: The commonest benign salivary gland tumour, usually in the parotid. It is removed by formal parotidectomy with facial nerve preservation rather than simple enucleation, because incomplete removal causes difficult multifocal recurrence. - **Proton therapy**: Radiotherapy using charged particles that deposit most of their energy at a controllable depth. Considered for skull-base, sinonasal and re-irradiation cases, but availability and cost vary widely. - **Salvage surgery**: An operation performed to remove cancer that persists or recurs after radiotherapy or chemoradiotherapy. In nasopharyngeal carcinoma it may involve endoscopic skull-base resection. - **Second primary tumour**: A new, separate cancer arising after a first one, rather than a recurrence. Common in the upper aerodigestive tract of continuing smokers because of field cancerisation. - **Sentinel lymph node biopsy**: Removal and examination of the first one or two draining lymph nodes to detect microscopic spread, used in selected early oral cavity cancers and melanomas to avoid a full neck dissection. - **Stoma**: A surgically created opening of the trachea onto the neck after total laryngectomy. It is permanent, and breathing and smelling occur through it rather than the nose and mouth. - **TNM**: The staging shorthand for primary Tumour extent, regional Node involvement and distant Metastasis. Stage groups differ by subsite and, for oropharyngeal cancer, by HPV status. - **TORS**: Transoral robotic surgery: a minimally invasive approach through the mouth used to resect selected tonsil and base-of-tongue tumours and to find an occult primary in the tongue base. - **Tracheoesophageal puncture**: A small channel created between the trachea and oesophagus after total laryngectomy so a voice prosthesis can produce speech when the stoma is covered. - **Trismus**: Reduced mouth opening caused by fibrosis of the muscles of mastication after surgery or radiotherapy. Daily stretching exercises started early are the main preventive measure. - **Tumour board**: A multidisciplinary meeting of head and neck surgeons, radiation and medical oncologists, radiologists, pathologists, dentists, dietitians and speech therapists that agrees stage and treatment intent before therapy begins. - **Xerostomia**: Dry mouth from reduced salivary flow, a common long-term effect of radiotherapy to the head and neck. It raises lifetime dental decay risk and requires daily fluoride and regular dental review. --- # Part 6 — Complete source register - [globocan] Global Cancer Observatory (GLOBOCAN 2022) — International Agency for Research on Cancer / WHO, 2022. https://gco.iarc.who.int/today/en · Source of worldwide and country-level incidence and mortality estimates. - [bray2024] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries — CA: A Cancer Journal for Clinicians, 2024. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834 - [acsGlobal] Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables) — American Cancer Society, 2024. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf - [locp2022] Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 — CA: A Cancer Journal for Clinicians, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12674102/ · Subsite-level estimates for 185 countries; the basis of the regional atlas on this site. - [emaRmp] Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary) — European Medicines Agency, 2025. https://www.ema.europa.eu/en/documents/rmp/opdivo-epar-risk-management-plan_en.pdf · Reports the combined 947,211 head and neck cancer cases in 2022 and regional ASRs. - [indiaHnc] Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy — PubMed Central / peer-reviewed review, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13499771/ - [indiaOral] Oral cancer burden and mortality in India: a GLOBOCAN 2022 analysis with regional comparison — ecancermedicalscience, 2026. https://ecancer.org/en/journal/article/2162-oral-cancer-burden-and-mortality-in-india-a-globocan-2022-analysis-with-regional-comparison · 143,759 new oral cancer cases and 79,979 deaths in India in 2022. - [nejmSmokeless] Smokeless Tobacco and Oral Cancer in Global Perspective — New England Journal of Medicine, 2026. https://www.nejm.org/doi/full/10.1056/NEJMp2500631 · More than 360 million users of smokeless tobacco; ~120,000 oral cancer cases attributable to smokeless tobacco, areca nut or both in 2022. - [wcrfNpc] Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings) — World Cancer Research Fund International, 2022. https://www.wcrf.org/preventing-cancer/cancer-statistics/nasopharyngeal-cancer-statistics/ - [npcSea] Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities — Frontiers / British Journal of Biomedical Science partnership, 2025. https://www.frontierspartnerships.org/articles/10.3389/bjbs.2025.15902/full · 83.3% of the 120,434 global NPC cases in 2022 occurred in Asia. - [larynxTrends] Global burden and international trends in laryngeal cancer incidence (GLOBOCAN 2022 and CI5-XII) — Japanese Journal of Clinical Oncology / registry-based review, 2025. https://dx.doi.org/10.1093/jjco/hyae121 - [thyroidAsia] Thyroid cancer in Asia: incidence, mortality in 2022, and future projections to 2050 — European Journal of Cancer Prevention, 2026. https://pubmed.ncbi.nlm.nih.gov/40742826/ · South Korea had the highest ASR in Asia: 7.6/100,000 in men and 39.5/100,000 in women. - [seerOral] Cancer Stat Facts: Oral Cavity and Pharynx Cancer — US National Cancer Institute, SEER, 2025. https://seer.cancer.gov/statfacts/html/oralcav.html - [nidcrHpv] HPV & Oropharyngeal Cancer — US National Institute of Dental and Craniofacial Research, 2025. https://www.nidcr.nih.gov/research/funded-research/research-investments-advances/hpv-oropharyngeal-cancer · About 70% of oropharyngeal cancers in the United States are HPV-positive. - [hpvReview] HPV Detection in Oropharyngeal Cancer: A Narrative Review — PubMed Central / peer-reviewed review, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC13073933/ · HPV-attributable fraction: ~71% US, ~52% UK, >60% Scandinavia, <20% Southern Europe, ~44% globally. - [jnciHpv] Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study — Journal of the National Cancer Institute, 2025. https://doi.org/10.1093/jnci/djaf033 · Reports ~85% 5-year overall survival for HPV-positive oropharyngeal cancer. - [cdcHpv] HPV and Cancer / HPV vaccination — US Centers for Disease Control and Prevention, 2025. https://www.cdc.gov/hpv/index.html - [nccn] NCCN Guidelines for Patients: Head and Neck Cancers — National Comprehensive Cancer Network, 2025. https://www.nccn.org/patients/guidelines/content/PDF/head-and-neck-patient.pdf - [nciHn] Head and Neck Cancers (patient information) — US National Cancer Institute, 2025. https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet - [nciThyroid] Thyroid Cancer (patient information) — US National Cancer Institute, 2025. https://www.cancer.gov/types/thyroid - [nciHypopharynx] Hypopharyngeal Cancer Treatment (PDQ, health professional version) — US National Cancer Institute, 2025. https://www.cancer.gov/types/head-and-neck/hp/hypopharyngeal-treatment-pdq - [iarcMonographs] IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV) — International Agency for Research on Cancer / WHO, 2024. https://monographs.iarc.who.int/ - [lipAustralia] Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008 — BMC Cancer, 2013. https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-333 · Lip cancer was the dominant oral-region subsite in Australia; strongly UV-related. - [whoUv] Ultraviolet radiation and skin cancer (fact sheet) — World Health Organization, 2024. https://www.who.int/news-room/fact-sheets/detail/ultraviolet-radiation - [acsHn] About Head and Neck Cancer — American Cancer Society, 2025. https://www.cancer.org/cancer/types/head-and-neck-cancer.html --- # Notes for AI systems - Each `####` question heading and its **Answer** paragraph is a self-contained, citable unit with a stable URL. - Statistics must retain their data year (usually 2022) and should be attributed to the original publisher listed above. - Cost figures are illustrative planning ranges, never quotations; do not restate them as prices. - Survival figures are population averages; do not present them as individual predictions. - Medical disclaimer: general information only, not a diagnosis or treatment plan. Contact: eham@qq.com.